Compound CID,Name,Synonyms,Molecular Weight,Molecular Formula,Polar Area,Complexity,XLogP,Heavy Atom Count,H-Bond Donor Count,H-Bond Acceptor Count,Rotatable Bond Count,InChI,SMILES,InChIKey,IUPAC Name,Exact Mass,Monoisotopic Mass,Charge,Covalent Unit Count,Isotopic Atom Count,Total Atom Stereo Count,Defined Atom Stereo Count,Undefined Atom Stereo Count,Total Bond Stereo Count,Defined Bond Stereo Count,Undefined Bond Stereo Count,Linked PubChem Literature Count,Linked PubChem Patent Count,Linked PubChem Patent Family Count,MeSH Headings,Annotation Content,Annotation Type Count,Linked BioAssays,Create Date,Data Source,Data Source Category,Tagged by PubChem
 137278711,Sotorasib,"Sotorasib|AMG-510|2296729-00-3|AMG510|Lumakras|AMG 510|AMG-510 racemate|Kras G12C inhibitor 9|2252403-56-6|sotorasibum|Kras mutant-targeting AMG 510|4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one|2B2VM6UC8G|Sotorasib [INN]|Sotorasib [USAN]|UNII-2B2VM6UC8G|CHEMBL4535757|CHEBI:178199|2296729-00-3 (racemate)|6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one|(1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one|2296729-66-1|6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one|(1R)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one|(1RA)-6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-4-((2S)-2-METHYL-4-(1-OXOPROP-2-EN-1-YL)PIPERAZIN-1-YL)-1-(4-METHYL-2-(PROPAN-2-YL)PYRIDIN-3-YL)PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE|(1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one|6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-(1M)-1-(4-METHYL-2-(PROPAN-2-YL)PYRIDIN-3-YL)-4-((2S)-2-METHYL-4-(PROP-2-ENOYL)PIPERAZIN-1-YL)PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE|PYRIDO(2,3-D)PYRIMIDIN-2(1H)-ONE, 6-FLUORO-7-(2-FLUORO-6-HYDROXYPHENYL)-1-(4-METHYL-2-(1-METHYLETHYL)-3-PYRIDINYL)-4-((2S)-2-METHYL-4-(1-OXO-2-PROPEN-1-YL)-1-PIPERAZINYL)-, (1R)-|AMG510 racemate|compound (R)-38 (PMID: 31820981)|compound (R)-38 [PMID: 31820981]|SOTORASIB RACEMATE|Lumykras|Sotorasib isomer|6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one|6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one|6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one|AMG-510(racemate)|SOTORASIB [JAN]|AMG-510(Sotorasib)|Sotorasib (AMG510)|Sotorasib [USAN:INN]|SOTORASIB [WHO-DD]|SOTORASIB [ORANGE BOOK]|SCHEMBL20560375|GTPL10678|C30H30F2N6O3|AMG 510 pound>>AMG-510|DTXSID001099260|GLXC-25372|6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl]-1H,2H-pyrido[2,3-d]pyrimidin-2-one|BCP30452|BCP33368|EX-A3538|BDBM50514402|NSC818433|WHO 11370|AKOS037649138|DB15569|NSC-818433|AC-35168|BA172505|BS-16684|HY-114277|CS-0081316|D70074|D77975|AMG510 ; AMG 510; AMG-510; AMG510|4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxy phenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H) -one|6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(2-propanyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl]pyrido[2,3-d]pyrimidin-2(1H)-one",560.600,C30H30F2N6O3,102.000,1030.000,4.000,41,1,7,5,"InChI=1S/C30H30F2N6O3/c1-6-23(40)36-12-13-37(18(5)15-36)28-19-14-21(32)26(24-20(31)8-7-9-22(24)39)34-29(19)38(30(41)35-28)27-17(4)10-11-33-25(27)16(2)3/h6-11,14,16,18,39H,1,12-13,15H2,2-5H3/t18-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C,NXQKSXLFSAEQCZ-SFHVURJKSA-N,"6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one",560.235,560.235,0,1,0,1,1,0,0,0,0,159,3228,1076,"",Biological Test Results|Interactions and Pathways|Chemical and Physical Properties|Classification|Drug and Medication Information|Literature|Patents|Pharmacology and Biochemistry|Safety and Hazards|Toxicity|Use and Manufacturing|Associated Disorders and Diseases|Biological Test Results: Active|Biological Test Results: Micromolar|Biological Test Results: Nanomolar,15,1|3|5|7|9|13|15|19|21|23|25|29|31|33|35|37|39|41|43|45|47|49|53|55|59|65|67|71|73|77|79|81|83|85|89|91|93|95|97|99|101|103|105|107|109|113|115|119|121|123|125|129|131|133|137|139|141|143|145|1559567|1559568|1559569|1559570|1559571|1559572|1559573|1559574|1559575|1559576|1559577|1559578|1559579|1559582|1559583|1559584|1559585|1559586|1559587|1559588|1559589|1559590|1559591|1559592|1559593|1559594|1559595|1559596|1559597|1559599|1559600|1559601|1559602|1559603|1559604|1559605|1559606|1652156|1697072|1697073|1729513|1729514|1729515|1729516|1729517|1729518|1729519|1729520|1729521|1729522|1729523|1729524|1729525|1729526|1769392|1769393|1769394|1769395|1769396|1769397|1769398|1769399|1769400|1769401|1777598|1777599|1777600|1806575|1889606|1889607|1889608|1901007|1901008|1901009|1901010|1918456|1918457|1918458|1918459|1918460|1918470|1937510|1937511|1937523|1939177|1964520|1964522|1964524|1964526|1964528|1982413|1982414|1982415|1982416|1982417|1982418|1982445|2005814|2005816|2005819|2005822|2005826,20190126,"001Chemical|10X CHEM|A2B Chem|AA BLOCKS|Aaron Chemicals LLC|AbaChemScene|AbovChem LLC|AEchem Scientific Corp., USA|AKos Consulting & Solutions|Aladdin Scientific|Amadis Chemical|Ambeed|Angel Pharmatech Ltd.|Apexmol|AppChem|AstaTech, Inc.|AvaChem Scientific|Axon Medchem|BenchChem|BindingDB|BioChemPartner|Biosynce Pharmatech|Biosynth|BLD Pharm|BOC Sciences|ChEBI|Chem-Space.com Database|ChEMBL|ChemIDplus|ChemShuttle|Combi-Blocks|Comparative Toxicogenomics Database (CTD)|CymitQuimica|Davey Lab, Department of Microbiology, NEIDL, Boston University|DC Chemicals|DrugBank|DTP/NCI|eNovation Chemicals|EPA DSSTox|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Glixx Labs Inc|Google Patents|Hangzhou APIChem Technology|Human Metabolome Database (HMDB)|InvivoChem|IUPHAR/BPS Guide to PHARMACOLOGY|J&H Chemical Co.,ltd|Key Organics/BIONET|Lan Pharmatech|Mcule|MedChemexpress MCE|Molecule Market|MolGenie|MolPort|Nature Chemical Biology|PATENTSCOPE (WIPO)|Pharmacore Co., Limited|Probes & Drugs portal|PubChem Reference Collection|Smolecule|Starshine Chemical|SureChEMBL|SynHet - Synthetic Heterocycles|TargetMol|THE BioTek|Thieme Chemistry|Wikidata|Win-Win Chemical",Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Legacy Depositors|Research and Development|Subscription Services,"C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor|C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor|D000970 - Antineoplastic Agents > D000074322 - Antineoplastic Agents, Immunological > D000082082 - Immune Checkpoint Inhibitors|L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents"
138611145,Adagrasib,"MRTX849|Adagrasib|2326521-71-3|MRTX-849|KRAZATI|Kras G12C inhibitor MRTX849|8EOO6HQF8Y|Adagrasib [USAN]|UNII-8EOO6HQF8Y|2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile|2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-|2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-|MFCD32263433|compound 20 (PMID: 32250617)|compound 20 [PMID: 32250617]|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-5H,6H,7H,8H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile|2-((S)-4-(7-(8-chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}-5H,6H,8H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile|Krazati (TN)|ADAGRASIB [INN]|Adagrasib (USAN/INN)|Adagrasib (MRTX849)|MRTX849(Adagrasib)?|ADAGRASIB [WHO-DD]|MRTX 849|CHEMBL4594350|SCHEMBL20974691|GTPL10888|DTXSID801336759|BCP31538|EX-A3258|MRTX-849; MRTX 849|BDBM50539763|NSC831453|WHO 11519|AKOS037648997|AT23561|NSC-831453|AC-35659|BM177692|BS-16211|HY-130149|CS-0105265|D12301|EN300-26953032|Z4145344023|((2S)-4-(7-(8-CHLORONAPHTHALEN-1-YL)-2-(((2S)-1- METHYLPYRROLIDIN-2-YL)METHOXY)-5,6,7,8- TETRAHYDROPYRIDO(3,4-D)PYRIMIDIN-4-YL)-1-(2-FLUOROPROP2-ENOYL)PIPERAZIN-2-YL)ACETONITRILE|((2S)-4-(7-(8-CHLORONAPHTHALEN-1-YL)-2-(((2S)-1-METHYLPYRROLIDIN-2-YL)METHOXY)-5,6,7,8-TETRAHYDROPYRIDO(3,4-D)PYRIMIDIN-4-YL)-1-(2-FLUOROPROP2-ENOYL)PIPERAZIN-2-YL)ACETONITRILE",604.100,C32H35ClFN7O2,88.800,1060.000,5.000,43,0,9,7,"InChI=1S/C32H35ClFN7O2/c1-21(34)31(42)41-17-16-40(18-23(41)11-13-35)30-25-12-15-39(28-10-4-7-22-6-3-9-26(33)29(22)28)19-27(25)36-32(37-30)43-20-24-8-5-14-38(24)2/h3-4,6-7,9-10,23-24H,1,5,8,11-12,14-20H2,2H3/t23-,24-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F,PEMUGDMSUDYLHU-ZEQRLZLVSA-N,"2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile",603.252,603.252,0,1,0,2,2,0,0,0,0,87,3107,960,"",Biological Test Results|Interactions and Pathways|Chemical and Physical Properties|Classification|Drug and Medication Information|Literature|Patents|Pharmacology and Biochemistry|Safety and Hazards|Toxicity|Use and Manufacturing|Associated Disorders and Diseases|Biological Test Results: Active|Biological Test Results: Micromolar,14,1|5|7|9|13|15|19|21|23|25|29|31|33|35|37|39|41|43|45|47|49|53|55|59|65|67|71|73|77|79|81|83|85|89|91|93|95|97|99|101|103|105|107|109|113|115|119|121|123|125|129|131|133|137|139|141|143|145|1652101|1652102|1652103|1652104|1652105|1652106|1652107|1652108|1652110|1652111|1652112|1652113|1652114|1652121|1652122|1652123|1652124|1652126|1652127|1652128|1652129|1652134|1652135|1652136|1652137|1652138|1652139|1652145|1652146|1652147|1652148|1652149|1652150|1652151|1652152|1652153|1652154|1652155|1652156|1652157|1652158|1652159|1652160|1652161|1652162|1652163|1652164|1652165|1652166|1652167|1652168|1652169|1652170|1652171|1652172|1652173|1652174|1652175|1652176|1670043|1671498|1694842|1694843|1694844|1697074|1697075|1818923|1818924|1818925|1818926|1835836|1836765|1838623|1839552|1840481|1841410|1842339|1843268|1844197|1853202|1889606|1889607|1889608|1893386|1893414|1893415|1893948|1915627|1915628|1915629|1915630|1915631|1937522|1982391|1982392|1982393|1982397|1982398|1982399|1982405|1982409|1982413|1982414|1982415|1982416|1982417|1982418|1982445|2032562|2032563|2032571|2032572|2032573|2032574|2032577|2032578|2032579|2032580|2032581|2032598|2032599|2032613,20190720,"001Chemical|10X CHEM|A2B Chem|AA BLOCKS|Aaron Chemicals LLC|AbaChemScene|abcr GmbH|AbMole Bioscience|AKos Consulting & Solutions|Aladdin Scientific|Allbio Pharm Co., Ltd|Amadis Chemical|Ambeed|Angel Pharmatech Ltd.|AppChem|AstaTech, Inc.|AvaChem Scientific|Axon Medchem|BenchChem|BindingDB|BioChemPartner|Biosynth|BLD Pharm|BOC Sciences|Chem-Space.com Database|ChEMBL|ChemIDplus|ChemShuttle|Combi-Blocks|CymitQuimica|DC Chemicals|DTP/NCI|Enamine|eNovation Chemicals|EPA DSSTox|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Google Patents|Hangzhou APIChem Technology|Hunan Huateng Pharmaceutical Co., Ltd.|InvivoChem|IUPHAR/BPS Guide to PHARMACOLOGY|KEGG|Key Organics/BIONET|Lan Pharmatech|Mcule|MedChemexpress MCE|Molecule Market|MolGenie|MolPort|MuseChem|Nature Chemical Biology|PATENTSCOPE (WIPO)|Pharmacore Co., Limited|Probes & Drugs portal|PubChem Reference Collection|Smolecule|Starshine Chemical|SureChEMBL|TargetMol|THE BioTek|Thieme Chemistry|Win-Win Chemical",Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Legacy Depositors|Research and Development|Subscription Services,C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor|C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor|D000970 - Antineoplastic Agents|L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents
156501355,Jdq-443,"Opnurasib|JDQ-443|JDQ443|2653994-08-0|NVP-JDQ443|(S)-JDQ-443|NVP-JDQ-443|2653994-10-4|JDQ 443|compound 5 [PMID: 35404998]|example 1a [WO2021120890A1]|1-[6-[(4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one|compound 5 (PMID: 35404998)|example 1a (WO2021120890A1)|1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one|opnurasib [INN]|Opnurasib [WHO-DD]|Opnurasib (USAN/INN)|OPNURASIB [USAN]|Q3W0H3V1LQ|CHEMBL5077861|JDQ-443 [WHO-DD]|SCHEMBL23533580|GTPL11715|KRAS G12C Inhibitor JDQ443|GLXC-25533|EX-A5693|JDQ-443?|BDBM50579985|NSC846146|AKOS040757949|AT36708|HY-139612A|NSC-846146|BJ182949|DA-59685|DA-74639|MS-29737|HY-139612|CS-0226220|CS-0311034|D13038|G92237|-PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-|1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one|1-(6-(4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one|1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one|1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one|1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one|1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one|2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-",526.000,C29H28ClN7O,84.600,936.000,4.600,38,1,4,4,"InChI=1S/C29H28ClN7O/c1-5-24(38)36-14-29(15-36)10-20(11-29)37-17(3)25(26-21-13-31-33-22(21)8-16(2)27(26)30)28(34-37)18-6-7-23-19(9-18)12-32-35(23)4/h5-9,12-13,20H,1,10-11,14-15H2,2-4H3,(H,31,33)",CC1=CC2=C(C=NN2)C(=C1Cl)C3=C(N(N=C3C4=CC5=C(C=C4)N(N=C5)C)C6CC7(C6)CN(C7)C(=O)C=C)C,AZUYLZMQTIKGSC-UHFFFAOYSA-N,1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one,525.204,525.204,0,1,0,0,0,0,0,0,0,4,41860,14009,"",Biological Test Results|Interactions and Pathways|Chemical and Physical Properties|Classification|Drug and Medication Information|Literature|Patents|Use and Manufacturing|Associated Disorders and Diseases|Biological Test Results: Active|Biological Test Results: Micromolar,11,1|3|5|7|9|13|15|19|21|23|25|29|31|33|35|37|39|41|43|45|47|49|53|55|59|65|67|71|73|77|79|81|83|85|89|91|93|95|97|99|101|103|105|107|109|113|115|119|121|123|125|129|131|133|137|139|141|143|145|1808173|1919572|1935072|1935073|1935074|1935079|1935080|1935081|1935082|1935083|1935084|1935085|1935086|1935087|1935088|1935089|1935090|1935091|1935092|1935093|1935094|1935095|1935096|1935097|1935098|1935099|1935100|1935101|1935102|1935103|1935104|1935105|1935106|1935107|1935108|1935109|1935110|1935111|1935112|1935113|1935114|1935115|1935116|1935117|1935118|1935119|1935120|1935121|1935122|1935123|1935124|1935125|1935126|1935127|1935128|1935129|1935130|1935131|1935132|1935133|1935134|1935135|1935136|1935137|1935138|1935139|1935140|1935141|1935142|1935143|1935144|1935145|1935146|1935147|1935148|1994546|1994547|1994548,20210821,"10X CHEM|A2B Chem|AbaChemScene|AbMole Bioscience|AKos Consulting & Solutions|Allbio Pharm Co., Ltd|Amadis Chemical|Angel Pharmatech Ltd.|AstaTech, Inc.|BindingDB|Biosynth|BLD Pharm|BOC Sciences|ChEMBL|DC Chemicals|Debye Scientific Co., Ltd|DTP/NCI|eNovation Chemicals|EvitaChem|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Glixx Labs Inc|Google Patents|IUPHAR/BPS Guide to PHARMACOLOGY|KEGG|Key Organics/BIONET|Mcule|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|PubChem Reference Collection|SureChEMBL|SynHet - Synthetic Heterocycles|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor|C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor
146624881,Divarasib,"Divarasib|GDC-6036|2417987-45-0|GDC6036|Divarasib [INN]|RG6330|RG-6330|Gdc 6036|E6S21PVT91|1-[(3S)-4-[7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one|RO7435846|1-((3S)-4-((7m)-7-(6-Amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one|2-Propen-1-one, 1-((3S)-4-((7R)-7-(6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl)-6-chloro-8-fluoro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)-4-quinazolinyl)-3-methyl-1-piperazinyl)-|2417917-17-8|1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((2S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one|1-{(3S)-4-[(7M)-7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-{[(2S)-1-methylpyrrolidin-2-yl]methoxy}quinazolin-4-yl]-3-methylpiperazin-1-yl}prop-2-en-1-one|2-Propen-1-one, 1-[(3S)-4-[(7R)-7-[6-amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl]-6-chloro-8-fluoro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-4-quinazolinyl]-3-methyl-1-piperazinyl]-|Divarasib [WHO-DD]|DIVARASIB [USAN]|UNII-E6S21PVT91|CHEMBL5095236|SCHEMBL22028856|GTPL11963|GDC 6036 [WHO-DD]|ZRBPIAWWRPFDPY-IRXDYDNUSA-N|BDBM535152|GLXC-25585|GLXC-27763|EX-A5694|US11236068, Example 17a|US11236068, Example 17b|KRAS G12C Inhibitor GDC-6036|NSC841802|AT41886|NSC-841802|MS-30794|HY-145928|CS-0435408|RO-7435846|1-((3S)-4-(7-(6-Amino-4-methyl-3-(trifluoromethyl)-2-pyridyl)-6-chloro-8-fluoro-2-(((2S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one|1-((3S)-4-(7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one|1-((S)-4-((R)-7-(6-Amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one|1-[(3S)-4-[(7R)-7-[6-Amino-4-methyl-3-(trifluoromethyl)-2-pyridinyl]-6-chloro-8-fluoro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-4-quinazolinyl]-3-methyl-1-piperazinyl]-2-propen-1-one",622.100,C29H32ClF4N7O2,101.000,997.000,5.400,43,1,12,6,"InChI=1S/C29H32ClF4N7O2/c1-5-21(42)40-9-10-41(16(3)13-40)27-18-12-19(30)22(26-23(29(32,33)34)15(2)11-20(35)36-26)24(31)25(18)37-28(38-27)43-14-17-7-6-8-39(17)4/h5,11-12,16-17H,1,6-10,13-14H2,2-4H3,(H2,35,36)/t16-,17-/m0/s1",C[C@H]1CN(CCN1C2=NC(=NC3=C(C(=C(C=C32)Cl)C4=C(C(=CC(=N4)N)C)C(F)(F)F)F)OC[C@@H]5CCCN5C)C(=O)C=C,ZRBPIAWWRPFDPY-IRXDYDNUSA-N,1-[(3S)-4-[7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one,621.224,621.224,0,1,0,2,2,0,0,0,0,4,441,137,"",Biological Test Results|Interactions and Pathways|Classification|Drug and Medication Information|Literature|Patents|Associated Disorders and Diseases|Biological Test Results: Active|Biological Test Results: Micromolar,9,1|3|5|7|9|13|15|19|21|23|25|29|33|35|37|39|41|43|45|47|49|53|55|59|65|67|71|73|77|79|81|83|85|89|91|93|95|97|99|101|103|105|107|109|113|115|119|121|123|125|129|131|133|137|139|141|143|145|1806303|1871172|1871173|1871174|1997345|2016477|2016480|2016481,20200627,"10X CHEM|A2B Chem|AbaChemScene|AbMole Bioscience|Allbio Pharm Co., Ltd|Amadis Chemical|Angel Pharmatech Ltd.|AstaTech, Inc.|Axon Medchem|BindingDB|BOC Sciences|ChEMBL|ChemIDplus|ChemShuttle|DTP/NCI|ECI Group, LCSB, University of Luxembourg|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Glixx Labs Inc|Google Patents|InvivoChem|IUPHAR/BPS Guide to PHARMACOLOGY|Key Organics/BIONET|Mcule|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|Probes & Drugs portal|PubChem Reference Collection|Starshine Chemical|SureChEMBL|SynHet - Synthetic Heterocycles|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor|C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor
134325731,KRas G12C inhibitor 3,"KRas G12C inhibitor 3|CHEMBL4648852|2206735-75-1|SCHEMBL19947721|BDBM50539761|AKOS040733548|DA-74791|HY-112493|CS-0046138|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",586.100,C32H36ClN7O2,88.800,1010.000,4.700,42,0,8,7,"InChI=1S/C32H36ClN7O2/c1-3-29(41)40-18-17-39(19-23(40)12-14-34)31-25-13-16-38(28-11-5-8-22-7-4-10-26(33)30(22)28)20-27(25)35-32(36-31)42-21-24-9-6-15-37(24)2/h3-5,7-8,10-11,23-24H,1,6,9,12-13,15-21H2,2H3/t23-,24-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,IYDWXYZUEBUWCQ-ZEQRLZLVSA-N,"2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",585.262,585.262,0,1,0,2,2,0,0,0,0,1,47,15,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar|Biological Test Results: Nanomolar,7,1652101|1652112|1652113|1652114|1652117|1652126|1652127|1652128|1652129|1652130|1652131|1652132|1652133|1652137|1652138|1652139|1652140|1652141|1652142|1652143|1652144|1652145|1652146|1652147,20180623,"AbaChemScene|AKos Consulting & Solutions|BindingDB|BOC Sciences|ChEMBL|Debye Scientific Co., Ltd|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
138678754,KRAS G12C inhibitor 15,"KRAS G12C inhibitor 15|2349393-21-9|CHEMBL4461434|SCHEMBL21050629|GTPL10677|BDBM50527057|AKOS040733539|compound 25 [PMID: 32023060]|(2R,4aR)-11-Chloro-9-fluoro-10-(2-fluoro-6-hydroxyphenyl)-2,6-dimethyl-3-(prop-2-enoyl)-2,3,4,4a-tetrahydro-1H-pyrazino[1',2':4,5]pyrazino[2,3-c]quinolin-5(6H)-one|DA-74788|MS-29265|HY-125873|CS-0102607|G16995|(4R,7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-4,9-dimethyl-5-prop-2-enoyl-2,5,9,12-tetrazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-8-one",498.900,C25H21ClF2N4O3,77.000,867.000,3.900,35,1,7,2,"InChI=1S/C25H21ClF2N4O3/c1-4-19(34)31-11-17-25(35)30(3)16-9-29-23-13(24(16)32(17)10-12(31)2)8-14(26)20(22(23)28)21-15(27)6-5-7-18(21)33/h4-9,12,17,33H,1,10-11H2,2-3H3/t12-,17-/m1/s1",C[C@@H]1CN2[C@H](CN1C(=O)C=C)C(=O)N(C3=C2C4=CC(=C(C(=C4N=C3)F)C5=C(C=CC=C5F)O)Cl)C,XDVMVEOFPVCHEL-SJKOYZFVSA-N,"(4R,7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-4,9-dimethyl-5-prop-2-enoyl-2,5,9,12-tetrazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-8-one",498.127,498.127,0,1,0,2,2,0,0,0,0,4,21,10,"",Biological Test Results|Interactions and Pathways|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,7,1605000|1605001|1605002|1605003|1605004|1605005|1605006|1605007|1605008|1605009|1605010|1605011|1605012|1605013|1605014|1605015|1605016|1605017|1605018|1605019|1605020|1605021|1605022|1605023|1605024|1605025|1605026|1605027|1605028|1605029|1605030|1605031,20190720,"10X CHEM|A2B Chem|AbaChemScene|AKos Consulting & Solutions|Amadis Chemical|AstaTech, Inc.|BindingDB|BOC Sciences|ChEMBL|Combi-Blocks|Debye Scientific Co., Ltd|eNovation Chemicals|Google Patents|InvivoChem|IUPHAR/BPS Guide to PHARMACOLOGY|Key Organics/BIONET|Mcule|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|SynHet - Synthetic Heterocycles|TargetMol|Thieme Chemistry",Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Research and Development|Subscription Services,""
156124862,KRAS G12D inhibitor 5,"KRAS G12D inhibitor 5|2621928-53-6|CHEMBL4857438|SCHEMBL23053408|EX-A5769|BDBM50579600|AKOS040757907|DA-64782|HY-139894|CS-0256221|5-chloro-4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]naphthalen-2-ol",593.100,C31H31ClF2N6O2,86.600,976.000,5.400,42,2,10,5,"InChI=1S/C31H31ClF2N6O2/c32-24-4-1-3-17-9-21(41)10-22(25(17)24)27-26(34)28-23(12-35-27)29(39-14-19-5-6-20(15-39)36-19)38-30(37-28)42-16-31-7-2-8-40(31)13-18(33)11-31/h1,3-4,9-10,12,18-20,36,41H,2,5-8,11,13-16H2/t18-,19?,20?,31+/m1/s1",C1C[C@]2(C[C@H](CN2C1)F)COC3=NC4=C(C(=NC=C4C(=N3)N5CC6CCC(C5)N6)C7=C8C(=CC(=C7)O)C=CC=C8Cl)F,MREIKMRVSAOCHR-RMIANRRMSA-N,"5-chloro-4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]naphthalen-2-ol",592.217,592.217,0,1,0,4,2,2,0,0,0,1,10,5,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar|Biological Test Results: Nanomolar,7,1785782|1806843|1919707,20210821,"AbaChemScene|AKos Consulting & Solutions|BindingDB|BOC Sciences|ChEMBL|Debye Scientific Co., Ltd|Excenen Pharmatech|Google Patents|InvivoChem|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156405061,KRAS G12D inhibitor 16,KRAS G12D inhibitor 16|CHEMBL4869200|2648221-12-7|SCHEMBL23409302|EX-A7709|BDBM50576730|DA-74801|HY-148260|CS-0617427,682.600,C32H39IN6O3,86.200,926.000,4.400,42,2,9,7,"InChI=1S/C32H39IN6O3/c33-26-3-1-2-21-14-24(40)15-28(29(21)26)38-9-6-25-27(18-38)35-31(36-30(25)39-16-22-4-5-23(17-39)34-22)42-20-32(7-8-32)19-37-10-12-41-13-11-37/h1-3,14-15,22-23,34,40H,4-13,16-20H2",C1CC2CN(CC1N2)C3=NC(=NC4=C3CCN(C4)C5=C6C(=CC(=C5)O)C=CC=C6I)OCC7(CC7)CN8CCOCC8,MWSOTQXCCZLZSY-UHFFFAOYSA-N,"4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-[[1-(morpholin-4-ylmethyl)cyclopropyl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]-5-iodonaphthalen-2-ol",682.213,682.213,0,1,0,2,0,2,0,0,0,1,14,5,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar|Biological Test Results: Nanomolar,7,1777607|1777608|1919966,20210821,"AbaChemScene|Amadis Chemical|BindingDB|ChEMBL|Debye Scientific Co., Ltd|Excenen Pharmatech|Google Patents|InvivoChem|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156125323,KRAS G12D inhibitor 1,"KRAS G12D inhibitor 1|CHEMBL4876040|4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynylnaphthalen-2-ol|2621928-43-4|SCHEMBL23053887|EX-A5768|BDBM50579597|HY-134811|CS-0159103|4-(4-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynylnaphthalen-2-ol",582.600,C33H32F2N6O2,86.600,1070.000,5.100,43,2,10,6,"InChI=1S/C33H32F2N6O2/c1-2-19-5-3-6-20-11-24(42)12-25(27(19)20)29-28(35)30-26(14-36-29)31(40-16-22-7-8-23(17-40)37-22)39-32(38-30)43-18-33-9-4-10-41(33)15-21(34)13-33/h1,3,5-6,11-12,14,21-23,37,42H,4,7-10,13,15-18H2/t21-,22?,23?,33+/m1/s1",C#CC1=CC=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OC[C@@]78CCCN7C[C@@H](C8)F)O,HQVNRYKTWPMSGZ-ADTQRWQWSA-N,"4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynylnaphthalen-2-ol",582.255,582.255,0,1,0,4,2,2,0,0,0,1,8,3,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar|Biological Test Results: Nanomolar,7,1785782|1806843|1919707,20210821,AbaChemScene|Amadis Chemical|BindingDB|ChEMBL|EvitaChem|Excenen Pharmatech|Google Patents|InvivoChem|MedChemexpress MCE|MolGenie|MolPort|Nature Chemical Biology|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Research and Development,""
138678786,KRAS G12C inhibitor 16,"KRAS G12C inhibitor 16|CHEMBL4567284|2349392-79-4|SCHEMBL21050662|BDBM50527046|AKOS040733540|DA-64766|PD168385|HY-125874|CS-0102608|1-[(7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-14-methyl-9-oxa-2,5,12-triazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-5-yl]prop-2-en-1-one",453.900,C24H21ClFN3O3,65.900,729.000,4.300,32,1,6,2,"InChI=1S/C24H21ClFN3O3/c1-3-20(31)28-7-8-29-14(11-28)12-32-19-10-27-23-13(2)21(16(25)9-15(23)24(19)29)22-17(26)5-4-6-18(22)30/h3-6,9-10,14,30H,1,7-8,11-12H2,2H3/t14-/m1/s1",CC1=C2C(=CC(=C1C3=C(C=CC=C3F)O)Cl)C4=C(C=N2)OC[C@@H]5N4CCN(C5)C(=O)C=C,BATBWOGNVDIMCI-CQSZACIVSA-N,"1-[(7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-14-methyl-9-oxa-2,5,12-triazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-5-yl]prop-2-en-1-one",453.126,453.126,0,1,0,1,1,0,0,0,0,1,16,6,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,6,1605003|1605004|1605005|1605006,20190720,"AbaChemScene|AKos Consulting & Solutions|BindingDB|BOC Sciences|ChEMBL|Debye Scientific Co., Ltd|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|SynHet - Synthetic Heterocycles|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156785232,KRAS mutant protein inhibitor 1,KRAS mutant protein inhibitor 1|CHEMBL4859820|2642305-16-4|BDBM50579589|AKOS040757929|DA-74813|HY-132920|CS-0254753,654.900,C31H27Cl3FN7O2,119.000,1200.000,5.400,44,1,8,5,"InChI=1S/C31H27Cl3FN7O2/c1-5-22(43)40-8-10-41(11-9-40)29-17-12-21(34)27(23-24(35)19(32)13-20(33)25(23)37)39-30(17)42(31(44)18(29)14-36)28-16(4)6-7-38-26(28)15(2)3/h5-7,12-13,15H,1,8-11,37H2,2-4H3",CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=C(C2=O)C#N)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C(=CC(=C5F)Cl)Cl)N,IBNSEKBMYPAXNN-UHFFFAOYSA-N,"7-(2-amino-3,5-dichloro-6-fluorophenyl)-6-chloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(4-prop-2-enoylpiperazin-1-yl)-1,8-naphthyridine-3-carbonitrile",653.128,653.128,0,1,0,0,0,0,0,0,0,1,8,2,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,6,1785778|1785779|1785780|1785781,20211110,"AbaChemScene|AKos Consulting & Solutions|BindingDB|BOC Sciences|ChEMBL|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156405076,KRAS G12D inhibitor 8,"KRAS G12D inhibitor 8|CHEMBL4875572|2648221-05-8|SCHEMBL23409321|BDBM50576725|DA-54680|HY-143599|CS-0373948|5-bromo-4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-[[1-[[(3R)-3-fluoropyrrolidin-1-yl]methyl]cyclopropyl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol",637.600,C32H38BrFN6O2,77.000,950.000,5.400,42,2,9,7,"InChI=1S/C32H38BrFN6O2/c33-26-3-1-2-20-12-24(41)13-28(29(20)26)39-11-7-25-27(17-39)36-31(37-30(25)40-15-22-4-5-23(16-40)35-22)42-19-32(8-9-32)18-38-10-6-21(34)14-38/h1-3,12-13,21-23,35,41H,4-11,14-19H2/t21-,22?,23?/m1/s1",C1CN(C[C@@H]1F)CC2(CC2)COC3=NC4=C(CCN(C4)C5=C6C(=CC(=C5)O)C=CC=C6Br)C(=N3)N7CC8CCC(C7)N8,WVLFHNZKPFLBQZ-DDRJZQQSSA-N,"5-bromo-4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-[[1-[[(3R)-3-fluoropyrrolidin-1-yl]methyl]cyclopropyl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-7-yl]naphthalen-2-ol",636.222,636.222,0,1,0,3,1,2,0,0,0,1,16,3,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,6,1777607|1777608|1919966,20210821,"AbaChemScene|BindingDB|BLD Pharm|ChEMBL|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
146389610,KRAS inhibitor-20,"KRAS inhibitor-20|CHEMBL5077647|1-[(3S)-4-[(6R,7R)-7-[3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl]-6-methyl-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydroquinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one|2411786-32-6|SCHEMBL21733761|NRFWNEBUKRLYDL-BVOGOJNSSA-N|BDBM50586341|DA-74810|HY-151287|CS-0610947",604.700,C31H40F4N6O2,87.800,988.000,5.400,43,1,11,6,"InChI=1S/C31H40F4N6O2/c1-6-25(42)40-10-11-41(19(4)15-40)29-22-12-17(2)21(26-27(31(33,34)35)18(3)13-23(36)28(26)32)14-24(22)37-30(38-29)43-16-20-8-7-9-39(20)5/h6,13,17,19-21H,1,7-12,14-16,36H2,2-5H3/t17-,19+,20+,21-/m1/s1",C[C@@H]1CC2=C(C[C@H]1C3=C(C(=CC(=C3F)N)C)C(F)(F)F)N=C(N=C2N4CCN(C[C@@H]4C)C(=O)C=C)OC[C@@H]5CCCN5C,NRFWNEBUKRLYDL-BVOGOJNSSA-N,"1-[(3S)-4-[(6R,7R)-7-[3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl]-6-methyl-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydroquinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one",604.315,604.315,0,1,0,4,4,0,0,0,0,1,14,4,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,6,1828009|1828010,20200627,"AbaChemScene|BindingDB|ChEMBL|Debye Scientific Co., Ltd|ECI Group, LCSB, University of Luxembourg|Google Patents|InvivoChem|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
137297882,KRAS G12C inhibitor 47,KRAS G12C inhibitor 47|CHEMBL4517656|SCHEMBL20296493|BDBM50514377|DA-64776|PD168338|HY-146537|CS-0437236|2253119-24-1,547.000,C30H28ClFN4O3,76.500,954.000,5.400,39,1,4,5,"InChI=1S/C30H28ClFN4O3/c1-4-27(38)34-12-14-35(15-13-34)29-21-16-22(31)20(28-23(32)9-7-11-26(28)37)17-25(21)36(30(39)33-29)24-10-6-5-8-19(24)18(2)3/h4-11,16-18,37H,1,12-15H2,2-3H3",CC(C)C1=CC=CC=C1N2C3=CC(=C(C=C3C(=NC2=O)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C=CC=C5F)O,AFCLJUXYULJJII-UHFFFAOYSA-N,6-chloro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-propan-2-ylphenyl)-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-2-one,546.183,546.183,0,1,0,0,0,0,0,0,0,1,76,7,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,6,1559566|1559567|1559568|1559569|1559570|1559571|1559572|1559573|1559574|1559575|1559576|1559577|1559578|1559579,20190126,"AbaChemScene|BindingDB|ChEMBL|Debye Scientific Co., Ltd|Google Patents|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
138678756,KRAS G12C inhibitor 14,"KRAS G12C inhibitor 14|2349393-95-7|CHEMBL4452974|SCHEMBL21050632|BDBM50527059|AKOS040733538|MS-29015|HY-125872|CS-0102606|G16994|(7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-9-methyl-5-prop-2-enoyl-2,5,9,12-tetrazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-8-one",484.900,C24H19ClF2N4O3,77.000,836.000,3.500,34,1,7,2,"InChI=1S/C24H19ClF2N4O3/c1-3-18(33)30-7-8-31-16(11-30)24(34)29(2)15-10-28-22-12(23(15)31)9-13(25)19(21(22)27)20-14(26)5-4-6-17(20)32/h3-6,9-10,16,32H,1,7-8,11H2,2H3/t16-/m1/s1",CN1C2=C(C3=CC(=C(C(=C3N=C2)F)C4=C(C=CC=C4F)O)Cl)N5CCN(C[C@@H]5C1=O)C(=O)C=C,NZIBTXKFKUORFB-MRXNPFEDSA-N,"(7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-9-methyl-5-prop-2-enoyl-2,5,9,12-tetrazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-8-one",484.111,484.111,0,1,0,1,1,0,0,0,0,1,17,6,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,6,1605000|1605003|1605004|1605005|1605006|1605007|1605008|1605009|1605010|1605011,20190720,"10X CHEM|A2B Chem|AbaChemScene|AKos Consulting & Solutions|Amadis Chemical|AstaTech, Inc.|BindingDB|BOC Sciences|ChEMBL|Google Patents|InvivoChem|Key Organics/BIONET|Mcule|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|SynHet - Synthetic Heterocycles|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
132145444,KRAS G12C inhibitor 5,"KRAS G12C inhibitor 5|2158297-63-1|CHEMBL4648671|2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-naphthalen-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile|2-((S)-1-Acryloyl-4-(2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-7-(naphthalen-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)piperazin-2-yl)acetonitrile|SCHEMBL19617338|BDBM50539754|AKOS040733550|DA-64765|PD195342|HY-114168|CS-0078097",551.700,C32H37N7O2,88.800,969.000,4.100,41,0,8,7,"InChI=1S/C32H37N7O2/c1-3-30(40)39-19-18-38(20-24(39)13-15-33)31-27-14-17-37(29-12-6-9-23-8-4-5-11-26(23)29)21-28(27)34-32(35-31)41-22-25-10-7-16-36(25)2/h3-6,8-9,11-12,24-25H,1,7,10,13-14,16-22H2,2H3/t24-,25-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=CC=CC=C54)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,OBKBMFMBHWUYHS-DQEYMECFSA-N,"2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-naphthalen-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",551.301,551.301,0,1,0,2,2,0,0,0,0,1,86,22,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,6,1652101|1652110|1652111|1652120|1652121|1652122|1652123|1652124|1652153,20180129,"AbaChemScene|AKos Consulting & Solutions|BenchChem|BindingDB|BLD Pharm|BOC Sciences|ChEMBL|CymitQuimica|Debye Scientific Co., Ltd|EvitaChem|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|Probes & Drugs portal|Starshine Chemical|SureChEMBL|TargetMol|THE BioTek",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
146389359,KRAS inhibitor-21,"KRAS inhibitor-21|CHEMBL5074707|2411786-50-8|SCHEMBL21733484|BDBM50586343|DA-74811|HY-151288|CS-0610949|1-[(3S)-4-[(6R,7R)-7-(3-hydroxynaphthalen-1-yl)-6-methyl-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydroquinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one",555.700,C33H41N5O3,82.000,919.000,5.600,41,1,7,6,"InChI=1S/C33H41N5O3/c1-5-31(40)37-13-14-38(22(3)19-37)32-29-15-21(2)27(28-17-25(39)16-23-9-6-7-11-26(23)28)18-30(29)34-33(35-32)41-20-24-10-8-12-36(24)4/h5-7,9,11,16-17,21-22,24,27,39H,1,8,10,12-15,18-20H2,2-4H3/t21-,22+,24+,27-/m1/s1",C[C@@H]1CC2=C(C[C@H]1C3=CC(=CC4=CC=CC=C43)O)N=C(N=C2N5CCN(C[C@@H]5C)C(=O)C=C)OC[C@@H]6CCCN6C,QFHHSQNNGXFEMZ-SMAWTLEESA-N,"1-[(3S)-4-[(6R,7R)-7-(3-hydroxynaphthalen-1-yl)-6-methyl-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydroquinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one",555.321,555.321,0,1,0,4,4,0,0,0,0,1,16,1,"",Biological Test Results|Classification|Literature|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,6,1828009|1828010,20200627,"AbaChemScene|BindingDB|ChEMBL|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156495623,KRAS ligand 3,"KRAS ligand 3|SCHEMBL23526003|BDBM609411|US11702418, Example 6-1|HY-161234|CS-0997821|(R)-4-methyl-N-(1-(2-methyl-3-(trifluoromethyl)phenyl)ethyl)-7-(4-methylpiperazin-1-yl)phthalazin-1-amine",443.500,C24H28F3N5,44.300,609.000,4.900,32,1,8,4,"InChI=1S/C24H28F3N5/c1-15-19(6-5-7-22(15)24(25,26)27)16(2)28-23-21-14-18(32-12-10-31(4)11-13-32)8-9-20(21)17(3)29-30-23/h5-9,14,16H,10-13H2,1-4H3,(H,28,30)/t16-/m1/s1",CC1=C(C=CC=C1C(F)(F)F)[C@@H](C)NC2=C3C=C(C=CC3=C(N=N2)C)N4CCN(CC4)C,AUDXCBLEOQOTQY-MRXNPFEDSA-N,4-methyl-7-(4-methylpiperazin-1-yl)-N-[(1R)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]phthalazin-1-amine,443.23,443.23,0,1,0,1,1,0,0,0,0,0,5,1,"",Biological Test Results|Classification|Patents|Biological Test Results: Active|Biological Test Results: Micromolar|Biological Test Results: Nanomolar,6,1919578|1919580,20210821,AbaChemScene|BindingDB|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
138460837,KRAS G12C inhibitor 61,"KRAS G12C inhibitor 61|2300967-40-0|SCHEMBL20805274|BDBM550333|DA-54676|HY-156549|CS-0884179|US11306087, Ex. # 3|4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one|4-((2S,5R,M)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-6-chloro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one",590.100,C31H33ClFN7O2,108.000,1060.000,4.600,42,1,6,5,"InChI=1S/C31H33ClFN7O2/c1-7-24(41)38-14-19(6)39(15-18(38)5)29-20-13-21(32)27(25-22(33)9-8-10-23(25)34)36-30(20)40(31(42)37-29)28-17(4)11-12-35-26(28)16(2)3/h7-13,16,18-19H,1,14-15,34H2,2-6H3/t18-,19+/m1/s1",C[C@@H]1CN([C@H](CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)Cl)C4=C(C=CC=C4F)N)C5=C(C=CN=C5C(C)C)C,HBHOIHAXRLHFTR-MOPGFXCFSA-N,"7-(2-amino-6-fluorophenyl)-6-chloro-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-1-(4-methyl-2-propan-2-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2-one",589.237,589.237,0,1,0,2,2,0,0,0,0,0,24,2,"",Biological Test Results|Classification|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,5,1806466,20190720,"AbaChemScene|BindingDB|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
667738,4-(Benzo[d]thiazol-2-ylthio)-3-chloroaniline,"4-(benzo[d]thiazol-2-ylthio)-3-chloroaniline|300809-71-6|KRAS inhibitor-9|4-(1,3-benzothiazol-2-ylsulfanyl)-3-chloroaniline|KRAS inhibitor-9?|Cambridge id 5175303|CBDivE_009171|IFLab1_000848|CHEMBL5307987|SCHEMBL19840432|HMS1414G12|AMA80971|EX-A4387|STK764096|AKOS000541330|BS-48318|DB-379571|HY-137497|CS-0139330|4-(2-Benzothiazolylthio)-3-chlorobenzenamine|E75345|4-(1,3-benzothiazol-2-ylthio)-3-chloroaniline|AE-641/32251028|SR-01000391076|SR-01000391076-1|BRD-K75536518-001-01-1|F0266-0133",292.800,C13H9ClN2S2,92.500,292.000,4.700,18,1,4,2,"InChI=1S/C13H9ClN2S2/c14-9-7-8(15)5-6-11(9)17-13-16-10-3-1-2-4-12(10)18-13/h1-7H,15H2",C1=CC=C2C(=C1)N=C(S2)SC3=C(C=C(C=C3)N)Cl,DTSNLMOLTVGCGZ-UHFFFAOYSA-N,"4-(1,3-benzothiazol-2-ylsulfanyl)-3-chloroaniline",291.99,291.99,0,1,0,0,0,0,0,0,0,3,21,6,"",Biological Test Results|Classification|Literature|Patents|Spectral Information,5,485395|492967|493162|504770|1159537|1224903|1259310|1259354|1259374|1259416|1259422|1347404|1508602|1671202|1794808|1918969|1963114,20050707,"10X CHEM|A2B Chem|AA BLOCKS|AbaChemScene|ABI Chem|AKos Consulting & Solutions|Amadis Chemical|Ambeed|AppChem|ASINEX|AstaTech, Inc.|Aurora Fine Chemicals LLC|BenchChem|Biosynth|BLD Pharm|Bradner/Qi Labs at DFCI|Broad Institute|Chem-Space.com Database|ChemBank|ChEMBL|ChemBlock|ChemBridge|ChemDB|ChemDiv|Chemenu Inc.|Chemieliva Pharmaceutical Co., Ltd|ChemShuttle|Collaborative Drug Discovery, Inc.|Combi-Blocks|Cooke Chemical Co., Ltd|CSNpharm|CymitQuimica|DC Chemicals|Debye Scientific Co., Ltd|DiRusso Lab, Biochemistry Department, University of Nebraska|DiscoveryGate|eMolecules|eNovation Chemicals|Excenen Pharmatech|Google Patents|IBM|ICCB-Longwood Screening Facility, Harvard Medical School|InvivoChem|J&H Chemical Co.,ltd|Key Organics/BIONET|LabNetwork, a WuXi AppTec Company|Lan Pharmatech|Life Chemicals|Mcule|MedChemexpress MCE|Molecule Market|MolGenie|MolPort|NextBio|Paczesny and Yang Labs, IUPUI and University of Michigan|Pan Lab, Icahn School of Medicine at Mount Sinai|PATENTSCOPE (WIPO)|Probes & Drugs portal|RR Scientific|Smolecule|Specs|Starshine Chemical|SureChEMBL|SynHet - Synthetic Heterocycles|TargetMol|The Scripps Research Institute Molecular Screening Center|TimTec|UCSC Chemical Screening Center|University of Kansas High Throughput Screening Laboratory|Vitas-M Laboratory|ZINC",Chemical Vendors|Curation Efforts|Governmental Organizations|Legacy Depositors|NIH Initiatives|Research and Development|Subscription Services,""
146472812,Ly-3499446,"LY3499446|LY-3499446|QZJ1I2EN1V|2409131-50-4|UNII-QZJ1I2EN1V|1-(4-(7-(2-Amino-7-fluoro-1,3-benzothiazol-4-yl)-6-chloro-8-fluoro-quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one|2-Propen-1-one, 1-(4-(7-2-amino-7-fluoro-4-benzothiazolyl)-6-chloro-8-fluoro-4-quinazolinyl)-1-piperazinyl)-|compound B [WO2022002018A1]|1-[4-[7-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-6-chloro-8-fluoro-quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one|compound B (WO2022002018A1)|1-[4-[7-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-6-chloro-8-fluoroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one|1-(4-(7-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-6-chloro-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one|KRASG12C?IN-13|CHEMBL5095252|SCHEMBL21839486|GTPL12066|KRAS G12C Inhibitor LY3499446|HY-164493|LY 3499446|D84872|1-(4-(7-(2-Amino-7-fluorobenzo[d]thiazol-4-yl)-6-chloro-8-fluoroquinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one|1-{4-[7-(2-AMINO-7-FLUORO-1,3-BENZOTHIAZOL-4-YL)-6-CHLORO-8-FLUOROQUINAZOLIN-4-YL]PIPERAZIN-1-YLPROP-2-EN-1-ONE",486.900,C22H17ClF2N6OS,116.000,746.000,4.400,33,1,9,3,"InChI=1S/C22H17ClF2N6OS/c1-2-15(32)30-5-7-31(8-6-30)21-12-9-13(23)16(17(25)18(12)27-10-28-21)11-3-4-14(24)20-19(11)29-22(26)33-20/h2-4,9-10H,1,5-8H2,(H2,26,29)",C=CC(=O)N1CCN(CC1)C2=NC=NC3=C(C(=C(C=C32)Cl)C4=C5C(=C(C=C4)F)SC(=N5)N)F,YNBBKDMAVRSYRE-UHFFFAOYSA-N,"1-[4-[7-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-6-chloro-8-fluoroquinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one",486.084,486.084,0,1,0,0,0,0,0,0,0,1,89,28,"",Interactions and Pathways|Classification|Drug and Medication Information|Literature|Patents,5,"",20200627,"A2B Chem|AA BLOCKS|AstaTech, Inc.|BLD Pharm|ChEMBL|ChemIDplus|eNovation Chemicals|FDA Global Substance Registration System (GSRS)|Google Patents|IUPHAR/BPS Guide to PHARMACOLOGY|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|PubChem Reference Collection|Starshine Chemical|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor|C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor
163206602,KRAS G12C inhibitor 50,"KRAS G12C inhibitor 50|SCHEMBL26124166|BDBM625377|US20230322788, Compound A4|HY-147631|2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(naphthalen-1-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile|2760354-12-7",550.700,C31H34N8O2,103.000,971.000,3.900,41,0,8,8,"InChI=1S/C31H34N8O2/c1-3-28(40)38-17-16-37(20-24(38)13-14-32)30-29-33-19-26(18-23-10-6-9-22-8-4-5-12-27(22)23)39(29)35-31(34-30)41-21-25-11-7-15-36(25)2/h3-6,8-10,12,19,24-25H,1,7,11,13,15-18,20-21H2,2H3/t24-,25-/m0/s1",CN1CCC[C@H]1COC2=NN3C(=CN=C3C(=N2)N4CCN([C@H](C4)CC#N)C(=O)C=C)CC5=CC=CC6=CC=CC=C65,OMJLVKOHXNQCJC-DQEYMECFSA-N,"2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(naphthalen-1-ylmethyl)imidazo[2,1-f][1,2,4]triazin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",550.28,550.28,0,1,0,2,2,0,0,0,0,0,12,6,"",Biological Test Results|Patents|Biological Test Results: Active|Biological Test Results: Micromolar,4,1919853,20220513,BindingDB|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
157827766,Glecirasib,"Glecirasib|KRAS G12C inhibitor 36|KRAS G12C inhibitor 62|2657613-87-9|2658588-10-2|glecirasib [INN]|UP75WH4QKM|CHEMBL5314518|SCHEMBL23830094|EX-A8185Q|JAB21822|JAB-21822|NSC855878|AT45426|NSC-855878|DA-54672|HY-143589|HY-157067|CS-0373885|CS-0904896|7-(2-amino-3,4,5,6-tetrafluorophenyl)-6-chloro-1,2-dihydro-1- [4-methyl-2-(1-methylethyl)-3-pyridinyl]-2-oxo-4-[4-(1-oxo-2-propen-1-yl)-1-piperazinyl]-1,8-Naphthyridine-3-carbonitrile",640.000,C31H26ClF4N7O2,119.000,1240.000,4.400,45,1,11,5,"InChI=1S/C31H26ClF4N7O2/c1-5-19(44)41-8-10-42(11-9-41)29-16-12-18(32)27(20-21(33)22(34)23(35)24(36)25(20)38)40-30(16)43(31(45)17(29)13-37)28-15(4)6-7-39-26(28)14(2)3/h5-7,12,14H,1,8-11,38H2,2-4H3",CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=C(C2=O)C#N)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C(=C(C(=C5F)F)F)F)N,QRRJEUIQLZNPIO-UHFFFAOYSA-N,"7-(2-amino-3,4,5,6-tetrafluorophenyl)-6-chloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(4-prop-2-enoylpiperazin-1-yl)-1,8-naphthyridine-3-carbonitrile",639.177,639.177,0,1,0,0,0,0,0,0,0,0,26,4,"",Classification|Drug and Medication Information|Patents|Associated Disorders and Diseases,4,"",20211203,"AbaChemScene|AstaTech, Inc.|BLD Pharm|ChEMBL|Debye Scientific Co., Ltd|DTP/NCI|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Google Patents|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
155332312,Garsorasib,"Garsorasib|2559761-14-5|Garsorasib [INN]|P491NE9G6Z|D-1553|UNII-P491NE9G6Z|4-((2S,5R)-4-Acryloyl-2,5-dimethylpiperazin-1-yl)-7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-6-fluoropyrido(2,3-d)pyrimidin-2(1H)-one|Pyrido(2,3-d)pyrimidin-2(1H)-one, 7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropyl-5-pyrimidinyl)-4-((2S,5R)-2,5-dimethyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)-6-fluoro-|D 1553|7-(2-Amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoropyrido[2,3-d]pyrimidin-2-one|Garsorasib [WHO-DD]|CHEMBL5095066|SCHEMBL22704797|GLXC-26938|KRAS G12C Inhibitor D-1553|EX-A5695|AKOS040757847|DA-63706|MS-30601|HY-145571|CS-0376098|G86338",598.600,C32H32F2N8O2,121.000,1150.000,3.100,44,1,8,6,"InChI=1S/C32H32F2N8O2/c1-4-24(43)40-13-17(3)41(14-16(40)2)30-20-12-22(34)28(25-21(33)6-5-7-23(25)35)38-31(20)42(32(44)39-30)29-26(18-8-9-18)36-15-37-27(29)19-10-11-19/h4-7,12,15-19H,1,8-11,13-14,35H2,2-3H3/t16-,17+/m1/s1",C[C@@H]1CN([C@H](CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)N)C5=C(N=CN=C5C6CC6)C7CC7,DKFRWZJCNPETGI-SJORKVTESA-N,"7-(2-amino-6-fluorophenyl)-1-(4,6-dicyclopropylpyrimidin-5-yl)-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoropyrido[2,3-d]pyrimidin-2-one",598.262,598.262,0,1,0,2,2,0,0,0,0,0,35,18,"",Classification|Drug and Medication Information|Patents|Associated Disorders and Diseases,4,"",20210123,"10X CHEM|A2B Chem|AbaChemScene|AKos Consulting & Solutions|Amadis Chemical|AstaTech, Inc.|Biosynce Pharmatech|BOC Sciences|ChEMBL|ChemIDplus|Debye Scientific Co., Ltd|eNovation Chemicals|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Glixx Labs Inc|Google Patents|InvivoChem|Key Organics/BIONET|Mcule|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|PubChem Reference Collection|Starshine Chemical|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1902 - Ras Inhibitor|C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor
22135411,3-(1H-Pyrrol-3-yl)-propionic acid,134448-22-9|3-(1H-pyrrol-3-yl)propanoic acid|3-(PYRROL-3-YL)-PROPIONIC ACID|3-(Pyrrol-3-yl)propionic acid|3-(1H-Pyrrol-3-yl)-propionic acid|MFCD09800535|omega-(2-carboxyethyl)pyrrole|SCHEMBL608745|3-(Pyrrol-3-yl)propionicacid|DTXSID20622728|3-(1h-Pyrrol-3-yl)propanoicacid|AKOS006329051|SB62323|AS-38249|RMC-9805; KRAS G12D inhibitor 18|CS-0170810|800-959-2,139.150,C7H9NO2,53.100,125.000,0.500,10,2,2,3,"InChI=1S/C7H9NO2/c9-7(10)2-1-6-3-4-8-5-6/h3-5,8H,1-2H2,(H,9,10)",C1=CNC=C1CCC(=O)O,RJYXUUHRYSSIKQ-UHFFFAOYSA-N,3-(1H-pyrrol-3-yl)propanoic acid,139.063,139.063,0,1,0,0,0,0,0,0,0,11,181,51,"",Classification|Literature|Patents|Safety and Hazards,4,"",20071205,"001Chemical|10X CHEM|3WAY PHARM INC|A&J Pharmtech CO., LTD.|A2B Chem|AA BLOCKS|AbaChemScene|abcr GmbH|Achemica|Achemo Scientific Limited|AHH Chemical co.,ltd|AKos Consulting & Solutions|Alfa Chemistry|Alichem|Amadis Chemical|Ambeed|Ambinter|Angel Pharmatech Ltd.|Angene Chemical|Annker Organics|Apexmol|AppChem|Assembly Blocks Pvt. Ltd.|AstaTech, Inc.|Aurora Fine Chemicals LLC|Aurum Pharmatech LLC|BenchChem|BePharm Ltd.|Bic Biotech|BLD Pharm|BOC Sciences|Chem-Space.com Database|Chemenu Inc.|Chemhere|Chemieliva Pharmaceutical Co., Ltd|ChemMol|ChemShuttle|ChemSpider|ChemTik|Collaborative Drug Discovery, Inc.|Cooke Chemical Co., Ltd|CymitQuimica|DiscoveryGate|eMolecules|eNovation Chemicals|EPA DSSTox|Finetech Industry Limited|Google Patents|Hairui Chemical|IBM|J&H Chemical Co.,ltd|Japan Chemical Substance Dictionary (Nikkaji)|Key Organics/BIONET|LabNetwork, a WuXi AppTec Company|Mcule|MolCore|MolGenie|MolPort|MuseChem|OXCHEM CORPORATION|PATENTSCOPE (WIPO)|Pharmacore Co., Limited|PubChem Reference Collection|RR Scientific|Santa Cruz Biotechnology, Inc.|Smolecule|Springer Nature|Starshine Chemical|SureChEMBL|Synblock Inc|SynHet - Synthetic Heterocycles|THE BioTek|Tractus|Wikidata|Wutech|ZINC",Chemical Vendors|Curation Efforts|Governmental Organizations|Journal Publishers|Legacy Depositors|Research and Development|Subscription Services,""
118019082,KRAS(G12C) inhibitor 1,KRAS(G12C) inhibitor 1|KRAS(G12C)-IN-1|CHEMBL4570801|SCHEMBL16647122|GLXC-20258|1-(4-(6-Chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one,462.900,C25H20ClFN4O2,69.600,721.000,5.100,33,1,6,3,"InChI=1S/C25H20ClFN4O2/c1-2-21(33)30-7-9-31(10-8-30)25-19-13-20(26)22(23(27)24(19)28-14-29-25)18-12-16(32)11-15-5-3-4-6-17(15)18/h2-6,11-14,32H,1,7-10H2",C=CC(=O)N1CCN(CC1)C2=NC=NC3=C(C(=C(C=C32)Cl)C4=CC(=CC5=CC=CC=C54)O)F,JIPIHCUZVBBERR-UHFFFAOYSA-N,1-[4-[6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one,462.126,462.126,0,1,0,0,0,0,0,0,0,0,52,10,"",Biological Test Results|Classification|Patents,3,1621758|1621759|1621760|1621761|1621762|1621793|1621794|1621795|1621796|1621797,20160223,ChEMBL|Glixx Labs Inc|Google Patents|IBM|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156472638,KRAS G12C inhibitor 19,"KRAS G12C inhibitor 19|2649788-46-3|Olomorasib|LY3537982|2-Amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluorobenzo[b]thiophene-3-carbonitrile|olomorasib [INN]|C2VJ83PSN7|SCHEMBL23496727|EX-A6653|NSC853962|AKOS040757943|NSC-853962|DA-64768|HY-132980|CS-0311440|LY-3537982|F78016|2-amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-Benzo[b]thiophene-3-carbonitrile|2-Amino-4-[(4R)-8-chloro-10-fluoro-12-oxo-3-(prop-2-enoyl)-2,3,4,4a,5,6-hexahydro-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-1-benzothiophene-3-carbonitrile|4-((S)-3-ACRYLOYL-8-CHLORO-10-FLUORO-12-OXO-2,3,4,4A,5,6-HEXAHYDRO-1H,12H-BENZO[B]PYRAZINO[1,2-E][1,5]OXAZOCIN-9-YL)-2-AMINO-7-FLUOROBENZO[B]THIOPHENE-3-CARBONITRILE|4-[(13aS)-10-chloro-8-fluoro-6-oxo-2-prop-2-enoyl-1,3,4,12,13,13a-hexahydropyrazino[2,1-d][1,5]benzoxazocin-9-yl]-2-amino-7-fluoro-1-benzothiophene-3-carbonitrile|Benzo[b]thiophene-3-carbonitrile, 2-amino-4-[(4aS)-8-chloro-10-fluoro-2,3,4,4a,5,6-hexahydro-12-oxo-3-(1-oxo-2-propen-1-yl)-1H,12H-pyrazino[2,1-d][1,5]benzoxazocin-9-yl]-7-fluoro-, (4R)-",529.000,C25H19ClF2N4O3S,128.000,952.000,4.800,36,1,8,2,"InChI=1S/C25H19ClF2N4O3S/c1-2-18(33)31-6-7-32-12(11-31)5-8-35-22-14(25(32)34)9-17(28)20(21(22)26)13-3-4-16(27)23-19(13)15(10-29)24(30)36-23/h2-4,9,12H,1,5-8,11,30H2/t12-/m0/s1",C=CC(=O)N1CCN2[C@H](C1)CCOC3=C(C(=C(C=C3C2=O)F)C4=C5C(=C(SC5=C(C=C4)F)N)C#N)Cl,OZUPICRWMLEFCS-LBPRGKRZSA-N,"4-[(13aS)-10-chloro-8-fluoro-6-oxo-2-prop-2-enoyl-1,3,4,12,13,13a-hexahydropyrazino[2,1-d][1,5]benzoxazocin-9-yl]-2-amino-7-fluoro-1-benzothiophene-3-carbonitrile",528.083,528.083,0,1,0,1,1,0,0,0,0,0,60,23,"",Classification|Drug and Medication Information|Patents,3,"",20210821,"10X CHEM|A2B Chem|AA BLOCKS|AbaChemScene|AKos Consulting & Solutions|Amadis Chemical|AstaTech, Inc.|BLD Pharm|BOC Sciences|Chem-Space.com Database|Debye Scientific Co., Ltd|DTP/NCI|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|SynHet - Synthetic Heterocycles|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163196440,KRAS inhibitor-11,"KRAS inhibitor-11|CHEMBL5073912|2761218-40-8|BDBM50587374|HY-145436|CS-0374241|(13S,16S,19S)-N-[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]-16-[(2S)-butan-2-yl]-5,8,14,17-tetraoxo-6,9,15,18,22,23,24-heptazatricyclo[20.2.1.09,13]pentacosa-1(25),23-diene-19-carboxamide",617.700,C29H47N9O6,211.000,1060.000,0.200,44,5,8,7,"InChI=1S/C29H47N9O6/c1-5-18(4)25-29(44)32-20(27(42)33-21(26(30)41)14-17(2)3)11-13-37-16-19(35-36-37)8-6-10-23(39)31-15-24(40)38-12-7-9-22(38)28(43)34-25/h16-18,20-22,25H,5-15H2,1-4H3,(H2,30,41)(H,31,39)(H,32,44)(H,33,42)(H,34,43)/t18-,20-,21-,22-,25-/m0/s1",CC[C@H](C)[C@H]1C(=O)N[C@@H](CCN2C=C(CCCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N1)N=N2)C(=O)N[C@@H](CC(C)C)C(=O)N,ZTEFZLXCKMSXDP-HLPFYSDJSA-N,"(13S,16S,19S)-N-[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]-16-[(2S)-butan-2-yl]-5,8,14,17-tetraoxo-6,9,15,18,22,23,24-heptazatricyclo[20.2.1.09,13]pentacosa-1(25),23-diene-19-carboxamide",617.365,617.365,0,1,0,5,5,0,0,0,0,1,0,0,"",Biological Test Results|Classification|Literature,3,1833617|1833618,20220428,AbaChemScene|Amadis Chemical|BindingDB|BLD Pharm|ChEMBL|InvivoChem|MedChemexpress MCE|MolGenie|TargetMol,Chemical Vendors|Curation Efforts|Research and Development,""
168201327,KRAS G12D inhibitor 18,"KRAS G12D inhibitor 18|2922732-54-3|RMC-9805|Zoldonrasib|zoldonrasib [INN]|XJ52BWK3XE|SCHEMBL26348957|GTPL13482|RMC9805|EX-A8179|RMI-5921|AT45104|AC-38191|DA-54679|Example A26 [WO2023060253A1]|HY-156819|CS-0897768|(2S)-2-cyclopentyl-2-{(5S)-7-[(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl]-2,7-diazaspiro[4.4]nonan-2-yl}-N-[(12M,22S,4S,63S)-12-{5-(4-cyclopropylpiperazin-1-yl)-2-[(1S)-1-methoxyethyl]pyridin-3-yl}-10,10-dimethyl-5,7-dioxo-11-(2,2,2-trifluoroethyl)-11H-8-oxa-1(5,3)-indola-2(4,2)-morpholina-6(1,3)-[1,2]diazinanacycloundecaphan-4-yl]acetamide|3034802-05-3",1168.400,C63H88F3N11O7,160.000,2370.000,7.200,84,2,17,12,"InChI=1S/C63H88F3N11O7/c1-39(82-5)52-47(30-44(33-67-52)72-25-23-71(24-26-72)42-14-15-42)55-48-32-61(2,3)38-84-60(81)49-11-8-20-77(69-49)58(79)50(31-45-34-73(27-28-83-45)43-16-17-51(46(48)29-43)76(55)37-63(64,65)66)68-57(78)54(40-9-6-7-10-40)74-21-18-62(35-74)19-22-75(36-62)59(80)56-53(70(56)4)41-12-13-41/h16-17,29-30,33,39-42,45,49-50,53-54,56,69H,6-15,18-28,31-32,34-38H2,1-5H3,(H,68,78)/t39-,45-,49-,50-,53+,54-,56+,62-,70?/m0/s1",C[C@@H](C1=C(C=C(C=N1)N2CCN(CC2)C3CC3)C4=C5CC(COC(=O)[C@@H]6CCCN(N6)C(=O)[C@H](C[C@H]7CN(CCO7)C8=CC5=C(N4CC(F)(F)F)C=C8)NC(=O)[C@H](C9CCCC9)N1CC[C@@]2(C1)CCN(C2)C(=O)[C@H]1[C@H](N1C)C1CC1)(C)C)OC,VKNNQJWNUPSOEK-VCAAAJMFSA-N,"(2S)-2-cyclopentyl-2-[(5S)-2-[(2R,3R)-3-cyclopropyl-1-methylaziridine-2-carbonyl]-2,7-diazaspiro[4.4]nonan-7-yl]-N-[(6S,8S,14S)-21-[5-(4-cyclopropylpiperazin-1-yl)-2-[(1S)-1-methoxyethyl]pyridin-3-yl]-18,18-dimethyl-9,15-dioxo-22-(2,2,2-trifluoroethyl)-5,16-dioxa-2,10,22,28-tetrazapentacyclo[18.5.2.12,6.110,14.023,27]nonacosa-1(26),20,23(27),24-tetraen-8-yl]acetamide",1167.68,1167.68,0,1,0,8,8,0,0,0,0,0,1,1,"",Classification|Drug and Medication Information|Patents,3,"",20230530,"10X CHEM|A2B Chem|AbaChemScene|Amadis Chemical|AstaTech, Inc.|Debye Scientific Co., Ltd|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Hangzhou APIChem Technology|IUPHAR/BPS Guide to PHARMACOLOGY|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
166509683,Paluratide,"LUNA18|2676177-63-0|Paluratide|paluratide [INN]|RAS inhibitor LUNA18|AW3YP3CD9X|SCHEMBL24821097|LUNA18( KRAS INHIBITOR)|GLXC-26241|EX-A8086|AT41275|DA-55070|HY-156002|CS-0890845|1,11-anhydro[N-methyl-L-alanyl-(2S)-azetidine-2-carbonyl-N-ethyl-4-methyl-L-phenylalanyl-N-methylglycyl-(2S)-2-amino-4-[3,5-difluoro-4-(trifluoromethyl)phenyl]butanoyl-L-prolyl-2-aminocyclopentane-1-carbonyl-(2S)-2-cyclopentyl-N-methylglycyl-N1,N1,N2-trimethyl- L -isoasparaginyl-N-methyl-L-leucyl-L-isoleucine]",1437.700,C73H105F5N12O12,270.000,3000.000,7.300,102,3,17,12,"InChI=1S/C73H105F5N12O12/c1-15-44(6)60-69(100)84(11)45(7)64(95)90-35-31-53(90)68(99)88(16-2)56(39-46-27-25-43(5)26-28-46)67(98)83(10)41-57(91)79-51(30-29-47-37-49(74)59(50(75)38-47)73(76,77)78)65(96)89-34-21-24-52(89)63(94)81-72(32-19-20-33-72)71(102)87(14)61(48-22-17-18-23-48)70(101)86(13)55(66(97)82(8)9)40-58(92)85(12)54(36-42(3)4)62(93)80-60/h25-28,37-38,42,44-45,48,51-56,60-61H,15-24,29-36,39-41H2,1-14H3,(H,79,91)(H,80,93)(H,81,94)/t44-,45-,51-,52-,53-,54-,55-,56-,60-,61-/m0/s1",CC[C@H](C)[C@H]1C(=O)N([C@H](C(=O)N2CC[C@H]2C(=O)N([C@H](C(=O)N(CC(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)NC4(CCCC4)C(=O)N([C@H](C(=O)N([C@@H](CC(=O)N([C@H](C(=O)N1)CC(C)C)C)C(=O)N(C)C)C)C5CCCC5)C)CCC6=CC(=C(C(=C6)F)C(F)(F)F)F)C)CC7=CC=C(C=C7)C)CC)C)C,ZQVKVYRBKAEFPD-DEBTURSASA-N,"(3S,9S,12S,17S,20S,23S,27S,30S,36S)-20-[(2S)-butan-2-yl]-30-cyclopentyl-3-[2-[3,5-difluoro-4-(trifluoromethyl)phenyl]ethyl]-10-ethyl-N,N,7,17,18,24,28,31-octamethyl-9-[(4-methylphenyl)methyl]-23-(2-methylpropyl)-2,5,8,11,16,19,22,25,29,32,35-undecaoxospiro[1,4,7,10,15,18,21,24,28,31,34-undecazatricyclo[34.3.0.012,15]nonatriacontane-33,1'-cyclopentane]-27-carboxamide",1436.79,1436.79,0,1,0,10,10,0,0,0,0,0,1,1,"",Classification|Drug and Medication Information|Patents,3,"",20230201,"10X CHEM|AbaChemScene|AstaTech, Inc.|Debye Scientific Co., Ltd|eNovation Chemicals|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Glixx Labs Inc|Google Patents|InvivoChem|MedChemexpress MCE|MolGenie|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
270269,4-{4-[(Bromoacetyl)amino]butyl}benzoic acid,"KRA-533|10161-87-2|4-{4-[(bromoacetyl)amino]butyl}benzoic acid|4-[4-[(2-bromoacetyl)amino]butyl]benzoic acid|NSC112533|4-(4-(2-Bromoacetamido)butyl)benzoic acid|Benzoic acid, 4-[4-[(2-bromoacetyl)amino]butyl]-|Benzoic acid,4-[4-[(2-bromoacetyl)amino]butyl]-|SCHEMBL23148266|DTXSID00296901|GLXC-21012|EX-A7621|AKOS040756416|AT34790|NSC-112533|MS-24599|DS-010455|HY-138188|CS-0145846",314.170,C13H16BrNO3,66.400,275.000,2.500,18,2,3,7,"InChI=1S/C13H16BrNO3/c14-9-12(16)15-8-2-1-3-10-4-6-11(7-5-10)13(17)18/h4-7H,1-3,8-9H2,(H,15,16)(H,17,18)",C1=CC(=CC=C1CCCCNC(=O)CBr)C(=O)O,WZQJLTLURXNPQG-UHFFFAOYSA-N,4-[4-[(2-bromoacetyl)amino]butyl]benzoic acid,313.031,313.031,0,1,0,0,0,0,0,0,0,0,7,3,"",Biological Test Results|Literature|Patents,3,248,20050326,"10X CHEM|A2B Chem|AA BLOCKS|AAA Chemistry|AbaChemScene|ABI Chem|AbovChem LLC|AKos Consulting & Solutions|Amadis Chemical|AstaTech, Inc.|BenchChem|BLD Pharm|ChemDB|Chemieliva Pharmaceutical Co., Ltd|ChemSpider|ChemTik|Combi-Blocks|DC Chemicals|Debye Scientific Co., Ltd|DiscoveryGate|DTP/NCI|eNovation Chemicals|EPA DSSTox|Excenen Pharmatech|Glixx Labs Inc|Google Patents|InvivoChem|J&H Chemical Co.,ltd|Key Organics/BIONET|Mcule|MedChemexpress MCE|NextBio|PATENTSCOPE (WIPO)|Probes & Drugs portal|Smolecule|SureChEMBL|SynHet - Synthetic Heterocycles|TargetMol|THE BioTek|Wikidata|ZINC",Chemical Vendors|Curation Efforts|Governmental Organizations|Legacy Depositors|Research and Development|Subscription Services,""
168268198,"(S)-2-amino-3'-(2-((S)-2-methylpiperazin-1-yl)pyrimidin-4-yl)-5',6,6',7-tetrahydro-4'H,5H-spiro[benzo[b]thiophene-4,7'-benzo[d]isoxazole]-3-carbonitrile","BI-2493|2937344-16-4|BI2493|(7S)-2'-amino-3-[2-[(2S)-2-methylpiperazin-1-yl]pyrimidin-4-yl]spiro[5,6-dihydro-4H-1,2-benzoxazole-7,4'-6,7-dihydro-5H-1-benzothiophene]-3'-carbonitrile|(S)-2-amino-3'-(2-((S)-2-methylpiperazin-1-yl)pyrimidin-4-yl)-5',6,6',7-tetrahydro-4'H,5H-spiro[benzo[b]thiophene-4,7'-benzo[d]isoxazole]-3-carbonitrile|(7~{S})-2'-azanyl-3-[2-[(2~{S})-2-methylpiperazin-1-yl]pyrimidin-4-yl]spiro[5,6-dihydro-4~{H}-1,2-benzoxazole-7,4'-6,7-dihydro-5~{H}-1-benzothiophene]-3'-carbonitrile|8XX44ZCU8N|EX-A6987B|GTPL12764|GLXC-27496|BI-2493 (KRAS INHIBITOR)|AT40248|DA-61653|HY-153723|CS-0835564|Spiro[1,2-benzisoxazole-7(4H),4'(5'H)-benzo[b]thiophene]-3'-carbonitrile, 2'-amino-5,6,6',7'-tetrahydro-3-[2-[(2S)-2-methyl-1-piperazinyl]-4-pyrimidinyl]-, (4'S)-",461.600,C24H27N7OS,145.000,777.000,3.700,33,2,9,2,"InChI=1S/C24H27N7OS/c1-14-13-27-10-11-31(14)23-28-9-6-17(29-23)20-15-4-2-7-24(21(15)32-30-20)8-3-5-18-19(24)16(12-25)22(26)33-18/h6,9,14,27H,2-5,7-8,10-11,13,26H2,1H3/t14-,24-/m0/s1",C[C@H]1CNCCN1C2=NC=CC(=N2)C3=NOC4=C3CCC[C@@]45CCCC6=C5C(=C(S6)N)C#N,PVOYBVVIBNPTPJ-BSEYFRJRSA-N,"(7S)-2'-amino-3-[2-[(2S)-2-methylpiperazin-1-yl]pyrimidin-4-yl]spiro[5,6-dihydro-4H-1,2-benzoxazole-7,4'-6,7-dihydro-5H-1-benzothiophene]-3'-carbonitrile",461.2,461.2,0,1,0,2,2,0,0,0,0,1,0,0,"",Interactions and Pathways|Classification|Literature,3,"",20230609,"10X CHEM|A2B Chem|AbaChemScene|Amadis Chemical|AstaTech, Inc.|ChemShuttle|Debye Scientific Co., Ltd|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|Glixx Labs Inc|InvivoChem|IUPHAR/BPS Guide to PHARMACOLOGY|MedChemexpress MCE|MolPort|NCBI Structure|Probes & Drugs portal|Protein Data Bank in Europe (PDBe)|SynHet - Synthetic Heterocycles|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163196255,KRAS G12C inhibitor 32,KRAS G12C inhibitor 32|SCHEMBL24161933|HY-142487|CS-0372523|2756739-00-9,635.900,C29H30Cl3FN6O3,83.100,966.000,6.100,42,1,9,5,"InChI=1S/C29H30Cl3FN6O3/c1-3-21(40)38-8-10-39(11-9-38)28-17-13-18(30)22-23-24(33)19(31)14-20(32)26(23)34-6-12-41-27(22)25(17)35-29(36-28)42-15-16-5-4-7-37(16)2/h3,13-14,16,34H,1,4-12,15H2,2H3/t16-/m0/s1",CN1CCC[C@H]1COC2=NC3=C4C(=C(C=C3C(=N2)N5CCN(CC5)C(=O)C=C)Cl)C6=C(C(=CC(=C6F)Cl)Cl)NCCO4,ZQYOQPIFEDBQMJ-INIZCTEOSA-N,"1-[4-[4,6,20-trichloro-3-fluoro-15-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-11-oxa-8,14,16-triazatetracyclo[10.8.0.02,7.013,18]icosa-1(20),2(7),3,5,12,14,16,18-octaen-17-yl]piperazin-1-yl]prop-2-en-1-one",634.143,634.143,0,1,0,1,1,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20220428,AbaChemScene|BLD Pharm|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
157023122,KRAS G12C inhibitor 24,"KRAS G12C inhibitor 24|2735742-75-1|SCHEMBL23986308|DA-64771|HY-145021|CS-0312211|1-[4-[7-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one",600.100,C28H28ClF2N7O2S,129.000,951.000,5.300,41,1,11,6,"InChI=1S/C28H28ClF2N7O2S/c1-3-20(39)37-9-11-38(12-10-37)26-17-13-18(29)21(16-6-7-19(30)25-24(16)33-27(32)41-25)22(31)23(17)34-28(35-26)40-14-15-5-4-8-36(15)2/h3,6-7,13,15H,1,4-5,8-12,14H2,2H3,(H2,32,33)/t15-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(C(=C(C=C3C(=N2)N4CCN(CC4)C(=O)C=C)Cl)C5=C6C(=C(C=C5)F)SC(=N6)N)F,CDTUKBVALQMBRD-HNNXBMFYSA-N,"1-[4-[7-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one",599.168,599.168,0,1,0,1,1,0,0,0,0,0,16,5,"",Classification|Patents,2,"",20211130,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
135148867,KRAS inhibitor-16,KRAS inhibitor-16|SCHEMBL20296651|DA-74807|HY-146546|CS-0437266|2230873-67-1,452.300,C20H16Cl2FN3O2S,84.900,625.000,5.300,29,1,6,3,"InChI=1S/C20H16Cl2FN3O2S/c1-2-16(28)25-5-7-26(8-6-25)20-13-10-15(22)17(18(23)19(13)24-29-20)12-9-11(27)3-4-14(12)21/h2-4,9-10,27H,1,5-8H2",C=CC(=O)N1CCN(CC1)C2=C3C=C(C(=C(C3=NS2)F)C4=C(C=CC(=C4)O)Cl)Cl,UPHZHQLQCQSBQD-UHFFFAOYSA-N,"1-[4-[5-chloro-6-(2-chloro-5-hydroxyphenyl)-7-fluoro-2,1-benzothiazol-3-yl]piperazin-1-yl]prop-2-en-1-one",451.032,451.032,0,1,0,0,0,0,0,0,0,0,29,6,"",Classification|Patents,2,"",20181215,"AbaChemScene|Debye Scientific Co., Ltd|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
164535036,Pan KRas-IN-1,"Pan KRas-IN-1|2791263-84-6|(3R)-1-(2-{[(2R,7aS)-2-fluoro-hexahydropyrrolizin-7a-yl]methoxy}-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3-methylpiperidin-3-ol|SCHEMBL24535715|DA-76579|HY-148098|CS-0610860|(3R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol",607.700,C33H36F3N5O3,94.800,1020.000,5.800,44,2,11,6,"InChI=1S/C33H36F3N5O3/c1-3-22-25(35)7-6-19-12-21(42)13-23(26(19)22)28-27(36)29-24(15-37-28)30(40-10-4-8-32(2,43)17-40)39-31(38-29)44-18-33-9-5-11-41(33)16-20(34)14-33/h6-7,12-13,15,20,42-43H,3-5,8-11,14,16-18H2,1-2H3/t20-,32-,33+/m1/s1",CCC1=C(C=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5CCC[C@@](C5)(C)O)OC[C@@]67CCCN6C[C@@H](C7)F)O)F,RZYWNBKMTZABBP-PAXFXPPDSA-N,"(3R)-1-[7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-3-methylpiperidin-3-ol",607.277,607.277,0,1,0,3,3,0,0,0,0,0,29,15,"",Classification|Patents,2,"",20220728,"10X CHEM|A2B Chem|AbaChemScene|Amadis Chemical|Debye Scientific Co., Ltd|eNovation Chemicals|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|SynHet - Synthetic Heterocycles|Synthonix, Inc.",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
137082288,KRAS inhibitor-7,KRAS inhibitor-7|2022986-68-9|SCHEMBL18128519|AKOS040733544|DA-74812|HY-135865|CS-0115618,529.000,C26H27ClF2N6O2,76.000,827.000,4.300,37,1,9,5,"InChI=1S/C26H27ClF2N6O2/c1-4-20(37)33-8-10-34(11-9-33)25-16-12-17(27)21(22-18(28)6-5-7-19(22)36)23(29)24(16)30-26(31-25)35-13-15(14-35)32(2)3/h4-7,12,15,36H,1,8-11,13-14H2,2-3H3",CN(C)C1CN(C1)C2=NC3=C(C(=C(C=C3C(=N2)N4CCN(CC4)C(=O)C=C)Cl)C5=C(C=CC=C5F)O)F,LLBYZJQEXCUAIN-UHFFFAOYSA-N,1-[4-[6-chloro-2-[3-(dimethylamino)azetidin-1-yl]-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one,528.185,528.185,0,1,0,0,0,0,0,0,0,0,27,9,"",Classification|Patents,2,"",20190125,"AbaChemScene|AKos Consulting & Solutions|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
138721313,KRAS G12C inhibitor 17,"KRAS G12C inhibitor 17|2349393-04-8|SCHEMBL21099618|AKOS040733541|DA-54663|HY-125875|CS-0102610|1-[(4R,7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-4-methyl-9-oxa-2,5,12-triazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-5-yl]prop-2-en-1-one",471.900,C24H20ClF2N3O3,65.900,762.000,4.500,33,1,7,2,"InChI=1S/C24H20ClF2N3O3/c1-3-19(32)29-10-13-11-33-18-8-28-23-14(24(18)30(13)9-12(29)2)7-15(25)20(22(23)27)21-16(26)5-4-6-17(21)31/h3-8,12-13,31H,1,9-11H2,2H3/t12-,13-/m1/s1",C[C@@H]1CN2[C@H](CN1C(=O)C=C)COC3=C2C4=CC(=C(C(=C4N=C3)F)C5=C(C=CC=C5F)O)Cl,VUKUQOCNPKSWQJ-CHWSQXEVSA-N,"1-[(4R,7R)-16-chloro-14-fluoro-15-(2-fluoro-6-hydroxyphenyl)-4-methyl-9-oxa-2,5,12-triazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),11,13,15,17-pentaen-5-yl]prop-2-en-1-one",471.116,471.116,0,1,0,2,2,0,0,0,0,0,17,6,"",Classification|Patents,2,"",20190720,"AbaChemScene|AKos Consulting & Solutions|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156461328,KRAS G12C inhibitor 26,"KRAS G12C inhibitor 26|2648584-52-3|SCHEMBL23481500|DA-54667|HY-142457|CS-0372422|2-[(2S)-1-(2-fluoroprop-2-enoyl)-4-[(7S)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile",588.600,C29H32F4N6O3,94.800,1020.000,3.600,42,0,12,7,"InChI=1S/C29H32F4N6O3/c1-18(30)27(40)39-13-12-38(15-19(39)9-10-34)26-22-17-41-25(21-7-3-4-8-23(21)29(31,32)33)14-24(22)35-28(36-26)42-16-20-6-5-11-37(20)2/h3-4,7-8,19-20,25H,1,5-6,9,11-17H2,2H3/t19-,20-,25-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CO[C@@H](C3)C4=CC=CC=C4C(F)(F)F)C(=N2)N5CCN([C@H](C5)CC#N)C(=O)C(=C)F,QHAKQJHNFQRVOF-RLSLOFABSA-N,"2-[(2S)-1-(2-fluoroprop-2-enoyl)-4-[(7S)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile",588.247,588.247,0,1,0,3,3,0,0,0,0,0,11,5,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163196188,KRAS G12D inhibitor 3,"KRAS G12D inhibitor 3|2757095-11-5|SCHEMBL24175932|EX-A7074|HY-115880|CS-0372213|4-[6-chloro-4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]quinazolin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol",634.100,C34H31ClF3N5O2,73.800,1140.000,6.800,45,2,10,6,"InChI=1S/C34H31ClF3N5O2/c1-2-23-27(37)7-4-18-10-22(44)11-24(28(18)23)29-26(35)12-25-31(30(29)38)40-33(41-32(25)42-15-20-5-6-21(16-42)39-20)45-17-34-8-3-9-43(34)14-19(36)13-34/h1,4,7,10-12,19-21,39,44H,3,5-6,8-9,13-17H2/t19-,20?,21?,34+/m1/s1",C#CC1=C(C=CC2=CC(=CC(=C21)C3=C(C=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OC[C@@]78CCCN7C[C@@H](C8)F)Cl)O)F,BIZPUCPPAVLJKY-FCHSEJRRSA-N,"4-[6-chloro-4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]quinazolin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol",633.212,633.212,0,1,0,4,2,2,0,0,0,0,3,2,"",Classification|Patents,2,"",20220428,AbaChemScene|Excenen Pharmatech|InvivoChem|MedChemexpress MCE|Probes & Drugs portal|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Research and Development,""
162472193,PROTAC KRAS G12C degrader-2,PROTAC KRAS G12C degrader-2|2378257-72-6|SCHEMBL23968665|EX-A11415|DA-57146|HY-153821|CS-0865003,958.500,C51H53ClFN9O7,172.000,1900.000,6.500,69,2,14,11,"InChI=1S/C51H53ClFN9O7/c1-3-43(65)60-20-22-61(23-21-60)47-39-27-40(52)44(37-26-34(63)24-32-6-4-5-7-35(32)37)45(53)46(39)55-51(56-47)69-30(2)28-57-16-18-58(19-17-57)29-31-12-14-59(15-13-31)33-8-9-36-38(25-33)50(68)62(49(36)67)41-10-11-42(64)54-48(41)66/h3-9,24-27,30-31,41,63H,1,10-23,28-29H2,2H3,(H,54,64,66)/t30-,41?/m1/s1",C[C@H](CN1CCN(CC1)CC2CCN(CC2)C3=CC4=C(C=C3)C(=O)N(C4=O)C5CCC(=O)NC5=O)OC6=NC7=C(C(=C(C=C7C(=N6)N8CCN(CC8)C(=O)C=C)Cl)C9=CC(=CC1=CC=CC=C19)O)F,KZQITCSEFGTWRQ-OWAVIYFHSA-N,"5-[4-[[4-[(2R)-2-[6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-2-yl]oxypropyl]piperazin-1-yl]methyl]piperidin-1-yl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione",957.374,957.374,0,1,0,2,1,1,0,0,0,0,2,1,"",Classification|Patents,2,"",20220206,"10X CHEM|AbaChemScene|Amadis Chemical|Debye Scientific Co., Ltd|eMolecules|Excenen Pharmatech|Google Patents|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156546145,KRAS G12C inhibitor 38,KRAS G12C inhibitor 38|2660324-77-4|SCHEMBL23588659|DA-74795|HY-143591|CS-0373916,700.800,C38H43F3N8O2,93.700,1270.000,6.900,51,1,11,8,"InChI=1S/C38H43F3N8O2/c1-3-30(50)49-20-37(21-49)10-14-47(15-11-37)35-27-16-26(24-7-8-24)32(31-23(2)6-9-29-28(31)17-42-45-29)34(51-22-38(39,40)41)33(27)43-36(44-35)48-18-25(19-48)46-12-4-5-13-46/h3,6,9,16-17,24-25H,1,4-5,7-8,10-15,18-22H2,2H3,(H,42,45)",CC1=C(C2=C(C=C1)NN=C2)C3=C(C=C4C(=C3OCC(F)(F)F)N=C(N=C4N5CCC6(CC5)CN(C6)C(=O)C=C)N7CC(C7)N8CCCC8)C9CC9,PBENVJNCTVARNW-UHFFFAOYSA-N,"1-[7-[6-cyclopropyl-7-(5-methyl-1H-indazol-4-yl)-2-(3-pyrrolidin-1-ylazetidin-1-yl)-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one",700.346,700.346,0,1,0,0,0,0,0,0,0,0,7,2,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
170835991,Kras G13D-IN-1,KRAS G13D-IN-1|CHEMBL5408905|BDBM50619564|HY-161066|CS-0911652,817.300,C43H45ClF4N8O2,104.000,1560.000,6.800,58,1,13,7,"InChI=1S/C43H45ClF4N8O2/c1-24-18-42(11-5-12-55(42)19-24)23-58-41-51-38-30(17-32(44)35(37(38)45)39-36(43(46,47)48)25(2)16-33(49)50-39)40(52-41)56-15-14-54(20-26(56)3)34(57)9-8-27-6-4-7-29-28-10-13-53(21-28)22-31(27)29/h4,6-9,16-17,26,28H,1,5,10-15,18-23H2,2-3H3,(H2,49,50)/b9-8+/t26-,28?,42-/m0/s1",C[C@H]1CN(CCN1C2=NC(=NC3=C(C(=C(C=C32)Cl)C4=C(C(=CC(=N4)N)C)C(F)(F)F)F)OC[C@@]56CCCN5CC(=C)C6)C(=O)/C=C/C7=C8CN9CCC(C9)C8=CC=C7,VALDJEIZODIXIN-UKTBRIRYSA-N,"(E)-1-[(3S)-4-[7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-[[(8S)-6-methylidene-2,3,5,7-tetrahydro-1H-pyrrolizin-8-yl]methoxy]quinazolin-4-yl]-3-methylpiperazin-1-yl]-3-(9-azatricyclo[7.2.1.02,7]dodeca-2,4,6-trien-6-yl)prop-2-en-1-one",816.329,816.329,0,1,0,3,2,1,1,1,0,0,0,0,"",Biological Test Results|Classification,2,1978447|1978448,20240302,AbaChemScene|BindingDB|ChEMBL|MedChemexpress MCE,Chemical Vendors|Curation Efforts|Research and Development,""
170957357,KRAS inhibitor-24,KRAS inhibitor-24|HY-159474,641.100,C33H39ClF2N6O3,104.000,1030.000,5.200,45,2,10,3,"InChI=1S/C33H39ClF2N6O3/c34-26-14-22(43)13-24-23(26)6-1-2-7-27(44)37-10-8-20-5-3-11-41(17-20)31-25-16-38-29(24)28(36)30(25)39-32(40-31)45-19-33-9-4-12-42(33)18-21(35)15-33/h13-14,16,20-21,43H,1-12,15,17-19H2,(H,37,44)/t20-,21+,33-/m0/s1",C1CCC(=O)NCC[C@@H]2CCCN(C2)C3=NC(=NC4=C(C(=NC=C43)C5=C(C1)C(=CC(=C5)O)Cl)F)OC[C@@]67CCCN6C[C@@H](C7)F,LYQOAXNUFSGZPC-BJQVUIHVSA-N,"(25S)-15-chloro-30-fluoro-4-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-13-hydroxy-1,3,5,9,22-pentazapentacyclo[23.3.1.16,10.02,7.011,16]triaconta-2,4,6(30),7,9,11(16),12,14-octaen-21-one",640.274,640.274,0,1,0,3,3,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20240318,MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol,Chemical Vendors|Governmental Organizations,""
156472654,KRAS G12C inhibitor 18,"KRAS G12C inhibitor 18|2649788-45-2|SCHEMBL23496744|AKOS040757942|DA-64767|HY-132979|CS-0311439|4-[(13aS)-10-chloro-8-fluoro-6-oxo-2-prop-2-enoyl-1,3,4,12,13,13a-hexahydropyrazino[2,1-d][1,5]benzoxazocin-9-yl]-2-amino-1-benzothiophene-3-carbonitrile",511.000,C25H20ClFN4O3S,128.000,916.000,4.700,35,1,7,2,"InChI=1S/C25H20ClFN4O3S/c1-2-19(32)30-7-8-31-13(12-30)6-9-34-23-15(25(31)33)10-17(27)21(22(23)26)14-4-3-5-18-20(14)16(11-28)24(29)35-18/h2-5,10,13H,1,6-9,12,29H2/t13-/m0/s1",C=CC(=O)N1CCN2[C@H](C1)CCOC3=C(C(=C(C=C3C2=O)F)C4=C5C(=CC=C4)SC(=C5C#N)N)Cl,FLOCSULDJZSEOQ-ZDUSSCGKSA-N,"4-[(13aS)-10-chloro-8-fluoro-6-oxo-2-prop-2-enoyl-1,3,4,12,13,13a-hexahydropyrazino[2,1-d][1,5]benzoxazocin-9-yl]-2-amino-1-benzothiophene-3-carbonitrile",510.093,510.093,0,1,0,1,1,0,0,0,0,0,17,8,"",Classification|Patents,2,"",20210821,"AbaChemScene|AKos Consulting & Solutions|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
135148820,KRAS inhibitor-18,KRAS inhibitor-18|SCHEMBL20296596|2230873-66-0|DA-74809|HY-146476|CS-0499080,453.900,C20H15ClF3N3O2S,84.900,657.000,4.800,30,1,8,3,"InChI=1S/C20H15ClF3N3O2S/c1-2-16(29)26-3-5-27(6-4-26)20-11-7-12(21)17(18(24)19(11)25-30-20)10-8-15(28)14(23)9-13(10)22/h2,7-9,28H,1,3-6H2",C=CC(=O)N1CCN(CC1)C2=C3C=C(C(=C(C3=NS2)F)C4=CC(=C(C=C4F)F)O)Cl,NDGHIBDKESCHLI-UHFFFAOYSA-N,"1-[4-[5-chloro-6-(2,4-difluoro-5-hydroxyphenyl)-7-fluoro-2,1-benzothiazol-3-yl]piperazin-1-yl]prop-2-en-1-one",453.053,453.053,0,1,0,0,0,0,0,0,0,0,28,6,"",Classification|Patents,2,"",20181215,"AbaChemScene|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
135148916,KRAS inhibitor-12,KRAS inhibitor-12|SCHEMBL20296706|2230874-00-5|DA-74806|HY-146533|CS-0437224,452.300,C19H16Cl2FN5OS,104.000,625.000,4.200,29,1,7,3,"InChI=1S/C19H16Cl2FN5OS/c1-2-14(28)26-5-7-27(8-6-26)19-10-9-12(21)15(16(22)17(10)25-29-19)18-11(20)3-4-13(23)24-18/h2-4,9H,1,5-8H2,(H2,23,24)",C=CC(=O)N1CCN(CC1)C2=C3C=C(C(=C(C3=NS2)F)C4=C(C=CC(=N4)N)Cl)Cl,MOIGORLHBXDEMI-UHFFFAOYSA-N,"1-[4-[6-(6-amino-3-chloropyridin-2-yl)-5-chloro-7-fluoro-2,1-benzothiazol-3-yl]piperazin-1-yl]prop-2-en-1-one",451.044,451.044,0,1,0,0,0,0,0,0,0,0,77,7,"",Classification|Patents,2,"",20181215,"AbaChemScene|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
166162638,pan-KRAS-IN-2,pan-KRAS-IN-2|2882825-14-9|SCHEMBL24711979|DA-66478|HY-156529|CS-0883585,584.700,C34H34F2N4O3,71.000,1030.000,6.500,43,1,9,6,"InChI=1S/C34H34F2N4O3/c1-3-25-29(36)9-6-22-16-24(41)17-28(30(22)25)26-7-8-27-31(21(26)2)37-33(38-32(27)39-11-5-14-42-15-13-39)43-20-34-10-4-12-40(34)19-23(35)18-34/h1,6-9,16-17,23,41H,4-5,10-15,18-20H2,2H3/t23-,34+/m1/s1",CC1=C(C=CC2=C1N=C(N=C2N3CCCOCC3)OC[C@@]45CCCN4C[C@@H](C5)F)C6=C7C(=CC(=C6)O)C=CC(=C7C#C)F,HYCYHHMWGDUNSM-NHOCJEJCSA-N,"5-ethynyl-6-fluoro-4-[2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-8-methyl-4-(1,4-oxazepan-4-yl)quinazolin-7-yl]naphthalen-2-ol",584.26,584.26,0,1,0,2,2,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20221220,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163408916,KRAS G12D inhibitor 15,"KRAS G12D inhibitor 15|2763155-39-9|SCHEMBL26708502|DA-54677|HY-147595|CS-0514061|[(3R,8R)-8-[[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-5-methoxypyrido[4,3-d]pyrimidin-2-yl]oxymethyl]-1,2,3,5,6,7-hexahydropyrrolizin-3-yl]methyl N-hexadecyl-N-methylcarbamate",924.200,C53H71F2N7O5,125.000,1580.000,13.100,67,2,13,25,"InChI=1S/C53H71F2N7O5/c1-5-7-8-9-10-11-12-13-14-15-16-17-18-19-28-60(3)52(64)66-34-39-25-27-53(26-20-29-62(39)53)35-67-51-58-48-45(49(59-51)61-32-37-22-23-38(33-61)56-37)50(65-4)57-47(46(48)55)42-31-40(63)30-36-21-24-43(54)41(6-2)44(36)42/h2,21,24,30-31,37-39,56,63H,5,7-20,22-23,25-29,32-35H2,1,3-4H3/t37?,38?,39-,53-/m1/s1",CCCCCCCCCCCCCCCCN(C)C(=O)OC[C@H]1CC[C@@]2(N1CCC2)COC3=NC4=C(C(=N3)N5CC6CCC(C5)N6)C(=NC(=C4F)C7=C8C(=CC(=C7)O)C=CC(=C8C#C)F)OC,JEMAATHHHQXSOT-WNBQDOJDSA-N,"[(3R,8R)-8-[[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-5-methoxypyrido[4,3-d]pyrimidin-2-yl]oxymethyl]-1,2,3,5,6,7-hexahydropyrrolizin-3-yl]methyl N-hexadecyl-N-methylcarbamate",923.548,923.548,0,1,0,4,2,2,0,0,0,0,1,1,"",Classification|Patents,2,"",20220630,"AbaChemScene|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
170836014,PROTAC KRAS G12D degrader 2,CHEMBL5426938|PROTAC KRAS G12D degrader 2|BDBM50626139|HY-161177|CS-0979320,885.000,C46H57FN8O9,207.000,1780.000,2.700,64,4,12,16,"InChI=1S/C46H57FN8O9/c1-28(2)22-36(50-46(63)64-27-30-6-4-3-5-7-30)42(59)49-32(23-31-12-15-48-41(31)58)8-11-40(57)54-20-18-52(19-21-54)26-29-13-16-53(17-14-29)38-25-34-33(24-35(38)47)44(61)55(45(34)62)37-9-10-39(56)51-43(37)60/h3-8,11,24-25,28-29,31-32,36-37H,9-10,12-23,26-27H2,1-2H3,(H,48,58)(H,49,59)(H,50,63)(H,51,56,60)/b11-8+/t31-,32+,36-,37?/m0/s1",CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)/C=C/C(=O)N2CCN(CC2)CC3CCN(CC3)C4=C(C=C5C(=C4)C(=O)N(C5=O)C6CCC(=O)NC6=O)F)NC(=O)OCC7=CC=CC=C7,OZVSHTNTPRENCA-HNPIODEQSA-N,"benzyl N-[(2S)-1-[[(E,2S)-5-[4-[[1-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxoisoindol-5-yl]piperidin-4-yl]methyl]piperazin-1-yl]-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate",884.423,884.423,0,1,0,4,3,1,1,1,0,0,0,0,"",Biological Test Results|Classification,2,2006872|2006877|2006878|2006879|2006880|2006881|2006882|2006883,20240302,AbaChemScene|BindingDB|ChEMBL|MedChemexpress MCE,Chemical Vendors|Curation Efforts|Research and Development,""
156303062,KRAS G12C inhibitor 20,"KRAS G12C inhibitor 20|2640858-10-0|SCHEMBL23282328|DA-54664|HY-145017|CS-0312203|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[3-(methoxymethyl)-1-methylazetidin-3-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile",634.100,C33H37ClFN7O3,98.100,1120.000,4.200,45,0,10,9,"InChI=1S/C33H37ClFN7O3/c1-22(35)31(43)42-15-14-41(16-24(42)10-12-36)30-25-11-13-40(28-9-5-7-23-6-4-8-26(34)29(23)28)17-27(25)37-32(38-30)45-21-33(20-44-3)18-39(2)19-33/h4-9,24H,1,10-11,13-21H2,2-3H3/t24-/m0/s1",CN1CC(C1)(COC)COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F,WGNKFEDTYNVQAY-DEOSSOPVSA-N,"2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[3-(methoxymethyl)-1-methylazetidin-3-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile",633.263,633.263,0,1,0,1,1,0,0,0,0,0,6,2,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Research and Development,""
135148832,KRAS inhibitor-15,KRAS inhibitor-15|SCHEMBL20296609|2230873-75-1|DA-54683|HY-146545|CS-0437263,451.300,C20H17Cl2FN4OS,90.700,623.000,4.900,29,1,6,3,"InChI=1S/C20H17Cl2FN4OS/c1-2-16(28)26-5-7-27(8-6-26)20-13-10-15(22)17(18(23)19(13)25-29-20)12-9-11(24)3-4-14(12)21/h2-4,9-10H,1,5-8,24H2",C=CC(=O)N1CCN(CC1)C2=C3C=C(C(=C(C3=NS2)F)C4=C(C=CC(=C4)N)Cl)Cl,RIJPTYRYUVYJJH-UHFFFAOYSA-N,"1-[4-[6-(5-amino-2-chlorophenyl)-5-chloro-7-fluoro-2,1-benzothiazol-3-yl]piperazin-1-yl]prop-2-en-1-one",450.048,450.048,0,1,0,0,0,0,0,0,0,0,31,6,"",Classification|Patents,2,"",20181215,"AbaChemScene|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156554934,KRAS G12C inhibitor 41,"KRAS G12C inhibitor 41|2660014-65-1|SCHEMBL23598802|DA-74796|HY-143596|CS-0373936|2-[(2S)-4-[7-(8-chloro-7-fluoronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-pyrimidin-5-ylprop-2-enoyl)piperazin-2-yl]acetonitrile",682.200,C36H37ClFN9O2,115.000,1220.000,4.800,49,0,11,8,"InChI=1S/C36H37ClFN9O2/c1-23(25-17-40-22-41-18-25)35(48)47-16-15-46(19-26(47)10-12-39)34-28-11-14-45(31-7-3-5-24-8-9-29(38)33(37)32(24)31)20-30(28)42-36(43-34)49-21-27-6-4-13-44(27)2/h3,5,7-9,17-18,22,26-27H,1,4,6,10-11,13-16,19-21H2,2H3/t26-,27-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=C(C=C5)F)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)C7=CN=CN=C7,INJGVJAHNUVYJU-SVBPBHIXSA-N,"2-[(2S)-4-[7-(8-chloro-7-fluoronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-pyrimidin-5-ylprop-2-enoyl)piperazin-2-yl]acetonitrile",681.274,681.274,0,1,0,2,2,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Research and Development,""
164875418,KRAS G12D inhibitor 17,"KRAS G12D inhibitor 17|Setidegrasib|2821793-99-9|setidegrasib [INN]|3NQ4ME292X|EX-A11454|DA-54678|HY-148273|CS-0618100|EN300-44826014|(2S,4R)-1-[(2S)-2-(4-{4-[({6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-(oxan-4-yloxy)quinazolin-8-yl}oxy)methyl]phenyl}-1H-1,2,3-triazol-1-yl)-3-methylbutanoyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide|(2S,4R)-1-[(2S)-2-[4-[4-[[6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-(oxan-4-yloxy)quinazolin-8-yl]oxymethyl]phenyl]triazol-1-yl]-3-methylbutanoyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide|2-Pyrrolidinecarboxamide, 1-[(2S)-2-[4-[4-[[[6-cyclopropyl-4-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]-8-quinazolinyl]oxy]methyl]phenyl]-1H-1,2,3-triazol-1-yl]-3-methyl-1-oxobutyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-, (2S,4R)-",1117.300,C60H65FN12O7S,259.000,2130.000,7.700,81,5,17,17,"InChI=1S/C60H65FN12O7S/c1-31(2)54(59(77)72-26-41(75)20-50(72)58(76)65-49(28-74)37-11-13-38(14-12-37)56-33(4)63-30-81-56)73-27-48(69-70-73)36-7-5-34(6-8-36)29-79-55-52(51-32(3)46(61)22-47-45(51)24-64-68-47)43(35-9-10-35)21-44-53(55)66-60(80-42-15-17-78-18-16-42)67-57(44)71-25-39-19-40(71)23-62-39/h5-8,11-14,21-22,24,27,30-31,35,39-42,49-50,54,62,74-75H,9-10,15-20,23,25-26,28-29H2,1-4H3,(H,64,68)(H,65,76)/t39-,40-,41+,49-,50-,54-/m0/s1",CC1=C(C=C2C(=C1C3=C(C=C4C(=C3OCC5=CC=C(C=C5)C6=CN(N=N6)[C@@H](C(C)C)C(=O)N7C[C@@H](C[C@H]7C(=O)N[C@@H](CO)C8=CC=C(C=C8)C9=C(N=CS9)C)O)N=C(N=C4N1C[C@@H]3C[C@H]1CN3)OC1CCOCC1)C1CC1)C=NN2)F,XXWMEQMGQNHRAF-WFJRNIGCSA-N,"(2S,4R)-1-[(2S)-2-[4-[4-[[6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-(oxan-4-yloxy)quinazolin-8-yl]oxymethyl]phenyl]triazol-1-yl]-3-methylbutanoyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide",1116.48,1116.48,0,1,0,6,6,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20220827,"10X CHEM|AbaChemScene|Debye Scientific Co., Ltd|Enamine|Excenen Pharmatech|FDA Global Substance Registration System (GSRS)|InvivoChem|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156768584,KRAS G12C inhibitor 35,KRAS G12C inhibitor 35|2650550-87-9|DA-74794|HY-143588|CS-0373866,605.000,C31H27ClF2N6O3,114.000,1170.000,4.600,43,1,9,5,"InChI=1S/C31H27ClF2N6O3/c1-5-23(42)38-10-12-39(13-11-38)29-18-14-21(33)27(24-22(41)7-6-20(32)25(24)34)37-30(18)40(31(43)19(29)15-35)28-17(4)8-9-36-26(28)16(2)3/h5-9,14,16,41H,1,10-13H2,2-4H3",CC1=C(C(=NC=C1)C(C)C)N2C3=NC(=C(C=C3C(=C(C2=O)C#N)N4CCN(CC4)C(=O)C=C)F)C5=C(C=CC(=C5F)Cl)O,VKOUGWHSWXDAGP-UHFFFAOYSA-N,"7-(3-chloro-2-fluoro-6-hydroxyphenyl)-6-fluoro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-2-oxo-4-(4-prop-2-enoylpiperazin-1-yl)-1,8-naphthyridine-3-carbonitrile",604.18,604.18,0,1,0,0,0,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20211110,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol",Chemical Vendors|Governmental Organizations,""
156805856,KRAS G12C inhibitor 45,"KRAS G12C inhibitor 45|2670380-74-0|SCHEMBL24108720|DA-54674|HY-142947|CS-0374000|4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-methylsulfonyl-6-propan-2-ylphenyl)pyrido[2,3-d]pyrimidin-2-one",637.700,C32H33F2N5O5S,132.000,1280.000,4.300,45,1,8,6,"InChI=1S/C32H33F2N5O5S/c1-7-26(41)37-15-19(5)38(16-18(37)4)30-21-14-23(34)28(27-22(33)11-9-12-24(27)40)35-31(21)39(32(42)36-30)29-20(17(2)3)10-8-13-25(29)45(6,43)44/h7-14,17-19,40H,1,15-16H2,2-6H3/t18-,19+/m1/s1",C[C@@H]1CN([C@H](CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CC=C5S(=O)(=O)C)C(C)C,DVYNJKUHECHEDC-MOPGFXCFSA-N,"4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-methylsulfonyl-6-propan-2-ylphenyl)pyrido[2,3-d]pyrimidin-2-one",637.217,637.217,0,1,0,2,2,0,0,0,0,0,15,7,"",Classification|Patents,2,"",20211110,"AbaChemScene|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
168476185,pan-KRAS-IN-3,pan-KRAS-IN-3|SCHEMBL25402404|DA-66479|HY-156555|CS-0884250|2875116-29-1,587.600,C33H32F3N5O2,74.600,1020.000,6.400,43,1,10,6,"InChI=1S/C33H32F3N5O2/c1-2-23-26(35)9-8-20-14-22(42)15-24(27(20)23)29-28(36)30-25(17-37-29)31(40-11-5-3-4-6-12-40)39-32(38-30)43-19-33-10-7-13-41(33)18-21(34)16-33/h1,8-9,14-15,17,21,42H,3-7,10-13,16,18-19H2/t21-,33+/m1/s1",C#CC1=C(C=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5CCCCCC5)OC[C@@]67CCCN6C[C@@H](C7)F)O)F,YFMORDIIDHJAKG-PPGPUPIYSA-N,"4-[4-(azepan-1-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol",587.251,587.251,0,1,0,2,2,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20230905,"AbaChemScene|Debye Scientific Co., Ltd|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156447104,KRAS G12D inhibitor 12,KRAS G12D inhibitor 12|SCHEMBL23464737|HY-143606|CS-0373962|2648552-54-7,469.900,C23H21ClFN5O3,101.000,751.000,2.800,33,2,8,2,"InChI=1S/C23H21ClFN5O3/c24-20-13(18-14(25)2-1-3-17(18)31)8-15-19-21(20)33-7-4-12-10-29(23(32)16-9-26-16)5-6-30(12)22(19)28-11-27-15/h1-3,8,11-12,16,26,31H,4-7,9-10H2/t12-,16+/m1/s1",C1COC2=C(C(=CC3=C2C(=NC=N3)N4[C@H]1CN(CC4)C(=O)[C@@H]5CN5)C6=C(C=CC=C6F)O)Cl,PIPHVUBZMLKXGQ-WBMJQRKESA-N,"[(2S)-aziridin-2-yl]-[(7R)-12-chloro-13-(2-fluoro-6-hydroxyphenyl)-10-oxa-2,5,16,18-tetrazatetracyclo[9.7.1.02,7.015,19]nonadeca-1(18),11,13,15(19),16-pentaen-5-yl]methanone",469.132,469.132,0,1,0,2,2,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20210821,AbaChemScene|BLD Pharm|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
170957253,KRAS inhibitor-26,KRAS inhibitor-26|HY-159476,676.700,C36H39F3N6O4,113.000,1160.000,4.800,49,2,12,3,"InChI=1S/C36H39F3N6O4/c37-23-15-36(8-2-10-45(36)18-23)20-49-35-42-33-27-16-41-32(31(33)39)26-14-24(46)13-22-5-6-28(38)25(30(22)26)3-1-4-29(47)40-9-7-21-17-44(34(27)43-35)11-12-48-19-21/h5-6,13-14,16,21,23,46H,1-4,7-12,15,17-20H2,(H,40,47)/t21?,23-,36+/m1/s1",C1CC2=C(C=CC3=CC(=CC(=C23)C4=NC=C5C(=C4F)N=C(N=C5N6CCOCC(C6)CCNC(=O)C1)OC[C@@]78CCCN7C[C@@H](C8)F)O)F,PXXIAPJIMONJNH-KXQJKLPKSA-N,"25,34-difluoro-8-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-30-hydroxy-14-oxa-3,7,9,11,19-pentazahexacyclo[22.7.1.12,6.111,16.05,10.028,32]tetratriaconta-1(32),2,4,6(34),7,9,24,26,28,30-decaen-20-one",676.298,676.298,0,1,0,3,2,1,0,0,0,0,0,0,"",Classification|Patents,2,"",20240318,MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol,Chemical Vendors|Governmental Organizations,""
162732889,KRAS G12C inhibitor 53,KRAS G12C inhibitor 53|HY-147634,441.800,C21H14ClF2N5O2,84.100,713.000,3.300,31,1,7,3,"InChI=1S/C21H14ClF2N5O2/c1-2-16(31)28-8-10(9-28)29-21-11-6-12(22)17(18-13(23)4-3-5-15(18)30)19(24)20(11)25-7-14(21)26-27-29/h2-7,10,30H,1,8-9H2",C=CC(=O)N1CC(C1)N2C3=C(C=NC4=C(C(=C(C=C43)Cl)C5=C(C=CC=C5F)O)F)N=N2,FLWRXXXGEGVGBY-UHFFFAOYSA-N,"1-[3-[8-chloro-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)triazolo[4,5-c]quinolin-1-yl]azetidin-1-yl]prop-2-en-1-one",441.08,441.08,0,1,0,0,0,0,0,0,0,0,9,5,"",Classification|Patents,2,"",20220405,Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol,Chemical Vendors|Governmental Organizations|Research and Development,""
137082301,KRAS inhibitor-6,KRAS inhibitor-6|2022986-61-2|SCHEMBL18128543|AKOS040733543|DA-64784|HY-135864|CS-0115617,546.000,C27H30ClF2N5O3,82.000,788.000,5.000,38,1,9,9,"InChI=1S/C27H30ClF2N5O3/c1-4-21(37)34-10-12-35(13-11-34)26-17-16-18(28)22(23-19(29)8-7-9-20(23)36)24(30)25(17)31-27(32-26)38-15-14-33(5-2)6-3/h4,7-9,16,36H,1,5-6,10-15H2,2-3H3",CCN(CC)CCOC1=NC2=C(C(=C(C=C2C(=N1)N3CCN(CC3)C(=O)C=C)Cl)C4=C(C=CC=C4F)O)F,HVAYAWHLWQQVTK-UHFFFAOYSA-N,1-[4-[6-chloro-2-[2-(diethylamino)ethoxy]-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one,545.201,545.201,0,1,0,0,0,0,0,0,0,0,28,8,"",Classification|Patents,2,"",20190125,"AbaChemScene|AKos Consulting & Solutions|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163196413,KRAS G12D inhibitor 14,"KRAS G12D inhibitor 14|2765254-39-3|EX-A7510|HY-144661|CS-0433545|4-(2,5-Diazabicyclo[2.2.2]octan-2-yl)-6-(2-methoxy-5-(trifluoromethyl)phenyl)thieno[2,3-d]pyrimidine",420.500,C20H19F3N4OS,78.500,597.000,4.500,29,1,9,3,"InChI=1S/C20H19F3N4OS/c1-28-16-5-2-11(20(21,22)23)6-14(16)17-7-15-18(25-10-26-19(15)29-17)27-9-12-3-4-13(27)8-24-12/h2,5-7,10,12-13,24H,3-4,8-9H2,1H3",COC1=C(C=C(C=C1)C(F)(F)F)C2=CC3=C(N=CN=C3S2)N4CC5CCC4CN5,DYYANULKLUNJSO-UHFFFAOYSA-N,"4-(2,5-diazabicyclo[2.2.2]octan-2-yl)-6-[2-methoxy-5-(trifluoromethyl)phenyl]thieno[2,3-d]pyrimidine",420.123,420.123,0,1,0,2,0,2,0,0,0,0,0,0,"",Classification|Patents,2,"",20220428,"10X CHEM|A2B Chem|AbaChemScene|Amadis Chemical|BLD Pharm|eNovation Chemicals|Excenen Pharmatech|J&H Chemical Co.,ltd|Mcule|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SynHet - Synthetic Heterocycles|TargetMol",Chemical Vendors|Governmental Organizations|Research and Development,""
135148879,KRAS inhibitor-14,KRAS inhibitor-14|SCHEMBL20296664|2230873-78-4|DA-54682|HY-146544|CS-0437262,486.800,C20H15Cl3FN3O2S,84.900,657.000,5.900,30,1,6,3,"InChI=1S/C20H15Cl3FN3O2S/c1-2-15(29)26-3-5-27(6-4-26)20-12-9-13(21)16(18(24)19(12)25-30-20)11-7-10(28)8-14(22)17(11)23/h2,7-9,28H,1,3-6H2",C=CC(=O)N1CCN(CC1)C2=C3C=C(C(=C(C3=NS2)F)C4=C(C(=CC(=C4)O)Cl)Cl)Cl,ZCRFSHDFEGWLDB-UHFFFAOYSA-N,"1-[4-[5-chloro-6-(2,3-dichloro-5-hydroxyphenyl)-7-fluoro-2,1-benzothiazol-3-yl]piperazin-1-yl]prop-2-en-1-one",484.993,484.993,0,1,0,0,0,0,0,0,0,0,28,6,"",Classification|Patents,2,"",20181215,"AbaChemScene|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
139520657,KRAS G12C inhibitor 37,"KRAS G12C inhibitor 37|2241720-04-5|SCHEMBL21393650|AHOBXXAGZPGARY-UHFFFAOYSA-N|1-[7-[2-[3-(dimethylamino)azetidin-1-yl]-6-ethenyl-7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one|DA-64772|HY-143590|CS-0373903",660.700,C35H39F3N8O2,93.700,1180.000,6.300,48,1,11,8,"InChI=1S/C35H39F3N8O2/c1-6-22-14-24-30(31(48-20-35(36,37)38)29(22)28-21(3)8-9-26-25(28)15-39-42-26)40-33(45-16-23(17-45)43(4)5)41-32(24)44-12-10-34(11-13-44)18-46(19-34)27(47)7-2/h6-9,14-15,23H,1-2,10-13,16-20H2,3-5H3,(H,39,42)",CC1=C(C2=C(C=C1)NN=C2)C3=C(C4=C(C=C3C=C)C(=NC(=N4)N5CC(C5)N(C)C)N6CCC7(CC6)CN(C7)C(=O)C=C)OCC(F)(F)F,AHOBXXAGZPGARY-UHFFFAOYSA-N,"1-[7-[2-[3-(dimethylamino)azetidin-1-yl]-6-ethenyl-7-(5-methyl-1H-indazol-4-yl)-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one",660.315,660.315,0,1,0,0,0,0,0,0,0,0,12,3,"",Classification|Patents,2,"",20191102,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|ECI Group, LCSB, University of Luxembourg|Google Patents|InvivoChem|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156554845,KRAS G12C inhibitor 40,"KRAS G12C inhibitor 40|2660014-14-0|SCHEMBL23598706|DA-64774|HY-143594|CS-0373933|2-[(2S)-4-[7-(8-chloro-7-fluoronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(E)-3-(1,2,4-triazol-1-yl)prop-2-enoyl]piperazin-2-yl]acetonitrile",671.200,C34H36ClFN10O2,120.000,1190.000,4.200,48,0,11,8,"InChI=1S/C34H36ClFN10O2/c1-42-13-3-5-25(42)20-48-34-40-28-19-43(29-6-2-4-23-7-8-27(36)32(35)31(23)29)14-10-26(28)33(41-34)44-16-17-46(24(18-44)9-12-37)30(47)11-15-45-22-38-21-39-45/h2,4,6-8,11,15,21-22,24-25H,3,5,9-10,13-14,16-20H2,1H3/b15-11+/t24-,25-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=C(C=C5)F)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)/C=C/N7C=NC=N7,BLVBQVLTXVPOLH-LPMFOMBZSA-N,"2-[(2S)-4-[7-(8-chloro-7-fluoronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(E)-3-(1,2,4-triazol-1-yl)prop-2-enoyl]piperazin-2-yl]acetonitrile",670.27,670.27,0,1,0,2,2,0,1,1,0,0,1,1,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Research and Development,""
163196253,KRAS G12C inhibitor 30,KRAS G12C inhibitor 30|2752352-90-0|DA-54670|HY-142481|CS-0372482,508.900,C25H22ClFN6O3,90.800,894.000,3.600,36,1,6,5,"InChI=1S/C25H22ClFN6O3/c1-3-20(34)28-15-7-4-8-16(13-15)31-11-6-12-32-21-22(29-24(31)32)30(2)25(36)33(23(21)35)14-17-18(26)9-5-10-19(17)27/h3-5,7-10,13H,1,6,11-12,14H2,2H3,(H,28,34)",CN1C2=C(C(=O)N(C1=O)CC3=C(C=CC=C3Cl)F)N4CCCN(C4=N2)C5=CC=CC(=C5)NC(=O)C=C,FYTIAUJXQNHTOR-UHFFFAOYSA-N,"N-[3-[3-[(2-chloro-6-fluorophenyl)methyl]-1-methyl-2,4-dioxo-7,8-dihydro-6H-purino[7,8-a]pyrimidin-9-yl]phenyl]prop-2-enamide",508.143,508.143,0,1,0,0,0,0,0,0,0,0,6,1,"",Classification|Patents,2,"",20220428,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|TargetMol",Chemical Vendors|Research and Development,""
135148687,KRAS inhibitor-13,"KRAS inhibitor-13|SCHEMBL20296448|HY-146543|CS-0437259|1-[(1S,5S)-6-[5-chloro-7-fluoro-6-(3-hydroxynaphthalen-1-yl)-2,1-benzothiazol-3-yl]-2,6-diazabicyclo[3.2.0]heptan-2-yl]prop-2-en-1-one|2230873-96-6",480.000,C25H19ClFN3O2S,84.900,791.000,6.200,33,1,6,3,"InChI=1S/C25H19ClFN3O2S/c1-2-21(32)29-8-7-19-20(29)12-30(19)25-17-11-18(26)22(23(27)24(17)28-33-25)16-10-14(31)9-13-5-3-4-6-15(13)16/h2-6,9-11,19-20,31H,1,7-8,12H2/t19-,20-/m0/s1",C=CC(=O)N1CC[C@H]2[C@@H]1CN2C3=C4C=C(C(=C(C4=NS3)F)C5=CC(=CC6=CC=CC=C65)O)Cl,URKYROWBWZUPML-PMACEKPBSA-N,"1-[(1S,5S)-6-[5-chloro-7-fluoro-6-(3-hydroxynaphthalen-1-yl)-2,1-benzothiazol-3-yl]-2,6-diazabicyclo[3.2.0]heptan-2-yl]prop-2-en-1-one",479.087,479.087,0,1,0,2,2,0,0,0,0,0,27,6,"",Classification|Patents,2,"",20181215,AbaChemScene|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
159448580,KRAS G12C inhibitor 44,KRAS G12C inhibitor 44|SCHEMBL23645261|HY-142946|CS-0373987|2927439-07-2,579.100,C31H36ClFN6O2,85.600,1040.000,5.300,41,0,8,6,"InChI=1S/C31H36ClFN6O2/c1-20(33)29(40)39-16-15-38(18-21(39)10-13-34)28-24-9-12-31(11-8-23-25(31)6-3-7-26(23)32)17-27(24)35-30(36-28)41-19-22-5-4-14-37(22)2/h3,6-7,21-22H,1,4-5,8-12,14-19H2,2H3/t21-,22-,31-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CC[C@]4(C3)CCC5=C4C=CC=C5Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F,LTBOVTGFAXPDLV-CYYCZYJVSA-N,"2-[(2S)-4-[(3R)-7-chloro-2'-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]spiro[1,2-dihydroindene-3,7'-6,8-dihydro-5H-quinazoline]-4'-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile",578.257,578.257,0,1,0,3,3,0,0,0,0,0,14,6,"",Classification|Patents,2,"",20211203,AbaChemScene|BLD Pharm|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
171102321,pan-KRAS-IN-6,pan-KRAS-IN-6|HY-162439|CS-1048630,635.100,C29H30ClF3N6O3S,138.000,1020.000,5.000,43,2,13,5,"InChI=1S/C29H30ClF3N6O3S/c1-28(40)12-38(7-8-41-13-28)25-17-9-18(30)20(16-3-4-19(32)24-23(16)35-26(34)43-24)21(33)22(17)36-27(37-25)42-14-29-5-2-6-39(29)11-15(31)10-29/h3-4,9,15,40H,2,5-8,10-14H2,1H3,(H2,34,35)/t15-,28?,29+/m1/s1",CC1(CN(CCOC1)C2=NC(=NC3=C(C(=C(C=C32)Cl)C4=C5C(=C(C=C4)F)SC(=N5)N)F)OC[C@@]67CCCN6C[C@@H](C7)F)O,NXVYZWVJBHOCQU-SMWMPNNISA-N,"4-[7-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-6-chloro-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]quinazolin-4-yl]-6-methyl-1,4-oxazepan-6-ol",634.174,634.174,0,1,0,3,2,1,0,0,0,0,0,0,"",Classification|Patents,2,"",20240405,AbaChemScene|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol,Chemical Vendors|Governmental Organizations,""
165178671,Sos1/kras-IN-1,SOS1/KRAS-IN-1|HY-153940|CS-0867886,457.500,C24H26F3N5O,76.300,681.000,4.600,33,2,9,4,"InChI=1S/C24H26F3N5O/c1-13(16-7-17(24(25,26)27)10-18(28)8-16)29-23-20-11-22-15(9-21(20)30-14(2)31-23)3-5-32(22)19-4-6-33-12-19/h7-11,13,19H,3-6,12,28H2,1-2H3,(H,29,30,31)/t13-,19?/m1/s1",CC1=NC2=C(C=C3C(=C2)CCN3C4CCOC4)C(=N1)N[C@H](C)C5=CC(=CC(=C5)N)C(F)(F)F,DPVUKUXCCDJCEG-BSOCMFCZSA-N,"N-[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]-2-methyl-6-(oxolan-3-yl)-7,8-dihydropyrrolo[2,3-g]quinazolin-4-amine",457.209,457.209,0,1,0,2,1,1,0,0,0,0,3,3,"",Classification|Patents,2,"",20221007,AbaChemScene|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol,Chemical Vendors|Governmental Organizations|Research and Development,""
166176932,KRAS G12C inhibitor 57,KRAS G12C inhibitor 57|CHEMBL5396975|BDBM50633192|HY-151968|CS-0626921,607.700,C35H38FN7O2,90.500,1150.000,5.200,45,0,8,7,"InChI=1S/C35H38FN7O2/c1-4-30(44)43-17-16-41(21-26(43)12-14-37)33-28-18-29(27-11-6-10-24-9-5-8-23(2)31(24)27)40(3)32(28)38-34(39-33)45-22-35-13-7-15-42(35)20-25(36)19-35/h4-6,8-11,18,25-26H,1,7,12-13,15-17,19-22H2,2-3H3/t25-,26+,35+/m1/s1",CC1=C2C(=CC=C1)C=CC=C2C3=CC4=C(N3C)N=C(N=C4N5CCN([C@H](C5)CC#N)C(=O)C=C)OC[C@@]67CCCN6C[C@@H](C7)F,HCSKCYFFHLJNOD-AWYDNWMNSA-N,"2-[(2S)-4-[2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7-methyl-6-(8-methylnaphthalen-1-yl)pyrrolo[2,3-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",607.307,607.307,0,1,0,3,3,0,0,0,0,0,0,0,"",Biological Test Results|Classification,2,2032562|2032563|2032564|2032565|2032566|2032567|2032568|2032569|2032570|2032571|2032572|2032573|2032574|2032575|2032576|2032577|2032578|2032579|2032580|2032581|2032582|2032583|2032584|2032585|2032586|2032587|2032588|2032589|2032590|2032591|2032592|2032593|2032594|2032595|2032596|2032597|2032599|2032600|2032601|2032602|2032603|2032604|2032605|2032606|2032607|2032608|2032609|2032610|2032611|2032612|2032613|2032614|2032615|2032616|2032617|2032618|2032619|2032620|2032621|2032622|2032623|2032624|2032625|2032626,20230103,AbaChemScene|BindingDB|ChEMBL|MedChemexpress MCE,Chemical Vendors|Curation Efforts|Research and Development,""
171479052,KRAS G12D inhibitor 24,KRAS G12D inhibitor 24|HY-158703|CS-1096844,614.700,C34H33F3N6O2,86.600,1140.000,5.100,45,2,11,6,"InChI=1S/C34H33F3N6O2/c1-4-24-27(36)8-5-19-11-23(44)12-25(28(19)24)30-29(37)31-26(14-38-30)32(43-15-21-6-7-22(16-43)39-21)41-33(40-31)45-18-34(2)17-42(3)10-9-20(34)13-35/h1,5,8,11-14,21-22,39,44H,6-7,9-10,15-18H2,2-3H3/b20-13+/t21-,22+,34-/m0/s1",C[C@]\1(CN(CC/C1=C\F)C)COC2=NC3=C(C(=NC=C3C(=N2)N4C[C@H]5CC[C@@H](C4)N5)C6=C7C(=CC(=C6)O)C=CC(=C7C#C)F)F,TXSGYODOAZBXEM-PDHRFWIKSA-N,"4-[4-[(1S,5R)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-[[(3S,4E)-4-(fluoromethylidene)-1,3-dimethylpiperidin-3-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol",614.262,614.262,0,1,0,3,3,0,1,1,0,0,0,0,"",Classification|Patents,2,"",20240620,AbaChemScene|MedChemexpress MCE|PATENTSCOPE (WIPO),Chemical Vendors|Governmental Organizations,""
155244644,KRAS G12C inhibitor 55,KRAS G12C inhibitor 55|SCHEMBL22600800|HY-147636,659.700,C36H40F3N7O2,90.500,1160.000,6.600,48,1,10,7,"InChI=1S/C36H40F3N7O2/c1-5-23-17-25-31(32(48-21-36(37,38)39)30(23)29-22(3)7-8-27-26(29)18-40-43-27)41-33(24-9-13-44(4)14-10-24)42-34(25)45-15-11-35(12-16-45)19-46(20-35)28(47)6-2/h5-8,17-18,24H,1-2,9-16,19-21H2,3-4H3,(H,40,43)",CC1=C(C2=C(C=C1)NN=C2)C3=C(C4=C(C=C3C=C)C(=NC(=N4)C5CCN(CC5)C)N6CCC7(CC6)CN(C7)C(=O)C=C)OCC(F)(F)F,MGBRYMOYNPZMKP-UHFFFAOYSA-N,"1-[7-[6-ethenyl-7-(5-methyl-1H-indazol-4-yl)-2-(1-methylpiperidin-4-yl)-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one",659.32,659.32,0,1,0,0,0,0,0,0,0,0,15,6,"",Classification|Patents,2,"",20201219,Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
162732836,KRAS G12C inhibitor 52,KRAS G12C inhibitor 52|SCHEMBL25412792|HY-147633,670.700,C34H32F2N8O3S,157.000,1370.000,4.300,48,1,11,4,"InChI=1S/C34H32F2N8O3S/c1-7-23(45)42-14-22-32(46)41(6)29-28(43(22)13-17(42)5)19-12-21(36)25(18-8-9-20(35)30-26(18)40-34(37)48-30)39-31(19)44(33(29)47)27-16(4)10-11-38-24(27)15(2)3/h7-12,15,17,22H,1,13-14H2,2-6H3,(H2,37,40)/t17-,22-/m1/s1",C[C@@H]1CN2[C@H](CN1C(=O)C=C)C(=O)N(C3=C2C4=CC(=C(N=C4N(C3=O)C5=C(C=CN=C5C(C)C)C)C6=C7C(=C(C=C6)F)SC(=N7)N)F)C,BVZBQFKRIRKRES-VGOFRKELSA-N,"(4R,7R)-15-(2-amino-7-fluoro-1,3-benzothiazol-4-yl)-16-fluoro-4,9-dimethyl-12-(4-methyl-2-propan-2-ylpyridin-3-yl)-5-prop-2-enoyl-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione",670.229,670.229,0,1,0,2,2,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20220405,MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
164517053,KRAS G12C inhibitor 54,KRAS G12C inhibitor 54|HY-147635,707.800,C36H40F3N7O3S,125.000,1380.000,7.300,50,1,11,7,"InChI=1S/C36H40F3N7O3S/c1-3-28(47)46-19-35(20-46)11-13-45(14-12-35)33-25-17-24(23-8-9-23)30(29-22(2)7-10-27-26(29)18-40-43-27)32(49-21-36(37,38)39)31(25)41-34(42-33)44-50(48)15-5-4-6-16-50/h3,7,10,17-18,23H,1,4-6,8-9,11-16,19-21H2,2H3,(H,40,43)",CC1=C(C2=C(C=C1)NN=C2)C3=C(C=C4C(=C3OCC(F)(F)F)N=C(N=C4N5CCC6(CC5)CN(C6)C(=O)C=C)N=S7(=O)CCCCC7)C8CC8,MOWSGIAREXMCDJ-UHFFFAOYSA-N,"1-[7-[6-cyclopropyl-7-(5-methyl-1H-indazol-4-yl)-2-[(1-oxothian-1-ylidene)amino]-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one",707.287,707.287,0,1,0,0,0,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20220727,MedChemexpress MCE|PATENTSCOPE (WIPO),Chemical Vendors|Governmental Organizations,""
156443495,KRAS G12C inhibitor 28,"KRAS G12C inhibitor 28|2649004-88-4|SCHEMBL23460319|DA-74790|HY-142460|CS-0372433|1-(4-dimethylphosphoryl-2-methyl-6-propan-2-ylphenyl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one",635.600,C33H36F2N5O4P,106.000,1210.000,4.000,45,1,7,6,"InChI=1S/C33H36F2N5O4P/c1-8-27(42)38-12-13-39(20(5)17-38)31-23-16-25(35)29(28-24(34)10-9-11-26(28)41)36-32(23)40(33(43)37-31)30-19(4)14-21(45(6,7)44)15-22(30)18(2)3/h8-11,14-16,18,20,41H,1,12-13,17H2,2-7H3/t20-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=C(C=C5C)P(=O)(C)C)C(C)C)C(=O)C=C,AULVAQHFJPQQED-FQEVSTJZSA-N,"1-(4-dimethylphosphoryl-2-methyl-6-propan-2-ylphenyl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one",635.247,635.247,0,1,0,1,1,0,0,0,0,0,9,5,"",Classification|Patents,2,"",20210821,"10X CHEM|A2B Chem|AbaChemScene|Amadis Chemical|BLD Pharm|Debye Scientific Co., Ltd|eNovation Chemicals|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156461319,KRAS G12C inhibitor 27,"KRAS G12C inhibitor 27|2648584-51-2|SCHEMBL23481490|DA-54668|HY-142458|CS-0372427|2-[(2S)-1-(2-fluoroprop-2-enoyl)-4-[(7R)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile",588.600,C29H32F4N6O3,94.800,1020.000,3.600,42,0,12,7,"InChI=1S/C29H32F4N6O3/c1-18(30)27(40)39-13-12-38(15-19(39)9-10-34)26-22-17-41-25(21-7-3-4-8-23(21)29(31,32)33)14-24(22)35-28(36-26)42-16-20-6-5-11-37(20)2/h3-4,7-8,19-20,25H,1,5-6,9,11-17H2,2H3/t19-,20-,25+/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CO[C@H](C3)C4=CC=CC=C4C(F)(F)F)C(=N2)N5CCN([C@H](C5)CC#N)C(=O)C(=C)F,QHAKQJHNFQRVOF-ZYLNGJIFSA-N,"2-[(2S)-1-(2-fluoroprop-2-enoyl)-4-[(7R)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-[2-(trifluoromethyl)phenyl]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile",588.247,588.247,0,1,0,3,3,0,0,0,0,0,12,5,"",Classification|Patents,2,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156295495,KRAS G12C inhibitor 46,"KRAS G12C inhibitor 46|2573769-23-8|SCHEMBL23272791|DA-64775|HY-142948|CS-0374015|16,19-difluoro-22-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-3-propan-2-yl-1,4,11,23,26-pentazapentacyclo[16.6.2.02,7.012,17.021,25]hexacosa-2(7),3,5,12(17),13,15,18,20,22,25-decaen-24-one",585.600,C32H33F2N7O2,94.000,1090.000,4.300,43,1,7,3,"InChI=1S/C32H33F2N7O2/c1-5-25(42)39-14-15-40(19(4)17-39)30-21-16-23(34)28-26-22(33)9-6-10-24(26)35-12-7-8-20-11-13-36-27(18(2)3)29(20)41(31(21)37-28)32(43)38-30/h5-6,9-11,13,16,18-19,35H,1,7-8,12,14-15,17H2,2-4H3/t19-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N3C4=C(CCCNC5=C(C(=CC=C5)F)C6=C(C=C2C3=N6)F)C=CN=C4C(C)C)C(=O)C=C,FFCREROHVMKRFT-IBGZPJMESA-N,"16,19-difluoro-22-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-3-propan-2-yl-1,4,11,23,26-pentazapentacyclo[16.6.2.02,7.012,17.021,25]hexacosa-2(7),3,5,12(17),13,15,18,20,22,25-decaen-24-one",585.266,585.266,0,1,0,1,1,0,0,0,0,0,14,6,"",Classification|Patents,2,"",20210821,"AbaChemScene|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
162732743,KRAS G12C inhibitor 51,"KRAS G12C inhibitor 51|2762632-78-8|DA-54675|HY-147632|6-cyclopropyl-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one",582.700,C33H35FN6O3,102.000,1100.000,4.800,43,1,6,6,"InChI=1S/C33H35FN6O3/c1-6-26(42)38-14-15-39(20(5)17-38)31-23-16-22(21-10-11-21)29(27-24(34)8-7-9-25(27)41)36-32(23)40(33(43)37-31)30-19(4)12-13-35-28(30)18(2)3/h6-9,12-13,16,18,20-21,41H,1,10-11,14-15,17H2,2-5H3/t20-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)C4CC4)C5=C(C=CC=C5F)O)C6=C(C=CN=C6C(C)C)C)C(=O)C=C,ITSNQKZLCHHZEF-FQEVSTJZSA-N,"6-cyclopropyl-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one",582.275,582.275,0,1,0,1,1,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20220405,"Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol",Chemical Vendors|Governmental Organizations,""
137082313,KRAS inhibitor-8,KRAS inhibitor-8|2022986-70-3|SCHEMBL18128570|ABVZCBJMBAVTME-UHFFFAOYSA-N|AKOS040733545|DA-54684|HY-135866|CS-0115620,565.900,C26H24ClF4N5O3,82.000,877.000,4.700,39,1,11,7,"InChI=1S/C26H24ClF4N5O3/c1-2-19(38)35-6-8-36(9-7-35)24-15-12-16(27)20(21-17(28)4-3-5-18(21)37)22(29)23(15)32-25(33-24)39-11-10-34-13-26(30,31)14-34/h2-5,12,37H,1,6-11,13-14H2",C=CC(=O)N1CCN(CC1)C2=NC(=NC3=C(C(=C(C=C32)Cl)C4=C(C=CC=C4F)O)F)OCCN5CC(C5)(F)F,ABVZCBJMBAVTME-UHFFFAOYSA-N,"1-[4-[6-chloro-2-[2-(3,3-difluoroazetidin-1-yl)ethoxy]-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one",565.15,565.15,0,1,0,0,0,0,0,0,0,0,27,8,"",Classification|Patents,2,"",20190125,"AbaChemScene|AKos Consulting & Solutions|BOC Sciences|Debye Scientific Co., Ltd|ECI Group, LCSB, University of Luxembourg|Google Patents|Mcule|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
135148873,KRAS inhibitor-17,KRAS inhibitor-17|SCHEMBL20296657|DA-74808|HY-146475|CS-0499076|2230873-65-9,466.400,C21H18Cl2FN3O2S,73.900,639.000,5.600,30,0,6,4,"InChI=1S/C21H18Cl2FN3O2S/c1-3-17(28)26-6-8-27(9-7-26)21-14-11-16(23)18(19(24)20(14)25-30-21)13-10-12(29-2)4-5-15(13)22/h3-5,10-11H,1,6-9H2,2H3",COC1=CC(=C(C=C1)Cl)C2=C(C3=NSC(=C3C=C2Cl)N4CCN(CC4)C(=O)C=C)F,UPTMOORQEKJHRA-UHFFFAOYSA-N,"1-[4-[5-chloro-6-(2-chloro-5-methoxyphenyl)-7-fluoro-2,1-benzothiazol-3-yl]piperazin-1-yl]prop-2-en-1-one",465.048,465.048,0,1,0,0,0,0,0,0,0,0,22,5,"",Classification|Patents,2,"",20181215,"AbaChemScene|Debye Scientific Co., Ltd|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
138911339,KRAS G12C inhibitor 13,KRAS G12C inhibitor 13|2241719-75-3|SCHEMBL21379069|MODIEPRURJWGTG-UHFFFAOYSA-N|RPD71975|AKOS040733537|DA-74787|HY-126292|CS-0101474,745.800,C40H46F3N7O4,109.000,1310.000,7.200,54,1,12,9,"InChI=1S/C40H46F3N7O4/c1-4-26-20-29-35(36(53-24-40(41,42)43)34(26)33-25(3)6-7-31-30(33)21-44-47-31)45-38(54-28-8-14-48(15-9-28)27-10-18-52-19-11-27)46-37(29)49-16-12-39(13-17-49)22-50(23-39)32(51)5-2/h4-7,20-21,27-28H,1-2,8-19,22-24H2,3H3,(H,44,47)",CC1=C(C2=C(C=C1)NN=C2)C3=C(C4=C(C=C3C=C)C(=NC(=N4)OC5CCN(CC5)C6CCOCC6)N7CCC8(CC7)CN(C8)C(=O)C=C)OCC(F)(F)F,MODIEPRURJWGTG-UHFFFAOYSA-N,"1-[7-[6-ethenyl-7-(5-methyl-1H-indazol-4-yl)-2-[1-(oxan-4-yl)piperidin-4-yl]oxy-8-(2,2,2-trifluoroethoxy)quinazolin-4-yl]-2,7-diazaspiro[3.5]nonan-2-yl]prop-2-en-1-one",745.356,745.356,0,1,0,0,0,0,0,0,0,0,20,4,"",Classification|Patents,2,"",20190902,"A2B Chem|AA BLOCKS|AbaChemScene|AKos Consulting & Solutions|Biosynth|BOC Sciences|Debye Scientific Co., Ltd|ECI Group, LCSB, University of Luxembourg|Google Patents|Lan Pharmatech|Mcule|MedChemexpress MCE|MolGenie|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Legacy Depositors|Research and Development,""
162679270,KRAS G12C inhibitor 23,"KRAS G12C inhibitor 23|2735721-00-1|SCHEMBL25679057|DA-54665|HY-145020|CS-0312209|11-fluoro-4-(4-methyl-2-propan-2-ylpyridin-3-yl)-1-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-6H-isochromeno[4,3-h]quinazolin-3-one",553.600,C32H32FN5O3,78.300,1050.000,4.500,41,0,5,4,"InChI=1S/C32H32FN5O3/c1-6-25(39)36-13-14-37(20(5)16-36)31-23-15-24(33)26-22-10-8-7-9-21(22)17-41-30(26)29(23)38(32(40)35-31)28-19(4)11-12-34-27(28)18(2)3/h6-12,15,18,20H,1,13-14,16-17H2,2-5H3/t20-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N(C3=C4C(=C(C=C32)F)C5=CC=CC=C5CO4)C6=C(C=CN=C6C(C)C)C)C(=O)C=C,UWIDMHGDYVIUOQ-FQEVSTJZSA-N,"11-fluoro-4-(4-methyl-2-propan-2-ylpyridin-3-yl)-1-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-6H-isochromeno[4,3-h]quinazolin-3-one",553.249,553.249,0,1,0,1,1,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20220329,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
4025318,KRAS G12C inhibitor 29,"KRAS G12C inhibitor 29|847337-63-7|3-(2-chloro-6-fluorobenzyl)-1-methyl-9-(3-methylphenyl)-6,7,8,9-tetrahydropyrimido[2,1-f]purine-2,4(1H,3H)-dione|3-[(2-chloro-6-fluorophenyl)methyl]-1-methyl-9-(3-methylphenyl)-7,8-dihydro-6H-purino[7,8-a]pyrimidine-2,4-dione|STL004186|AKOS001408232|DA-54669|HY-142478|CS-0372473|Z246074520",453.900,C23H21ClFN5O2,61.700,743.000,4.200,32,0,5,3,"InChI=1S/C23H21ClFN5O2/c1-14-6-3-7-15(12-14)28-10-5-11-29-19-20(26-22(28)29)27(2)23(32)30(21(19)31)13-16-17(24)8-4-9-18(16)25/h3-4,6-9,12H,5,10-11,13H2,1-2H3",CC1=CC(=CC=C1)N2CCCN3C2=NC4=C3C(=O)N(C(=O)N4C)CC5=C(C=CC=C5Cl)F,GWEBJSRHSQNRTI-UHFFFAOYSA-N,"3-[(2-chloro-6-fluorophenyl)methyl]-1-methyl-9-(3-methylphenyl)-7,8-dihydro-6H-purino[7,8-a]pyrimidine-2,4-dione",453.137,453.137,0,1,0,0,0,0,0,0,0,0,0,0,"",Classification|Spectral Information,2,"",20050913,"A2B Chem|AbaChemScene|ABI Chem|AKos Consulting & Solutions|Ambinter|Aurora Fine Chemicals LLC|BenchChem|BLD Pharm|Chem-Space.com Database|ChemDB|ChemSpider|Debye Scientific Co., Ltd|DiscoveryGate|Enamine|InvivoChem|LabNetwork, a WuXi AppTec Company|Mcule|MedChemexpress MCE|MolPort|NextBio|TargetMol|TimTec|Vitas-M Laboratory|ZINC",Chemical Vendors|Legacy Depositors|Research and Development|Subscription Services,""
154644326,KRAS G12C inhibitor 42,"KRAS G12C inhibitor 42|2454488-02-7|SCHEMBL22220331|DA-74797|HY-143598|CS-0373939|2-[(2S)-4-[8-fluoro-7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",579.700,C33H34FN7O2,98.500,1040.000,4.800,43,0,9,7,"InChI=1S/C33H34FN7O2/c1-4-27(42)41-17-16-40(19-23(41)13-14-35)32-26-18-36-30(25-12-6-10-22-9-5-8-21(2)28(22)25)29(34)31(26)37-33(38-32)43-20-24-11-7-15-39(24)3/h4-6,8-10,12,18,23-24H,1,7,11,13,15-17,19-20H2,2-3H3/t23-,24-/m0/s1",CC1=C2C(=CC=C1)C=CC=C2C3=NC=C4C(=C3F)N=C(N=C4N5CCN([C@H](C5)CC#N)C(=O)C=C)OC[C@@H]6CCCN6C,JCIQWPCUVDTKAS-ZEQRLZLVSA-N,"2-[(2S)-4-[8-fluoro-7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyrido[4,3-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",579.276,579.276,0,1,0,2,2,0,0,0,0,0,12,2,"",Classification|Patents,2,"",20200928,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
168476134,KRAS degrader-1,KRAS degrader-1|HY-153880|CS-0866296,1283.300,C55H57Br2ClFIN8O7,155.000,1970.000,9.600,75,1,14,22,"InChI=1S/C55H57Br2ClFIN8O7/c1-35(59)54(70)68-20-19-67(32-39(68)13-15-61)52-41-14-18-66(49-10-3-7-37-6-2-9-46(58)50(37)49)33-48(41)63-55(64-52)75-34-40-8-4-16-65(40)17-5-21-71-22-23-72-24-25-73-26-27-74-51-44(56)29-36(30-45(51)57)28-43-42-31-38(60)11-12-47(42)62-53(43)69/h2-3,6-7,9-12,28-31,39-40H,1,4-5,8,13-14,16-27,32-34H2,(H,62,69)/b43-28-/t39-,40-/m0/s1",C=C(C(=O)N1CCN(C[C@@H]1CC#N)C2=NC(=NC3=C2CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)OC[C@@H]6CCCN6CCCOCCOCCOCCOC7=C(C=C(C=C7Br)/C=C\8/C9=C(C=CC(=C9)I)NC8=O)Br)F,LOEMJPPVFFSXHV-FXFGZECXSA-N,"2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-[3-[2-[2-[2-[2,6-dibromo-4-[(Z)-(5-iodo-2-oxo-1H-indol-3-ylidene)methyl]phenoxy]ethoxy]ethoxy]ethoxy]propyl]pyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile",1282.14,1280.14,0,1,0,2,2,0,1,1,0,0,0,0,"",Classification|Patents,2,"",20230905,AbaChemScene|MedChemexpress MCE|PATENTSCOPE (WIPO),Chemical Vendors|Governmental Organizations,""
122674123,KRAS inhibitor-22,KRAS inhibitor-22|SCHEMBL18210507|HY-153412|CS-0759425,516.900,C23H21ClF4N2O5,84.900,751.000,3.600,35,1,9,8,"InChI=1S/C23H21ClF4N2O5/c1-34-18-5-4-13(24)7-15(18)23(33)30-6-2-3-12(10-30)22(32)29-9-14(31)11-35-21-19(27)16(25)8-17(26)20(21)28/h4-5,7-8,12H,2-3,6,9-11H2,1H3,(H,29,32)/t12-/m0/s1",COC1=C(C=C(C=C1)Cl)C(=O)N2CCC[C@@H](C2)C(=O)NCC(=O)COC3=C(C(=CC(=C3F)F)F)F,RJCMMQRYZAOCME-LBPRGKRZSA-N,"(3S)-1-(5-chloro-2-methoxybenzoyl)-N-[2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]piperidine-3-carboxamide",516.108,516.108,0,1,0,1,1,0,0,0,0,0,7,1,"",Classification|Patents,2,"",20161208,AbaChemScene|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
166550950,pan-KRAS-IN-4,pan-KRAS-IN-4|SCHEMBL25260276|HY-156528|CS-0883564,636.700,C36H34F2N6O3,94.900,1220.000,5.600,47,1,10,7,"InChI=1S/C36H34F2N6O3/c1-3-25-28(37)10-7-21-15-24(45)16-26(30(21)25)32-31(38)33-27(17-39-32)34(42-18-22-8-9-23(19-42)44(22)29(46)4-2)41-35(40-33)47-20-36-11-5-13-43(36)14-6-12-36/h1,4,7,10,15-17,22-23,45H,2,5-6,8-9,11-14,18-20H2/t22-,23+",C=CC(=O)N1[C@@H]2CC[C@H]1CN(C2)C3=NC(=NC4=C(C(=NC=C43)C5=C6C(=CC(=C5)O)C=CC(=C6C#C)F)F)OCC78CCCN7CCC8,YUFVOCUAYXHCEL-ZRZAMGCNSA-N,"1-[(1S,5R)-3-[7-(8-ethynyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]prop-2-en-1-one",636.266,636.266,0,1,0,2,2,0,0,0,0,0,1,1,"",Classification|Patents,2,"",20230202,AbaChemScene|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156697803,KRAS G12C inhibitor 60,KRAS G12C inhibitor 60,627.600,C31H30F5N7O2,108.000,1160.000,4.600,45,1,10,5,"InChI=1S/C31H30F5N7O2/c1-6-23(44)41-13-17(4)42(14-16(41)3)28-19-12-21(33)26(24-20(32)8-7-9-22(24)37)39-29(19)43(30(45)40-28)27-15(2)10-11-38-25(27)18(5)31(34,35)36/h6-12,16-18H,1,13-14,37H2,2-5H3/t16-,17+,18+/m1/s1",C[C@@H]1CN([C@H](CN1C(=O)C=C)C)C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)N)C5=C(C=CN=C5[C@H](C)C(F)(F)F)C,LGGOSJPOQWNBDO-SQNIBIBYSA-N,"7-(2-amino-6-fluorophenyl)-4-[(2S,5R)-2,5-dimethyl-4-prop-2-enoylpiperazin-1-yl]-6-fluoro-1-[4-methyl-2-[(2S)-1,1,1-trifluoropropan-2-yl]pyridin-3-yl]pyrido[2,3-d]pyrimidin-2-one",627.238,627.238,0,1,0,3,3,0,0,0,0,0,0,0,"",Classification|Patents,2,"",20211110,BLD Pharm|PATENTSCOPE (WIPO),Chemical Vendors|Governmental Organizations,""
163338296,"4-[4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynylnaphthalen-2-ol",KRAS G12D inhibitor 1|2621928-43-4|SCHEMBL25381331|MS-30440|G18296,582.600,C33H32F2N6O2,86.600,1070.000,5.100,43,2,10,6,"InChI=1S/C33H32F2N6O2/c1-2-19-5-3-6-20-11-24(42)12-25(27(19)20)29-28(35)30-26(14-36-29)31(40-16-22-7-8-23(17-40)37-22)39-32(38-30)43-18-33-9-4-10-41(33)15-21(34)13-33/h1,3,5-6,11-12,14,21-23,37,42H,4,7-10,13,15-18H2/t21-,22-,23+,33+/m1/s1",C#CC1=CC=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5C[C@H]6CC[C@@H](C5)N6)OC[C@@]78CCCN7C[C@@H](C8)F)O,HQVNRYKTWPMSGZ-LLXWCGCWSA-N,"4-[4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynylnaphthalen-2-ol",582.255,582.255,0,1,0,4,4,0,0,0,0,0,28,8,"",Classification|Patents,2,"",20220610,"10X CHEM|A2B Chem|AstaTech, Inc.|Google Patents|Key Organics/BIONET|Mcule|MolPort|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
168909406,"(4S)-2-azanyl-4-methyl-4-[3-[2-[(2S)-2-methyl-1,4-diazepan-1-yl]pyrimidin-4-yl]-1,2,4-oxadiazol-5-yl]-6,7-dihydro-5H-1-benzothiophene-3-carbonitrile","(4S)-2-azanyl-4-methyl-4-[3-[2-[(2S)-2-methyl-1,4-diazepan-1-yl]pyrimidin-4-yl]-1,2,4-oxadiazol-5-yl]-6,7-dihydro-5H-1-benzothiophene-3-carbonitrile|pan-KRAS degrader 1|SCHEMBL25242611|EX-A10583|2937327-83-6|WYU",450.600,C22H26N8OS,158.000,719.000,3.400,32,2,10,3,"InChI=1S/C22H26N8OS/c1-13-12-25-8-4-10-30(13)21-26-9-6-15(27-21)19-28-20(31-29-19)22(2)7-3-5-16-17(22)14(11-23)18(24)32-16/h6,9,13,25H,3-5,7-8,10,12,24H2,1-2H3/t13-,22-/m0/s1",C[C@H]1CNCCCN1C2=NC=CC(=N2)C3=NOC(=N3)[C@]4(CCCC5=C4C(=C(S5)N)C#N)C,ITTALXOYNGAVCQ-XMHCIUCPSA-N,"(4S)-2-amino-4-methyl-4-[3-[2-[(2S)-2-methyl-1,4-diazepan-1-yl]pyrimidin-4-yl]-1,2,4-oxadiazol-5-yl]-6,7-dihydro-5H-1-benzothiophene-3-carbonitrile",450.195,450.195,0,1,0,2,2,0,0,0,0,0,2,2,"",Interactions and Pathways|Patents,2,"",20231109,Excenen Pharmatech|NCBI Structure|PATENTSCOPE (WIPO)|Protein Data Bank in Europe (PDBe)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
157023643,KRAS G12C inhibitor 21,KRAS G12C inhibitor 21|2737269-61-1|DA-74789|HY-145018|CS-0312207,580.100,C34H30ClN3O4,81.200,1050.000,6.800,42,1,4,6,"InChI=1S/C34H30ClN3O4/c1-4-32(40)36-17-21(18-36)19-37-30-16-28(35)27(26-14-23(39)13-22-9-5-6-11-25(22)26)15-31(30)38(34(42)33(37)41)29-12-8-7-10-24(29)20(2)3/h4-16,20-21,39H,1,17-19H2,2-3H3",CC(C)C1=CC=CC=C1N2C3=C(C=C(C(=C3)C4=CC(=CC5=CC=CC=C54)O)Cl)N(C(=O)C2=O)CC6CN(C6)C(=O)C=C,RGGFDCIDHSJZIS-UHFFFAOYSA-N,"6-chloro-7-(3-hydroxynaphthalen-1-yl)-1-(2-propan-2-ylphenyl)-4-[(1-prop-2-enoylazetidin-3-yl)methyl]quinoxaline-2,3-dione",579.192,579.192,0,1,0,0,0,0,0,0,0,0,10,2,"",Patents,1,"",20211130,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol",Chemical Vendors|Governmental Organizations|Research and Development,""
156898354,KRAS G12C inhibitor 25,KRAS G12C inhibitor 25|2734060-73-0|SCHEMBL23931956|DA-54666|HY-145022|CS-0312217,555.700,C32H41N7O2,88.800,969.000,4.100,41,0,8,7,"InChI=1S/C32H41N7O2/c1-3-30(40)39-19-18-37(21-25(39)14-15-33)31-27-13-12-24(38-17-6-9-23-8-4-5-11-29(23)38)20-28(27)34-32(35-31)41-22-26-10-7-16-36(26)2/h3-5,8,11,24-26H,1,6-7,9-10,12-14,16-22H2,2H3/t24-,25+,26+/m1/s1",CN1CCC[C@H]1COC2=NC3=C(CC[C@H](C3)N4CCCC5=CC=CC=C54)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,BVNQVRSIVGNVET-ZNZIZOMTSA-N,"2-[(2S)-4-[(7R)-7-(3,4-dihydro-2H-quinolin-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-5,6,7,8-tetrahydroquinazolin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",555.332,555.332,0,1,0,3,3,0,0,0,0,0,12,6,"",Patents,1,"",20211110,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
138611445,KRAS G12C inhibitor 39,"KRAS G12C inhibitor 39|2326522-16-9|SCHEMBL20975014|DA-64773|HY-143592|CS-0373926|2-[(2S)-4-[7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(E)-3-(1-methylpyrazol-4-yl)prop-2-enoyl]piperazin-2-yl]acetonitrile",645.800,C37H43N9O2,107.000,1180.000,4.300,48,0,9,8,"InChI=1S/C37H43N9O2/c1-26-7-4-8-28-9-5-11-33(35(26)28)44-18-15-31-32(24-44)40-37(48-25-30-10-6-17-42(30)2)41-36(31)45-19-20-46(29(23-45)14-16-38)34(47)13-12-27-21-39-43(3)22-27/h4-5,7-9,11-13,21-22,29-30H,6,10,14-15,17-20,23-25H2,1-3H3/b13-12+/t29-,30-/m0/s1",CC1=C2C(=CC=C1)C=CC=C2N3CCC4=C(C3)N=C(N=C4N5CCN([C@H](C5)CC#N)C(=O)/C=C/C6=CN(N=C6)C)OC[C@@H]7CCCN7C,XLWQRAXKTKNFIV-QFFHNCJUSA-N,"2-[(2S)-4-[7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-[(E)-3-(1-methylpyrazol-4-yl)prop-2-enoyl]piperazin-2-yl]acetonitrile",645.354,645.354,0,1,0,2,2,0,1,1,0,0,28,7,"",Patents,1,"",20190720,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
170836109,KRAS ligand 4,KRAS ligand 4|HY-161236|CS-0997838,541.000,C24H28ClF3N6O3,114.000,843.000,2.200,37,2,10,5,"InChI=1S/C24H28ClF3N6O3/c1-13(15-8-16(24(26,27)28)10-17(29)9-15)30-20-18-11-34(12-19(18)31-22(25)32-20)21(36)23(37-3)4-6-33(7-5-23)14(2)35/h8-10,13H,4-7,11-12,29H2,1-3H3,(H,30,31,32)/t13-/m1/s1",C[C@H](C1=CC(=CC(=C1)N)C(F)(F)F)NC2=NC(=NC3=C2CN(C3)C(=O)C4(CCN(CC4)C(=O)C)OC)Cl,MUDCKDVOSZLIJH-CYBMUJFWSA-N,"1-[4-[4-[[(1R)-1-[3-amino-5-(trifluoromethyl)phenyl]ethyl]amino]-2-chloro-5,7-dihydropyrrolo[3,4-d]pyrimidine-6-carbonyl]-4-methoxypiperidin-1-yl]ethanone",540.186,540.186,0,1,0,1,1,0,0,0,0,0,0,0,"",Classification,1,"",20240302,AbaChemScene|MedChemexpress MCE,Chemical Vendors,""
172419445,KRAS inhibitor-25,KRAS inhibitor-25|HY-159475,614.100,C32H38ClF2N5O3,94.800,974.000,6.000,43,2,10,3,"InChI=1S/C32H38ClF2N5O3/c33-25-14-21(41)13-23-22(25)7-3-1-2-4-9-32(42)10-6-11-39(18-32)29-24-16-36-27(23)26(35)28(24)37-30(38-29)43-19-31-8-5-12-40(31)17-20(34)15-31/h13-14,16,20,41-42H,1-12,15,17-19H2/t20-,31+,32?/m1/s1",C1CCCC2(CCCN(C2)C3=NC(=NC4=C(C(=NC=C43)C5=C(CC1)C(=CC(=C5)O)Cl)F)OC[C@@]67CCCN6C[C@@H](C7)F)O,SSELACRWBGIDIN-CSPKMPOGSA-N,"15-chloro-28-fluoro-4-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1,3,5,9-tetrazapentacyclo[21.3.1.16,10.02,7.011,16]octacosa-2,4,6(28),7,9,11(16),12,14-octaene-13,23-diol",613.263,613.263,0,1,0,3,2,1,0,0,0,0,0,0,"",Classification,1,"",20241114,MedChemexpress MCE|TargetMol,Chemical Vendors,""
172420098,KRAS inhibitor-31,KRAS inhibitor-31|HY-159652,617.600,C33H30F3N5O4,93.100,1130.000,4.400,45,1,12,5,"InChI=1S/C33H30F3N5O4/c1-2-22-24(35)6-5-18-11-21(42)12-23(25(18)22)28-27(36)29-26-30(41-9-4-10-43-15-20(41)16-44-31(26)37-28)39-32(38-29)45-17-33-7-3-8-40(33)14-19(34)13-33/h1,5-6,11-12,19-20,42H,3-4,7-10,13-17H2/t19-,20+,33+/m1/s1",C#CC1=C(C=CC2=CC(=CC(=C21)C3=C(C4=C5C(=NC(=N4)OC[C@@]67CCCN6C[C@@H](C7)F)N8CCCOC[C@H]8COC5=N3)F)O)F,LWYZDHJRUISMAW-FSSPWDJASA-N,"5-ethynyl-6-fluoro-4-[(8S)-14-fluoro-17-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-6,10-dioxa-2,12,16,18-tetrazatetracyclo[9.7.1.02,8.015,19]nonadeca-1(18),11,13,15(19),16-pentaen-13-yl]naphthalen-2-ol",617.225,617.225,0,1,0,3,3,0,0,0,0,0,0,0,"",Classification,1,"",20241119,MedChemexpress MCE|TargetMol,Chemical Vendors,""
172677015,KRAS G12C inhibitor 69,KRAS G12C inhibitor 69|HY-170550,588.000,C29H29ClF3N5O3,82.000,963.000,5.200,41,1,10,6,"InChI=1S/C29H29ClF3N5O3/c1-2-22(40)36-9-11-37(12-10-36)27-18-13-19(30)23(24-20(32)5-3-6-21(24)39)25(33)26(18)34-28(35-27)41-16-29-7-4-8-38(29)15-17(31)14-29/h2-3,5-6,13,17,39H,1,4,7-12,14-16H2/t17-,29+/m1/s1",C=CC(=O)N1CCN(CC1)C2=NC(=NC3=C(C(=C(C=C32)Cl)C4=C(C=CC=C4F)O)F)OC[C@@]56CCCN5C[C@@H](C6)F,QAOKBMKTEBRJEC-JWRCQZCYSA-N,"1-[4-[6-chloro-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one",587.191,587.191,0,1,0,2,2,0,0,0,0,0,0,0,"",Classification,1,"",20250307,MedChemexpress MCE,Chemical Vendors,""
156747886,KRAS G12D inhibitor 11,"KRAS G12D inhibitor 11|2648551-72-6|DA-74800|HY-143604|CS-0373957|[1-[7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperidin-4-yl]boronic acid",515.500,C29H38BN5O3,85.200,770.000,"",38,2,8,6,"InChI=1S/C29H38BN5O3/c1-20-6-3-7-21-8-4-10-26(27(20)21)35-17-13-24-25(18-35)31-29(38-19-23-9-5-14-33(23)2)32-28(24)34-15-11-22(12-16-34)30(36)37/h3-4,6-8,10,22-23,36-37H,5,9,11-19H2,1-2H3/t23-/m0/s1",B(C1CCN(CC1)C2=NC(=NC3=C2CCN(C3)C4=CC=CC5=CC=CC(=C54)C)OC[C@@H]6CCCN6C)(O)O,ICCOZNHBVIPEIG-QHCPKHFHSA-N,"[1-[7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperidin-4-yl]boronic acid",515.307,515.307,0,1,0,1,1,0,0,0,0,0,8,2,"",Patents,1,"",20211110,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol",Chemical Vendors|Governmental Organizations|Research and Development,""
163196254,KRAS G12C inhibitor 31,KRAS G12C inhibitor 31|2752352-86-4|DA-74792|HY-142485|CS-0372487,508.900,C25H22ClFN6O3,90.800,886.000,3.600,36,1,6,5,"InChI=1S/C25H22ClFN6O3/c1-3-20(34)28-15-8-10-16(11-9-15)31-12-5-13-32-21-22(29-24(31)32)30(2)25(36)33(23(21)35)14-17-18(26)6-4-7-19(17)27/h3-4,6-11H,1,5,12-14H2,2H3,(H,28,34)",CN1C2=C(C(=O)N(C1=O)CC3=C(C=CC=C3Cl)F)N4CCCN(C4=N2)C5=CC=C(C=C5)NC(=O)C=C,VXJGLDRLVRUPIS-UHFFFAOYSA-N,"N-[4-[3-[(2-chloro-6-fluorophenyl)methyl]-1-methyl-2,4-dioxo-7,8-dihydro-6H-purino[7,8-a]pyrimidin-9-yl]phenyl]prop-2-enamide",508.143,508.143,0,1,0,0,0,0,0,0,0,0,0,0,"",Classification,1,"",20220428,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|MedChemexpress MCE|TargetMol",Chemical Vendors,""
172638483,KRAS G12D inhibitor 19,KRAS G12D inhibitor 19|HY-160445,624.700,C35H34F2N6O3,95.900,1170.000,4.700,46,2,11,8,"InChI=1S/C35H34F2N6O3/c1-2-25-28(36)6-3-19-9-23(44)11-26(29(19)25)31-30(37)32-27(12-38-31)33(42-13-20-4-5-21(14-42)39-20)41-34(40-32)46-18-35(7-8-35)17-43-15-24-10-22(43)16-45-24/h1,3,6,9,11-12,20-22,24,39,44H,4-5,7-8,10,13-18H2/t20?,21?,22-,24-/m0/s1",C#CC1=C(C=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OCC7(CC7)CN8C[C@@H]9C[C@H]8CO9)O)F,GTODZMKQAVURTR-AELPEBTASA-N,"4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[[1-[[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]methyl]cyclopropyl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol",624.266,624.266,0,1,0,4,2,2,0,0,0,0,0,0,"",Classification,1,"",20241231,MedChemexpress MCE|TargetMol,Chemical Vendors,""
132145288,KRas G12C inhibitor 1,"KRas G12C inhibitor 1|2158297-28-8|SCHEMBL19617157|AKOS040733546|DA-54662|HY-112491|CS-0046136|1-[(3S)-4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one",542.700,C31H38N6O3,85.300,891.000,4.400,40,1,8,6,"InChI=1S/C31H38N6O3/c1-4-29(39)36-14-15-37(21(2)18-36)30-26-11-13-35(28-17-24(38)16-22-8-5-6-10-25(22)28)19-27(26)32-31(33-30)40-20-23-9-7-12-34(23)3/h4-6,8,10,16-17,21,23,38H,1,7,9,11-15,18-20H2,2-3H3/t21-,23-/m0/s1",C[C@H]1CN(CCN1C2=NC(=NC3=C2CCN(C3)C4=CC(=CC5=CC=CC=C54)O)OC[C@@H]6CCCN6C)C(=O)C=C,LTVKHYYCQYQXDM-GMAHTHKFSA-N,"1-[(3S)-4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one",542.301,542.301,0,1,0,2,2,0,0,0,0,0,49,12,"",Patents,1,"",20180129,"AbaChemScene|AKos Consulting & Solutions|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156410088,KRAS G12D inhibitor 6,KRAS G12D inhibitor 6|2648552-32-1|SCHEMBL23415474|AKOS040757938|DA-74802|HY-139910|CS-0310582,601.100,C32H37ClN8O2,111.000,1040.000,3.600,43,1,9,7,"InChI=1S/C32H37ClN8O2/c1-38-13-4-7-23(38)20-43-32-36-27-19-39(28-9-3-6-21-5-2-8-25(33)29(21)28)14-11-24(27)30(37-32)40-15-16-41(22(18-40)10-12-34)31(42)26-17-35-26/h2-3,5-6,8-9,22-23,26,35H,4,7,10-11,13-20H2,1H3/t22-,23-,26+/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)[C@H]7CN7,CSLYXEVBZNMNDE-JCYRPKCISA-N,"2-[(2S)-1-[(2R)-aziridine-2-carbonyl]-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile",600.273,600.273,0,1,0,3,3,0,0,0,0,0,10,2,"",Patents,1,"",20210821,"AbaChemScene|AKos Consulting & Solutions|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
157023450,KRAS G12C inhibitor 22,"KRAS G12C inhibitor 22|2736599-72-5|DA-64770|HY-145019|CS-0312208|2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(5,6,7,8-tetrahydronaphthalen-1-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",555.700,C32H41N7O2,88.800,969.000,4.200,41,0,8,7,"InChI=1S/C32H41N7O2/c1-3-30(40)39-19-18-38(20-24(39)13-15-33)31-27-14-17-37(29-12-6-9-23-8-4-5-11-26(23)29)21-28(27)34-32(35-31)41-22-25-10-7-16-36(25)2/h3,6,9,12,24-25H,1,4-5,7-8,10-11,13-14,16-22H2,2H3/t24-,25-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4CCCC5)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,KTRZIDXGTRBXAH-DQEYMECFSA-N,"2-[(2S)-4-[2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-7-(5,6,7,8-tetrahydronaphthalen-1-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",555.332,555.332,0,1,0,2,2,0,0,0,0,0,0,0,"",Patents,1,"",20211130,"AbaChemScene|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol",Chemical Vendors|Governmental Organizations,""
163196256,KRAS G12C inhibitor 34,"KRAS G12C inhibitor 34|2749948-26-1|SCHEMBL24070494|DA-54671|HY-142511|CS-0372560|(4aR)-7-chloro-8-(5-methyl-1H-indazol-4-yl)-10-(2-propan-2-ylanilino)-3-prop-2-enoyl-2,4,4a,5-tetrahydro-1H-pyrazino[2,1-c][1,4]benzoxazepin-11-one",570.100,C32H32ClN5O3,90.600,981.000,6.500,41,2,5,5,"InChI=1S/C32H32ClN5O3/c1-5-27(39)37-12-13-38-20(16-37)17-41-31-29(32(38)40)26(35-24-9-7-6-8-21(24)18(2)3)14-22(30(31)33)28-19(4)10-11-25-23(28)15-34-36-25/h5-11,14-15,18,20,35H,1,12-13,16-17H2,2-4H3,(H,34,36)/t20-/m1/s1",CC1=C(C2=C(C=C1)NN=C2)C3=CC(=C4C(=C3Cl)OC[C@H]5CN(CCN5C4=O)C(=O)C=C)NC6=CC=CC=C6C(C)C,SPPFMHRDAZXATL-HXUWFJFHSA-N,"(4aR)-7-chloro-8-(5-methyl-1H-indazol-4-yl)-10-(2-propan-2-ylanilino)-3-prop-2-enoyl-2,4,4a,5-tetrahydro-1H-pyrazino[2,1-c][1,4]benzoxazepin-11-one",569.219,569.219,0,1,0,1,1,0,0,0,0,0,2,1,"",Patents,1,"",20220428,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
132145654,KRAS-G12C inhibitor 13,KRAS-G12C inhibitor 13|2158296-45-6|SCHEMBL19617582,528.600,C30H36N6O3,85.300,853.000,4.000,39,1,8,6,"InChI=1S/C30H36N6O3/c1-3-28(38)34-13-15-35(16-14-34)29-25-10-12-36(27-18-23(37)17-21-7-4-5-9-24(21)27)19-26(25)31-30(32-29)39-20-22-8-6-11-33(22)2/h3-5,7,9,17-18,22,37H,1,6,8,10-16,19-20H2,2H3/t22-/m1/s1",CN1CCC[C@@H]1COC2=NC3=C(CCN(C3)C4=CC(=CC5=CC=CC=C54)O)C(=N2)N6CCN(CC6)C(=O)C=C,GQSSXKRUKAMOQS-JOCHJYFZSA-N,"1-[4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-1-yl]prop-2-en-1-one",528.285,528.285,0,1,0,1,1,0,0,0,0,0,55,13,"",Patents,1,"",20180129,DC Chemicals|Google Patents|PATENTSCOPE (WIPO)|Starshine Chemical|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
168355656,KRAS G12C inhibitor 58,KRAS G12C inhibitor 58|HY-153461|CS-0775266,1074.600,C51H64ClF4N9O8S,209.000,2000.000,6.400,74,2,17,11,"InChI=1S/C51H64ClF4N9O8S/c1-28(2)42(61(6)46(67)31-12-14-63(24-31)48(69)44(52)53)45(66)59-37-21-40-58-38(25-74-40)30-10-11-39-33(19-30)35(22-50(4,5)27-73-49(70)36-9-8-13-65(60-36)47(37)68)43(64(39)26-51(54,55)56)34-20-32(62-15-17-72-18-16-62)23-57-41(34)29(3)71-7/h10-11,19-20,23,25,28-29,31,36-37,42,44,60H,8-9,12-18,21-22,24,26-27H2,1-7H3,(H,59,66)/t29-,31+,36-,37+,42-,44+/m0/s1",C[C@@H](C1=C(C=C(C=N1)N2CCOCC2)C3=C4CC(COC(=O)[C@@H]5CCCN(N5)C(=O)[C@@H](CC6=NC(=CS6)C7=CC4=C(N3CC(F)(F)F)C=C7)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@@H]8CCN(C8)C(=O)[C@@H](F)Cl)(C)C)OC,KDHLCKSULTVNFP-SGVGZKEWSA-N,"(3R)-1-[(2S)-2-chloro-2-fluoroacetyl]-N-[(2S)-1-[[(7R,13S)-20-[2-[(1S)-1-methoxyethyl]-5-morpholin-4-ylpyridin-3-yl]-17,17-dimethyl-8,14-dioxo-21-(2,2,2-trifluoroethyl)-15-oxa-4-thia-9,21,27,28-tetrazapentacyclo[17.5.2.12,5.19,13.022,26]octacosa-1(25),2,5(28),19,22(26),23-hexaen-7-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylpyrrolidine-3-carboxamide",1073.42,1073.42,0,1,0,6,6,0,0,0,0,0,0,0,"",Classification,1,"",20230706,AbaChemScene|MedChemexpress MCE,Chemical Vendors,""
167010841,PROTAC KRAS G12C degrader-3,PROTAC KRAS G12C degrader-3|SCHEMBL24321181|HY-153881|CS-0866302,1159.800,C63H75ClN14O6,216.000,2260.000,7.000,84,3,16,16,"InChI=1S/C63H75ClN14O6/c1-6-56(81)77-31-30-76(37-45(77)18-22-65)58-48-21-25-75(53-13-9-11-42-10-8-12-51(64)57(42)53)38-52(48)67-63(68-58)84-39-47-32-46(36-71(47)5)73-26-28-74(29-27-73)62(83)43-19-23-72(24-20-43)35-41-14-16-44(17-15-41)78-59(69-70-60(78)61(82)66-7-2)50-33-49(40(3)4)54(79)34-55(50)80/h6,8-17,33-34,40,43,45-47,79-80H,1,7,18-21,23-32,35-39H2,2-5H3,(H,66,82)/t45-,46-,47-/m0/s1",CCNC(=O)C1=NN=C(N1C2=CC=C(C=C2)CN3CCC(CC3)C(=O)N4CCN(CC4)[C@H]5C[C@H](N(C5)C)COC6=NC7=C(CCN(C7)C8=CC=CC9=C8C(=CC=C9)Cl)C(=N6)N1CCN([C@H](C1)CC#N)C(=O)C=C)C1=CC(=C(C=C1O)O)C(C)C,RKQABCMDWYZJBX-OLCJBLMYSA-N,"4-[4-[[4-[4-[(3S,5S)-5-[[7-(8-chloronaphthalen-1-yl)-4-[(3S)-3-(cyanomethyl)-4-prop-2-enoylpiperazin-1-yl]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-2-yl]oxymethyl]-1-methylpyrrolidin-3-yl]piperazine-1-carbonyl]piperidin-1-yl]methyl]phenyl]-5-(2,4-dihydroxy-5-propan-2-ylphenyl)-N-ethyl-1,2,4-triazole-3-carboxamide",1158.57,1158.57,0,1,0,3,3,0,0,0,0,0,2,1,"",Patents,1,"",20230321,AbaChemScene|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
172677349,KRAS inhibitor-40,KRAS inhibitor-40|HY-168442,1102.700,C53H68ClF4N9O8S,207.000,2320.000,5.300,76,2,18,10,"InChI=1S/C53H68ClF4N9O8S/c1-29(2)42(63(6)50(72)52(56)10-13-65(14-11-52)48(70)45(54)55)46(68)61-38-22-40-60-39(26-76-40)31-19-32-23-53(57,58)27-66-43(32)34(20-31)36(24-51(4,5)28-75-49(71)37-9-8-12-67(62-37)47(38)69)44(66)35-21-33(64-15-17-74-18-16-64)25-59-41(35)30(3)73-7/h19-21,25-26,29-30,32,37-38,42-43,45,62H,8-18,22-24,27-28H2,1-7H3,(H,61,68)/t30-,32?,37-,38-,42-,43?,45-/m0/s1",C[C@@H](C1=C(C=C(C=N1)N2CCOCC2)C3=C4CC(COC(=O)[C@@H]5CCCN(N5)C(=O)[C@H](CC6=NC(=CS6)C7=CC8CC(CN3C8C4=C7)(F)F)NC(=O)[C@H](C(C)C)N(C)C(=O)C9(CCN(CC9)C(=O)[C@H](F)Cl)F)(C)C)OC,HCNZTKDLHLGHKH-PSQNEMMXSA-N,"1-[(2R)-2-chloro-2-fluoroacetyl]-N-[(2S)-1-[[(7S,13S)-23,23-difluoro-20-[2-[(1S)-1-methoxyethyl]-5-morpholin-4-ylpyridin-3-yl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,30,31-tetrazahexacyclo[23.3.1.12,5.19,13.019,27.021,26]hentriaconta-1(29),2,5(31),19,27-pentaen-7-yl]amino]-3-methyl-1-oxobutan-2-yl]-4-fluoro-N-methylpiperidine-4-carboxamide",1101.45,1101.45,0,1,0,7,5,2,0,0,0,0,0,0,"",Classification,1,"",20250307,MedChemexpress MCE,Chemical Vendors,""
168448409,KRas G12R inhibitor 1,KRas G12R inhibitor 1,867.200,C39H34ClF7N6O7,144.000,1610.000,7.600,60,0,19,11,"InChI=1S/C39H34ClF7N6O7/c1-20(54)37(59-33(56)38(42,43)44,60-34(57)39(45,46)47)32(55)53-22-10-11-23(53)18-51(17-22)31-25-16-48-29(24-8-2-6-21-7-3-9-26(40)27(21)24)28(41)30(25)49-35(50-31)58-19-36-12-4-14-52(36)15-5-13-36/h2-3,6-9,16,22-23H,4-5,10-15,17-19H2,1H3/t22-,23+",CC(=O)C(C(=O)N1[C@@H]2CC[C@H]1CN(C2)C3=NC(=NC4=C(C(=NC=C43)C5=CC=CC6=C5C(=CC=C6)Cl)F)OCC78CCCN7CCC8)(OC(=O)C(F)(F)F)OC(=O)C(F)(F)F,WIVPYDFPOIFDHJ-ZRZAMGCNSA-N,"[1-[(1R,5S)-3-[7-(8-chloronaphthalen-1-yl)-8-fluoro-2-(1,2,3,5,6,7-hexahydropyrrolizin-8-ylmethoxy)pyrido[4,3-d]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-1,3-dioxo-2-(2,2,2-trifluoroacetyl)oxybutan-2-yl] 2,2,2-trifluoroacetate",866.207,866.207,0,1,0,2,2,0,0,0,0,0,0,0,"",Classification,1,"",20230818,BLD Pharm,Chemical Vendors,""
89535456,KRas inhibitor GM-3-18,"KRas inhibitor GM-3-18|SCHEMBL14907228|GLXC-27992|GM-3-18|4-Chloro-N-(3,4-dihydroisoquinolin-2(1H)-yl)benzamide",286.750,C16H15ClN2O,32.299,341.000,3.600,20,1,2,2,"InChI=1S/C16H15ClN2O/c17-15-7-5-13(6-8-15)16(20)18-19-10-9-12-3-1-2-4-14(12)11-19/h1-8H,9-11H2,(H,18,20)",C1CN(CC2=CC=CC=C21)NC(=O)C3=CC=C(C=C3)Cl,QNDVPIUKZOWWIN-UHFFFAOYSA-N,"4-chloro-N-(3,4-dihydro-1H-isoquinolin-2-yl)benzamide",286.087,286.087,0,1,0,0,0,0,0,0,0,0,2,1,"",Patents,1,"",20150213,Glixx Labs Inc|Google Patents|SureChEMBL,Chemical Vendors|Curation Efforts|Research and Development,""
171713834,KRAS G12D inhibitor 22,KRAS G12D inhibitor 22|CS-1048650,644.700,C35H32F4N6O2,86.600,1260.000,5.700,47,2,12,6,"InChI=1S/C35H32F4N6O2/c1-2-23-26(36)7-4-19-10-22(46)11-24(27(19)23)29-28(37)30-25(12-40-29)31(44-13-20-5-6-21(14-44)41-20)43-32(42-30)47-18-34-8-3-9-45(34)17-33(15-34)16-35(33,38)39/h1,4,7,10-12,20-21,41,46H,3,5-6,8-9,13-18H2",C#CC1=C(C=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OCC78CCCN7CC9(C8)CC9(F)F)O)F,WXTUTIXWTVXXEV-UHFFFAOYSA-N,"4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-2-[(1',1'-difluorospiro[2,3,5,7-tetrahydro-1H-pyrrolizine-6,2'-cyclopropane]-8-yl)methoxy]-8-fluoropyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol",644.252,644.252,0,1,0,4,0,4,0,0,0,0,0,0,"",Classification,1,"",20240704,AbaChemScene,Chemical Vendors,""
172420090,KRAS G12C inhibitor 68,KRAS G12C inhibitor 68|HY-159611,634.800,C35H44F2N6O3,74.300,1130.000,3.800,46,0,10,7,"InChI=1S/C35H44F2N6O3/c1-5-30(44)41-15-13-40(14-16-41)28-19-43-26(28)8-6-7-25-27(43)18-29(39-32(25)34(36)37)42-12-10-24(17-23(42)3)31-22(2)9-11-38-33(31)35(45-4)20-46-21-35/h5-7,9,11,18,23-24,26,28,34H,1,8,10,12-17,19-21H2,2-4H3/t23-,24+,26+,28-/m1/s1",C[C@@H]1C[C@H](CCN1C2=NC(=C3C=CC[C@H]4[C@@H](CN4C3=C2)N5CCN(CC5)C(=O)C=C)C(F)F)C6=C(C=CN=C6C7(COC7)OC)C,FMBHZLHLHLRGAZ-LARAJFFGSA-N,"1-[4-[(4R,5S)-10-(difluoromethyl)-12-[(2R,4S)-4-[2-(3-methoxyoxetan-3-yl)-4-methylpyridin-3-yl]-2-methylpiperidin-1-yl]-2,11-diazatricyclo[7.4.0.02,5]trideca-1(13),7,9,11-tetraen-4-yl]piperazin-1-yl]prop-2-en-1-one",634.344,634.344,0,1,0,4,4,0,0,0,0,0,0,0,"",Classification,1,"",20241119,MedChemexpress MCE|TargetMol,Chemical Vendors,""
156410031,KRAS G12D inhibitor 7,"KRAS G12D inhibitor 7|2648552-34-3|SCHEMBL23415412|AKOS040757939|DA-74803|HY-139911|CS-0310584|2-[(2S)-1-[(2R)-aziridine-2-carbonyl]-4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile",582.700,C32H38N8O3,131.000,1040.000,2.600,43,2,10,7,"InChI=1S/C32H38N8O3/c1-37-11-4-6-23(37)20-43-32-35-28-19-38(29-16-24(41)15-21-5-2-3-7-25(21)29)12-9-26(28)30(36-32)39-13-14-40(22(18-39)8-10-33)31(42)27-17-34-27/h2-3,5,7,15-16,22-23,27,34,41H,4,6,8-9,11-14,17-20H2,1H3/t22-,23-,27+/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC(=CC5=CC=CC=C54)O)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)[C@H]7CN7,VLIVLXJUKMHJOI-VMODYCNZSA-N,"2-[(2S)-1-[(2R)-aziridine-2-carbonyl]-4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazin-2-yl]acetonitrile",582.307,582.307,0,1,0,3,3,0,0,0,0,0,14,5,"",Patents,1,"",20210821,"AbaChemScene|AKos Consulting & Solutions|BLD Pharm|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
134326383,KRas G12C inhibitor 4,"KRas G12C inhibitor 4|2206736-07-2|2-Piperazineacetonitrile, 4-[7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[2-(1-piperidinyl)ethoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(1-oxo-2-propen-1-yl)-, (2S)-|SCHEMBL19948449|DTXSID701099716|AKOS040733549|DA-54673|HY-112494|CS-0046139|(2S)-4-[7-(8-Chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[2-(1-piperidinyl)ethoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(1-oxo-2-propen-1-yl)-2-piperazineacetonitrile|2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-(2-piperidin-1-ylethoxy)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",600.200,C33H38ClN7O2,88.800,1000.000,5.000,43,0,8,8,"InChI=1S/C33H38ClN7O2/c1-2-30(42)41-19-18-40(22-25(41)12-14-35)32-26-13-17-39(29-11-7-9-24-8-6-10-27(34)31(24)29)23-28(26)36-33(37-32)43-21-20-38-15-4-3-5-16-38/h2,6-11,25H,1,3-5,12-13,15-23H2/t25-/m0/s1",C=CC(=O)N1CCN(C[C@@H]1CC#N)C2=NC(=NC3=C2CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)OCCN6CCCCC6,XCJKUQVOWJDAQL-VWLOTQADSA-N,"2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-(2-piperidin-1-ylethoxy)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",599.278,599.278,0,1,0,1,1,0,0,0,0,0,36,11,"",Patents,1,"",20180623,"10X CHEM|A2B Chem|AA BLOCKS|AbaChemScene|AKos Consulting & Solutions|BOC Sciences|CymitQuimica|Debye Scientific Co., Ltd|EPA DSSTox|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156409969,KRAS G12D inhibitor 10,"KRAS G12D inhibitor 10|2648551-54-4|SCHEMBL23415342|DA-64780|HY-143603|CS-0373955|(2S)-N-(2-chloroethyl)-2-(cyanomethyl)-4-[7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxamide",617.200,C33H41ClN8O2,101.000,1010.000,4.300,44,1,8,8,"InChI=1S/C33H41ClN8O2/c1-23-6-3-7-24-8-4-10-29(30(23)24)40-17-12-27-28(21-40)37-32(44-22-26-9-5-16-39(26)2)38-31(27)41-18-19-42(25(20-41)11-14-35)33(43)36-15-13-34/h3-4,6-8,10,25-26H,5,9,11-13,15-22H2,1-2H3,(H,36,43)/t25-,26-/m0/s1",CC1=C2C(=CC=C1)C=CC=C2N3CCC4=C(C3)N=C(N=C4N5CCN([C@H](C5)CC#N)C(=O)NCCCl)OC[C@@H]6CCCN6C,AVILYLLOEJVMCV-UIOOFZCWSA-N,"(2S)-N-(2-chloroethyl)-2-(cyanomethyl)-4-[7-(8-methylnaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperazine-1-carboxamide",616.304,616.304,0,1,0,2,2,0,0,0,0,0,9,2,"",Patents,1,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
164173905,KRAS G12C inhibitor 49,"KRAS G12C inhibitor 49|2761380-32-7|SCHEMBL25532675|DA-64777|HY-147630|2-[6-chloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-2-oxopyrido[2,3-d]pyrimidin-7-yl]benzaldehyde",571.100,C31H31ClN6O3,99.100,1040.000,4.200,41,0,5,6,"InChI=1S/C31H31ClN6O3/c1-6-25(40)36-13-14-37(20(5)16-36)29-23-15-24(32)27(22-10-8-7-9-21(22)17-39)34-30(23)38(31(41)35-29)28-19(4)11-12-33-26(28)18(2)3/h6-12,15,17-18,20H,1,13-14,16H2,2-5H3/t20-/m0/s1",C[C@H]1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)Cl)C4=CC=CC=C4C=O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C,ZXUJCJOXPIRART-FQEVSTJZSA-N,"2-[6-chloro-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]-2-oxopyrido[2,3-d]pyrimidin-7-yl]benzaldehyde",570.215,570.215,0,1,0,1,1,0,0,0,0,0,3,1,"",Patents,1,"",20220706,"Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
171391857,pan-KRAS-IN-13,pan-KRAS-IN-13|HY-162446|CS-1048778,602.600,C32H29F3N6O3,95.900,1120.000,3.700,44,2,12,5,"InChI=1S/C32H29F3N6O3/c1-2-21-23(34)5-4-17-10-20(42)11-22(24(17)21)27-26(35)28-25-29(41-9-7-36-13-19(41)15-43-30(25)37-27)39-31(38-28)44-16-32-6-3-8-40(32)14-18(33)12-32/h1,4-5,10-11,18-19,36,42H,3,6-9,12-16H2/t18-,19-,32+/m1/s1",C#CC1=C(C=CC2=CC(=CC(=C21)C3=C(C4=C5C(=NC(=N4)OC[C@@]67CCCN6C[C@@H](C7)F)N8CCNC[C@@H]8COC5=N3)F)O)F,UVGWOZIDYLZZNM-ACIAVJDNSA-N,"5-ethynyl-6-fluoro-4-[(7R)-13-fluoro-16-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-9-oxa-2,5,11,15,17-pentazatetracyclo[8.7.1.02,7.014,18]octadeca-1(17),10,12,14(18),15-pentaen-12-yl]naphthalen-2-ol",602.225,602.225,0,1,0,3,3,0,0,0,0,0,0,0,"",Classification,1,"",20240530,AbaChemScene|MedChemexpress MCE,Chemical Vendors,""
162494732,KRAS G12C inhibitor 56,KRAS G12C inhibitor 56|SCHEMBL24091826|HY-148261|CS-0617473,617.800,C32H39N7O4S,172.000,1080.000,5.300,44,1,11,8,"InChI=1S/C32H39N7O4S/c1-5-28(40)39-14-10-20(11-15-39)42-27-17-26(41-19(2)22-8-7-13-38(22)4)35-31(36-27)23-16-25(37-43-23)32(3)12-6-9-24-29(32)21(18-33)30(34)44-24/h5,16-17,19-20,22H,1,6-15,34H2,2-4H3/t19-,22-,32+/m0/s1",C[C@@H]([C@@H]1CCCN1C)OC2=NC(=NC(=C2)OC3CCN(CC3)C(=O)C=C)C4=CC(=NO4)[C@]5(CCCC6=C5C(=C(S6)N)C#N)C,VPGFGUVVEBRZJS-RKGKDDSLSA-N,"(4S)-2-amino-4-methyl-4-[5-[4-[(1S)-1-[(2S)-1-methylpyrrolidin-2-yl]ethoxy]-6-(1-prop-2-enoylpiperidin-4-yl)oxypyrimidin-2-yl]-1,2-oxazol-3-yl]-6,7-dihydro-5H-1-benzothiophene-3-carbonitrile",617.278,617.278,0,1,0,3,3,0,0,0,0,0,1,1,"",Patents,1,"",20220206,AbaChemScene|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163196189,KRAS G12D inhibitor 3 (TFA),KRAS G12D inhibitor 3 (TFA)|HY-115880A|CS-0416077,748.100,C36H32ClF6N5O4,111.000,1220.000,"",52,3,15,6,"InChI=1S/C34H31ClF3N5O2.C2HF3O2/c1-2-23-27(37)7-4-18-10-22(44)11-24(28(18)23)29-26(35)12-25-31(30(29)38)40-33(41-32(25)42-15-20-5-6-21(16-42)39-20)45-17-34-8-3-9-43(34)14-19(36)13-34;3-2(4,5)1(6)7/h1,4,7,10-12,19-21,39,44H,3,5-6,8-9,13-17H2;(H,6,7)/t19-,20?,21?,34+;/m1./s1",C#CC1=C(C=CC2=CC(=CC(=C21)C3=C(C=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OC[C@@]78CCCN7C[C@@H](C8)F)Cl)O)F.C(=O)(C(F)(F)F)O,PROPDCKDMWSZSE-AJFXEZLGSA-N,"4-[6-chloro-4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]quinazolin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol;2,2,2-trifluoroacetic acid",747.205,747.205,0,2,0,4,2,2,0,0,0,0,0,0,"",Classification,1,"",20220428,AbaChemScene|MedChemexpress MCE|Probes & Drugs portal|TargetMol,Chemical Vendors|Research and Development,""
171714060,KRAS G12D inhibitor 23,KRAS G12D inhibitor 23|CS-1096833,651.700,C35H34F5N5O2,73.800,1150.000,7.300,47,2,12,7,"InChI=1S/C35H34F5N5O2/c1-4-22-26(36)8-5-18-11-21(46)12-23(28(18)22)29-27(37)13-24-31(30(29)38)42-34(43-33(24)45-14-19-6-7-20(15-45)41-19)47-17-35(2)16-44(3)10-9-25(35)32(39)40/h1,5,8,11-13,19-20,25,32,41,46H,6-7,9-10,14-17H2,2-3H3/t19-,20+,25-,35+/m1/s1",C[C@]1(CN(CC[C@@H]1C(F)F)C)COC2=NC3=C(C(=C(C=C3C(=N2)N4C[C@H]5CC[C@@H](C4)N5)F)C6=C7C(=CC(=C6)O)C=CC(=C7C#C)F)F,PAWQTWDCMZJMOA-RODPATAHSA-N,"4-[4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-2-[[(3S,4S)-4-(difluoromethyl)-1,3-dimethylpiperidin-3-yl]methoxy]-6,8-difluoroquinazolin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol",651.263,651.263,0,1,0,4,4,0,0,0,0,0,0,0,"",Classification,1,"",20240704,AbaChemScene,Chemical Vendors,""
168439396,KRAS G12D inhibitor 3 TFA,KRAS G12D inhibitor 3 TFA|2757095-12-6,730.100,C36H30ClF6N5O3,79.800,1350.000,8.000,51,1,14,8,"InChI=1S/C36H30ClF6N5O3/c1-2-23-27(39)7-4-18-10-22(51-33(49)36(41,42)43)11-24(28(18)23)29-26(37)12-25-31(30(29)40)45-34(46-32(25)47-15-20-5-6-21(16-47)44-20)50-17-35-8-3-9-48(35)14-19(38)13-35/h1,4,7,10-12,19-21,44H,3,5-6,8-9,13-17H2/t19-,20?,21?,35+/m1/s1",C#CC1=C(C=CC2=CC(=CC(=C21)C3=C(C=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OC[C@@]78CCCN7C[C@@H](C8)F)Cl)OC(=O)C(F)(F)F)F,TWEQBEFABPHLAR-RCKNTVAISA-N,"[4-[6-chloro-4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]quinazolin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-yl] 2,2,2-trifluoroacetate",729.194,729.194,0,1,0,4,2,2,0,0,0,0,0,0,"",Classification,1,"",20230818,BLD Pharm,Chemical Vendors,""
171391879,pan-KRAS-IN-14,pan-KRAS-IN-14|HY-163488|CS-1049531,624.700,C35H31F3N6O2,86.600,1260.000,5.600,46,2,11,7,"InChI=1S/C35H31F3N6O2/c1-3-6-27-29-32(30(38)31(40-27)25-13-23(45)11-19-7-8-26(37)24(4-2)28(19)25)41-34(42-33(29)43-16-21-12-22(17-43)39-21)46-18-35-9-5-10-44(35)15-20(36)14-35/h2,7-8,11,13,20-22,39,45H,5,9-10,12,14-18H2,1H3/t20-,21?,22?,35+/m1/s1",CC#CC1=C2C(=C(C(=N1)C3=C4C(=CC(=C3)O)C=CC(=C4C#C)F)F)N=C(N=C2N5CC6CC(C5)N6)OC[C@@]78CCCN7C[C@@H](C8)F,RFESPHBPXZKJSG-UTJMDAJZSA-N,"4-[4-(3,6-diazabicyclo[3.1.1]heptan-3-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-5-prop-1-ynylpyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol",624.246,624.246,0,1,0,4,2,2,0,0,0,0,0,0,"",Classification,1,"",20240530,AbaChemScene|MedChemexpress MCE,Chemical Vendors,""
170453287,PROTAC KRAS G12D degrader 1,PROTAC KRAS G12D degrader 1|HY-161176|CS-0979304,1103.300,C59H72F2N10O7S,236.000,2020.000,8.400,79,5,17,20,"InChI=1S/C59H72F2N10O7S/c1-7-43-46(60)19-16-37-23-41(72)24-44(49(37)43)51-50(61)52-45(26-62-51)55(70-27-38-17-18-39(28-70)65-38)68-58(67-52)78-30-40-11-10-21-69(40)20-8-9-22-77-31-48(74)66-54(59(4,5)6)57(76)71-29-42(73)25-47(71)56(75)64-33(2)35-12-14-36(15-13-35)53-34(3)63-32-79-53/h12-16,19,23-24,26,32-33,38-40,42,47,54,65,72-73H,7-11,17-18,20-22,25,27-31H2,1-6H3,(H,64,75)(H,66,74)/t33-,38?,39?,40-,42+,47-,54+/m0/s1",CCC1=C(C=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OC[C@@H]7CCCN7CCCCOCC(=O)N[C@H](C(=O)N8C[C@@H](C[C@H]8C(=O)N[C@@H](C)C9=CC=C(C=C9)C1=C(N=CS1)C)O)C(C)(C)C)O)F,KHIURKSPHCFKCV-FQLPBZNCSA-N,"(2S,4R)-1-[(2S)-2-[[2-[4-[(2S)-2-[[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-7-(8-ethyl-7-fluoro-3-hydroxynaphthalen-1-yl)-8-fluoropyrido[4,3-d]pyrimidin-2-yl]oxymethyl]pyrrolidin-1-yl]butoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide",1102.53,1102.53,0,1,0,7,5,2,0,0,0,0,0,0,"",Classification,1,"",20240206,AbaChemScene|MedChemexpress MCE|Probes & Drugs portal,Chemical Vendors|Research and Development,""
139388585,KRAS inhibitor-4,"KRAS inhibitor-4|2374152-69-7|SCHEMBL21243937|AKOS040733542|DA-64783|HY-130260|CS-0106134|1-[(2R)-4-[(6R,7R)-7-(5-chloro-6-methyl-1H-indazol-4-yl)-2-[3-(dimethylamino)azetidin-1-yl]-6-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2-methylpiperazin-1-yl]prop-2-en-1-one",563.100,C30H39ClN8O,84.500,931.000,4.800,40,1,7,5,"InChI=1S/C30H39ClN8O/c1-7-26(40)39-9-8-37(14-19(39)4)29-22-10-17(2)21(27-23-13-32-35-25(23)11-18(3)28(27)31)12-24(22)33-30(34-29)38-15-20(16-38)36(5)6/h7,11,13,17,19-21H,1,8-10,12,14-16H2,2-6H3,(H,32,35)/t17-,19-,21-/m1/s1",C[C@@H]1CC2=C(C[C@H]1C3=C(C(=CC4=C3C=NN4)C)Cl)N=C(N=C2N5CCN([C@@H](C5)C)C(=O)C=C)N6CC(C6)N(C)C,LFJQRYJTQCRQSF-YFVAEKQCSA-N,"1-[(2R)-4-[(6R,7R)-7-(5-chloro-6-methyl-1H-indazol-4-yl)-2-[3-(dimethylamino)azetidin-1-yl]-6-methyl-5,6,7,8-tetrahydroquinazolin-4-yl]-2-methylpiperazin-1-yl]prop-2-en-1-one",562.294,562.294,0,1,0,3,3,0,0,0,0,0,14,3,"",Patents,1,"",20191102,"AbaChemScene|AKos Consulting & Solutions|BOC Sciences|Debye Scientific Co., Ltd|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
156766505,KRAS G12C inhibitor 33,"KRAS G12C inhibitor 33|2648985-02-6|SCHEMBL25248712|DA-74793|HY-142490|CS-0372530|2-methyl-6-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-3-naphthalen-1-yl-8-(4-prop-2-enoylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-one",539.600,C30H33N7O3,94.500,982.000,3.500,40,0,8,6,"InChI=1S/C30H33N7O3/c1-4-25(38)35-15-17-36(18-16-35)28-26-27(32-30(33-28)40-19-22-11-8-14-34(22)3)29(39)37(20(2)31-26)24-13-7-10-21-9-5-6-12-23(21)24/h4-7,9-10,12-13,22H,1,8,11,14-19H2,2-3H3/t22-/m0/s1",CC1=NC2=C(C(=O)N1C3=CC=CC4=CC=CC=C43)N=C(N=C2N5CCN(CC5)C(=O)C=C)OC[C@@H]6CCCN6C,BZZYACFDPKVXKG-QFIPXVFZSA-N,"2-methyl-6-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-3-naphthalen-1-yl-8-(4-prop-2-enoylpiperazin-1-yl)pyrimido[5,4-d]pyrimidin-4-one",539.264,539.264,0,1,0,1,1,0,0,0,0,0,13,2,"",Patents,1,"",20211110,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
163322025,KRAS G12D inhibitor 13,"KRAS G12D inhibitor 13|2648552-62-7|DA-64781|HY-143607|CS-0373967|4-[(2R,6R)-4-[(2S)-aziridine-2-carbonyl]-2,6-dimethylpiperazin-1-yl]-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2-one",589.600,C31H33F2N7O3,124.000,1080.000,3.200,43,2,8,5,"InChI=1S/C31H33F2N7O3/c1-15(2)25-27(16(3)9-10-34-25)40-28-19(11-21(33)26(36-28)24-20(32)7-6-8-23(24)41)29(37-31(40)43)39-17(4)13-38(14-18(39)5)30(42)22-12-35-22/h6-11,15,17-18,22,35,41H,12-14H2,1-5H3/t17-,18-,22+/m1/s1",C[C@@H]1CN(C[C@H](N1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C)C(=O)[C@@H]6CN6,GWDIBFOCNIJWFJ-HMFYCAOWSA-N,"4-[(2R,6R)-4-[(2S)-aziridine-2-carbonyl]-2,6-dimethylpiperazin-1-yl]-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2-one",589.261,589.261,0,1,0,3,3,0,0,0,0,0,0,0,"",Classification,1,"",20220602,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|TargetMol",Chemical Vendors,""
163408777,KRAS G12C inhibitor 43,"KRAS G12C inhibitor 43|SCHEMBL23632581|HY-142945|CS-0373983|2-[(2S)-4-[7-(3-methoxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyrido[2,3-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile|2648808-69-7",577.700,C33H35N7O3,108.000,1020.000,4.700,43,0,9,8,"InChI=1S/C33H35N7O3/c1-4-30(41)40-17-16-39(20-23(40)13-14-34)32-27-11-12-29(28-19-25(42-3)18-22-8-5-6-10-26(22)28)35-31(27)36-33(37-32)43-21-24-9-7-15-38(24)2/h4-6,8,10-12,18-19,23-24H,1,7,9,13,15-17,20-21H2,2-3H3/t23-,24-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(C=CC(=N3)C4=CC(=CC5=CC=CC=C54)OC)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,JXYVRMVMAUIZEY-ZEQRLZLVSA-N,"2-[(2S)-4-[7-(3-methoxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]pyrido[2,3-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",577.28,577.28,0,1,0,2,2,0,0,0,0,0,12,5,"",Patents,1,"",20220630,AbaChemScene|Google Patents|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
168432137,KRAS G12C inhibitor 59,KRAS G12C inhibitor 59|HY-153899|CS-0866603,715.700,C32H39F6N7O5,123.000,1250.000,"",50,3,17,7,"InChI=1S/C32H35F6N7O3.2H2O/c1-17-10-22(40)27(35)25(26(17)32(36,37)38)24-11-23-21(15-47-24)28(43-8-9-45(29(46)18(2)33)20(14-43)4-6-39)42-30(41-23)48-16-31-5-3-7-44(31)13-19(34)12-31;;/h10,19-20,24H,2-5,7-9,11-16,40H2,1H3;2*1H2/t19-,20+,24+,31+;;/m1../s1",CC1=CC(=C(C(=C1C(F)(F)F)[C@@H]2CC3=C(CO2)C(=NC(=N3)OC[C@@]45CCCN4C[C@@H](C5)F)N6CCN([C@H](C6)CC#N)C(=O)C(=C)F)F)N.O.O,AOJAYETXIQKLPX-KTINEONYSA-N,"2-[(2S)-4-[(7S)-7-[3-amino-2-fluoro-5-methyl-6-(trifluoromethyl)phenyl]-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile;dihydrate",715.292,715.292,0,3,0,4,4,0,0,0,0,0,0,0,"",Classification,1,"",20230801,AbaChemScene|MedChemexpress MCE|TargetMol,Chemical Vendors,""
155471755,KRAS inhibitor-10,"KRAS inhibitor-10|2578876-75-0|7-[2-(3-amino-4-methoxyphenyl)ethoxy]-N-ethyl-6-methoxy-1-(4-methoxy-2-methylphenyl)-3,4-dihydro-1H-isoquinoline-2-carboxamide|SCHEMBL22877429|AKOS040755449|MS-29641|HY-138295|CS-0147176|G18148",519.600,C30H37N3O5,95.300,741.000,4.700,38,2,6,9,"InChI=1S/C30H37N3O5/c1-6-32-30(34)33-13-11-21-17-27(37-5)28(38-14-12-20-7-10-26(36-4)25(31)16-20)18-24(21)29(33)23-9-8-22(35-3)15-19(23)2/h7-10,15-18,29H,6,11-14,31H2,1-5H3,(H,32,34)",CCNC(=O)N1CCC2=CC(=C(C=C2C1C3=C(C=C(C=C3)OC)C)OCCC4=CC(=C(C=C4)OC)N)OC,WKOOIGPIJNQBPY-UHFFFAOYSA-N,"7-[2-(3-amino-4-methoxyphenyl)ethoxy]-N-ethyl-6-methoxy-1-(4-methoxy-2-methylphenyl)-3,4-dihydro-1H-isoquinoline-2-carboxamide",519.273,519.273,0,1,0,1,0,1,0,0,0,0,1,1,"",Patents,1,"",20210130,"10X CHEM|A2B Chem|AA BLOCKS|AbaChemScene|AKos Consulting & Solutions|Amadis Chemical|AstaTech, Inc.|BOC Sciences|DC Chemicals|eNovation Chemicals|EvitaChem|InvivoChem|Key Organics/BIONET|Mcule|MedChemexpress MCE|MolPort|PATENTSCOPE (WIPO)|Probes & Drugs portal|SureChEMBL|SynHet - Synthetic Heterocycles|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
134325670,KRas G12C inhibitor 2,"KRas G12C inhibitor 2|2206735-61-5|2-[(2S)-4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile|SCHEMBL19947651|BCP29475|AKOS040733547|DA-64769|HY-112492|CS-0046137",567.700,C32H37N7O3,109.000,1000.000,3.800,42,1,9,7,"InChI=1S/C32H37N7O3/c1-3-30(41)39-16-15-38(19-23(39)10-12-33)31-27-11-14-37(29-18-25(40)17-22-7-4-5-9-26(22)29)20-28(27)34-32(35-31)42-21-24-8-6-13-36(24)2/h3-5,7,9,17-18,23-24,40H,1,6,8,10-11,13-16,19-21H2,2H3/t23-,24-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC(=CC5=CC=CC=C54)O)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)C=C,YKGVCHZNLOIACZ-ZEQRLZLVSA-N,"2-[(2S)-4-[7-(3-hydroxynaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",567.296,567.296,0,1,0,2,2,0,0,0,0,0,36,9,"",Patents,1,"",20180623,"AbaChemScene|AKos Consulting & Solutions|BenchChem|BioChemPartner|BOC Sciences|CymitQuimica|Debye Scientific Co., Ltd|EvitaChem|Google Patents|InvivoChem|Mcule|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol|THE BioTek",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
162642758,PROTAC KRAS G12C degrader-1,PROTAC KRAS G12C degrader-1|2984236-79-3|EX-A11811|MS-31717|HY-139186|CS-0181600|G18266,917.500,C50H54ClFN8O6,177.000,1700.000,10.500,66,4,12,19,"InChI=1S/C50H54ClFN8O6/c1-2-41(63)58-24-26-59(27-25-58)46-36-30-37(51)42(35-29-32(61)28-31-16-11-12-17-33(31)35)44(52)45(36)56-50(57-46)54-23-14-10-8-6-4-3-5-7-9-13-22-53-38-19-15-18-34-43(38)49(66)60(48(34)65)39-20-21-40(62)55-47(39)64/h2,11-12,15-19,28-30,39,53,61H,1,3-10,13-14,20-27H2,(H,54,56,57)(H,55,62,64)",C=CC(=O)N1CCN(CC1)C2=NC(=NC3=C(C(=C(C=C32)Cl)C4=CC(=CC5=CC=CC=C54)O)F)NCCCCCCCCCCCCNC6=CC=CC7=C6C(=O)N(C7=O)C8CCC(=O)NC8=O,FMYAMLPDKZOVMB-UHFFFAOYSA-N,"4-[12-[[6-chloro-8-fluoro-7-(3-hydroxynaphthalen-1-yl)-4-(4-prop-2-enoylpiperazin-1-yl)quinazolin-2-yl]amino]dodecylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione",916.384,916.384,0,1,0,1,0,1,0,0,0,0,0,0,"",Classification,1,"",20220315,"10X CHEM|AbaChemScene|AstaTech, Inc.|DC Chemicals|Excenen Pharmatech|Key Organics/BIONET|Mcule|MedChemexpress MCE|Probes & Drugs portal",Chemical Vendors|Research and Development,""
156447243,KRAS G12D inhibitor 9,KRAS G12D inhibitor 9|2648551-39-5|SCHEMBL23464928|DA-74804|HY-143602|CS-0373953,569.700,C33H43N7O2,78.700,907.000,6.100,42,0,9,9,"InChI=1S/C33H43N7O2/c1-24-7-4-8-25-9-5-11-30(31(24)25)40-19-14-28-29(21-40)36-33(42-22-27-10-6-16-38(27)2)37-32(28)39-17-12-26(13-18-39)35-23-34-15-20-41-3/h4-5,7-9,11,26-27H,6,10,12-22H2,1-3H3/t27-/m0/s1",CC1=C2C(=CC=C1)C=CC=C2N3CCC4=C(C3)N=C(N=C4N5CCC(CC5)N=C=NCCOC)OC[C@@H]6CCCN6C,BYHDIQXMLFJXAX-MHZLTWQESA-N,"",569.348,569.348,0,1,0,1,1,0,0,0,0,0,1,1,"",Patents,1,"",20210821,"AbaChemScene|BLD Pharm|Debye Scientific Co., Ltd|InvivoChem|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL|TargetMol",Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
168355659,KRAS G12D modulator-1,KRAS G12D modulator-1|HY-153555|CS-0783523|2883034-05-5,549.600,C30H36FN5O4,105.000,879.000,3.400,40,3,10,5,"InChI=1S/C30H36FN5O4/c31-20-13-30(7-3-8-36(30)14-20)18-40-29-32-26-17-34(27-12-21(37)10-19-4-1-2-5-24(19)27)9-6-25(26)28(33-29)35-15-22(38)11-23(39)16-35/h1-2,4-5,10,12,20,22-23,37-39H,3,6-9,11,13-18H2/t20-,22-,23-,30+/m1/s1",C1C[C@]2(C[C@H](CN2C1)F)COC3=NC4=C(CCN(C4)C5=CC(=CC6=CC=CC=C65)O)C(=N3)N7C[C@@H](C[C@H](C7)O)O,SOXZOPVYHSBBKU-SIVBMPLWSA-N,"(3R,5R)-1-[2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7-(3-hydroxynaphthalen-1-yl)-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]piperidine-3,5-diol",549.275,549.275,0,1,0,4,4,0,0,0,0,0,0,0,"",Classification,1,"",20230706,AbaChemScene|BLD Pharm|MedChemexpress MCE|TargetMol,Chemical Vendors,""
163409094,KRAS G12C inhibitor 48,"KRAS G12C inhibitor 48|HY-146061|CS-0498800|(E)-2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-2-(cyanomethyl)piperazine-1-carbonyl)-3-cyclopropylacrylonitrile",651.200,C36H39ClN8O2,113.000,1260.000,5.400,47,0,9,8,"InChI=1S/C36H39ClN8O2/c1-42-15-4-7-28(42)23-47-36-40-31-22-43(32-9-3-6-25-5-2-8-30(37)33(25)32)16-13-29(31)34(41-36)44-17-18-45(27(21-44)12-14-38)35(46)26(20-39)19-24-10-11-24/h2-3,5-6,8-9,19,24,27-28H,4,7,10-13,15-18,21-23H2,1H3/b26-19+/t27-,28-/m0/s1",CN1CCC[C@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN([C@H](C6)CC#N)C(=O)/C(=C/C7CC7)/C#N,CROGWWKTKKFIJR-YUWSGBISSA-N,"(E)-2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-2-(cyanomethyl)piperazine-1-carbonyl]-3-cyclopropylprop-2-enenitrile",650.288,650.288,0,1,0,2,2,0,1,1,0,0,0,0,"",Patents,1,"",20220630,AbaChemScene|BLD Pharm|MedChemexpress MCE|PATENTSCOPE (WIPO)|TargetMol,Chemical Vendors|Governmental Organizations,""
156316523,KRAS inhibitor-23,KRAS inhibitor-23|SCHEMBL23300844|HY-160220S|CS-0926824,620.100,C32H30ClFN6O4,110.000,1220.000,3.900,44,1,8,4,"InChI=1S/C32H30ClFN6O4/c1-6-23(42)38-12-13-39-21(15-38)31(43)37(5)29-28(39)18-14-19(33)26(24-20(34)8-7-9-22(24)41)36-30(18)40(32(29)44)27-17(4)10-11-35-25(27)16(2)3/h6-11,14,16,21,41H,1,12-13,15H2,2-5H3/t21-/m1/s1/i5D3",[2H]C([2H])([2H])N1C(=O)[C@H]2CN(CCN2C3=C1C(=O)N(C4=NC(=C(C=C34)Cl)C5=C(C=CC=C5F)O)C6=C(C=CN=C6C(C)C)C)C(=O)C=C,PYKBFRQMXJWLGG-UVQYGLIPSA-N,"(7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-12-(4-methyl-2-propan-2-ylpyridin-3-yl)-5-prop-2-enoyl-9-(trideuteriomethyl)-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione",619.219,619.219,0,1,3,1,1,0,0,0,0,0,12,2,"",Patents,1,"",20210821,AbaChemScene|Google Patents|MedChemexpress MCE|PATENTSCOPE (WIPO)|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
171714246,pan-KRAS-IN-15,pan-KRAS-IN-15|HY-163489|CS-1049535,642.700,C36H37F3N6O2,86.600,1190.000,6.500,47,2,11,7,"InChI=1S/C36H37F3N6O2/c1-3-6-28-30-33(31(39)32(41-28)26-14-24(46)13-20-7-10-27(38)25(4-2)29(20)26)42-35(43-34(30)44-17-22-8-9-23(18-44)40-22)47-19-36-11-5-12-45(36)16-21(37)15-36/h7,10,13-14,21-23,40,46H,4-5,8-9,11-12,15-19H2,1-2H3/t21-,22?,23?,36+/m1/s1",CCC1=C(C=CC2=CC(=CC(=C21)C3=NC(=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OC[C@@]78CCCN7C[C@@H](C8)F)C#CC)O)F,SIMPKPVADZRVHT-AWMQPXEISA-N,"4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-5-prop-1-ynylpyrido[4,3-d]pyrimidin-7-yl]-5-ethyl-6-fluoronaphthalen-2-ol",642.293,642.293,0,1,0,4,2,2,0,0,0,0,0,0,"",Classification,1,"",20240704,AbaChemScene|MedChemexpress MCE|TargetMol,Chemical Vendors,""
134817259,KRAS inhibitor Cmpd2,KRAS inhibitor Cmpd2|SCHEMBL22374836,446.800,C21H21BrClN3O,56.900,514.000,4.800,27,3,2,4,"InChI=1S/C21H21BrClN3O/c22-14-3-6-20-18(10-14)19(12-25-20)21(27)26-16-7-8-24-17(11-16)9-13-1-4-15(23)5-2-13/h1-6,10,12,16-17,24-25H,7-9,11H2,(H,26,27)/t16-,17+/m1/s1",C1CN[C@H](C[C@@H]1NC(=O)C2=CNC3=C2C=C(C=C3)Br)CC4=CC=C(C=C4)Cl,GGXKHDYKPGTZBA-SJORKVTESA-N,"5-bromo-N-[(2S,4R)-2-[(4-chlorophenyl)methyl]piperidin-4-yl]-1H-indole-3-carboxamide",445.056,445.056,0,1,0,2,2,0,0,0,0,0,1,1,"",Patents,1,"",20181002,DC Chemicals|PATENTSCOPE (WIPO)|SureChEMBL,Chemical Vendors|Curation Efforts|Governmental Organizations|Research and Development,""
4903596,"2-[4-(2-Methyl-3,5-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)piperazin-1-yl]ethanol","KRAS inhibitor-3|900897-56-5|2-[4-(2-methyl-3,5-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)piperazin-1-yl]ethanol|2-(4-(2-methyl-3,5-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)piperazin-1-yl)ethan-1-ol|2-(4-(2-methyl-3,5-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)piperazin-1-yl)ethanol|KRAS inhibitor 11|starbld0016423|SCHEMBL23521085|STK852950|AKOS002300298|DA-74805|MS-27155|HY-122914|CS-0090403|F3348-0505|Z432419308|2-[4-(2-METHYL-3,5-DIPHENYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)PIPERAZINO]-1-ETHANOL",413.500,C25H27N5O,56.900,556.000,3.600,31,1,5,5,"InChI=1S/C25H27N5O/c1-19-24(21-10-6-3-7-11-21)25-26-22(20-8-4-2-5-9-20)18-23(30(25)27-19)29-14-12-28(13-15-29)16-17-31/h2-11,18,31H,12-17H2,1H3",CC1=NN2C(=CC(=NC2=C1C3=CC=CC=C3)C4=CC=CC=C4)N5CCN(CC5)CCO,MTHOJIJARWDIJS-UHFFFAOYSA-N,"2-[4-(2-methyl-3,5-diphenylpyrazolo[1,5-a]pyrimidin-7-yl)piperazin-1-yl]ethanol",413.222,413.222,0,1,0,0,0,0,0,0,0,0,8,5,"",Patents,1,"",20050917,"10X CHEM|A2B Chem|AA BLOCKS|AbaChemScene|ABI Chem|AKos Consulting & Solutions|Angel Pharmatech Ltd.|Aurora Fine Chemicals LLC|BenchChem|BLD Pharm|Chem-Space.com Database|ChemBridge|ChemDB|ChemDiv|ChemSpider|Collaborative Drug Discovery, Inc.|Debye Scientific Co., Ltd|DiscoveryGate|eMolecules|Enamine|Google Patents|Guri Giaever, Pharmaceutical Sciences, University of British Columbia|Innovapharm|InvivoChem|Key Organics/BIONET|LabNetwork, a WuXi AppTec Company|Life Chemicals|Mcule|MedChemexpress MCE|MolPort|NextBio|PATENTSCOPE (WIPO)|Probes & Drugs portal|Smolecule|Starshine Chemical|SureChEMBL|SynHet - Synthetic Heterocycles|TargetMol|TimTec|University of Kansas High Throughput Screening Laboratory|Vitas-M Laboratory|ZINC",Chemical Vendors|Curation Efforts|Governmental Organizations|Legacy Depositors|Research and Development|Subscription Services,""
12595100,"1-(7,8-Dichloro-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one","61563-45-9|1-(7,8-Dichloro-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one|1-(7,8-dichloro-1,2,3,4-tetrahydroisoquinolin-2-yl)ethan-1-one|LZTR1-KRAS modulator 1|N-acetyl-7,8-dichloro-1,2,3,4-tetrahydroisoquinoline|SCHEMBL11190519|DTXSID40503782|PSQATYDOUXPBMP-UHFFFAOYSA-N|1-(7,8-DICHLORO-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)ETHANONE|DB-406805|CS-0668542|2-acetyl-7,8-dichloro-1,2,3,4-tetrahydroisoquinoline|Z1861995405|1-(7,8-Dichloro-3,4-dihydro-2(1H)-isoquinolinyl)ethanone",244.110,C11H11Cl2NO,20.300,259.000,2.500,15,0,1,0,"InChI=1S/C11H11Cl2NO/c1-7(15)14-5-4-8-2-3-10(12)11(13)9(8)6-14/h2-3H,4-6H2,1H3",CC(=O)N1CCC2=C(C1)C(=C(C=C2)Cl)Cl,PSQATYDOUXPBMP-UHFFFAOYSA-N,"1-(7,8-dichloro-3,4-dihydro-1H-isoquinolin-2-yl)ethanone",243.022,243.022,0,1,0,0,0,0,0,0,0,0,9,5,"",Patents,1,"",20070208,"001Chemical|A&J Pharmtech CO., LTD.|A2B Chem|AA BLOCKS|AbaChemScene|Alichem|Ambinter|Angene Chemical|BenchChem|BePharm Ltd.|BLD Pharm|Chemenu Inc.|Chemhere|Chemieliva Pharmaceutical Co., Ltd|ChemTik|CymitQuimica|Debye Scientific Co., Ltd|Enamine|EPA DSSTox|Google Patents|Hairui Chemical|IBM|J&H Chemical Co.,ltd|MolCore|NextMove Software|OXCHEM CORPORATION|PATENTSCOPE (WIPO)|RR Scientific|Starshine Chemical|SureChEMBL|TargetMol|Wikidata|ZINC",Chemical Vendors|Curation Efforts|Governmental Organizations|Legacy Depositors|Research and Development,""
169449366,"(2S,4R)-1-[(2R)-2-[3-[4-[(3S)-4-[4-[5-[(4S)-2-azanyl-3-cyano-4-methyl-6,7-dihydro-5H-1-benzothiophen-4-yl]-1,2,4-oxadiazol-3-yl]pyrimidin-2-yl]-3-methyl-1,4-diazepan-1-yl]butoxy]-1,2-oxazol-5-yl]-3-methyl-butanoyl]-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide","(2S,4R)-1-[(2R)-2-[3-[4-[(3S)-4-[4-[5-[(4S)-2-azanyl-3-cyano-4-methyl-6,7-dihydro-5H-1-benzothiophen-4-yl]-1,2,4-oxadiazol-3-yl]pyrimidin-2-yl]-3-methyl-1,4-diazepan-1-yl]butoxy]-1,2-oxazol-5-yl]-3-methyl-butanoyl]-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-4-oxidanyl-pyrrolidine-2-carboxamide|Pan-Mutation KRAS PROTAC|EX-A9933|2938169-99-2|X53",989.200,C50H60N12O6S2,295.000,1800.000,7.300,70,3,18,16,"InChI=1S/C50H60N12O6S2/c1-29(2)41(47(65)62-27-34(63)22-37(62)46(64)54-25-32-11-13-33(14-12-32)43-31(4)55-28-69-43)38-23-40(58-67-38)66-21-7-6-18-60-19-9-20-61(30(3)26-60)49-53-17-15-36(56-49)45-57-48(68-59-45)50(5)16-8-10-39-42(50)35(24-51)44(52)70-39/h11-15,17,23,28-30,34,37,41,63H,6-10,16,18-22,25-27,52H2,1-5H3,(H,54,64)/t30-,34+,37-,41+,50-/m0/s1",C[C@H]1CN(CCCN1C2=NC=CC(=N2)C3=NOC(=N3)[C@]4(CCCC5=C4C(=C(S5)N)C#N)C)CCCCOC6=NOC(=C6)[C@@H](C(C)C)C(=O)N7C[C@@H](C[C@H]7C(=O)NCC8=CC=C(C=C8)C9=C(N=CS9)C)O,YIBGZBSCYLTBRE-GMDSDUMKSA-N,"(2S,4R)-1-[(2R)-2-[3-[4-[(3S)-4-[4-[5-[(4S)-2-amino-3-cyano-4-methyl-6,7-dihydro-5H-1-benzothiophen-4-yl]-1,2,4-oxadiazol-3-yl]pyrimidin-2-yl]-3-methyl-1,4-diazepan-1-yl]butoxy]-1,2-oxazol-5-yl]-3-methylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide",988.42,988.42,0,1,0,5,5,0,0,0,0,0,0,0,"",Interactions and Pathways,1,"",20231209,Excenen Pharmatech|NCBI Structure|Protein Data Bank in Europe (PDBe),Chemical Vendors|Governmental Organizations,""
167995148,"4-[4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[(2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl)methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynylnaphthalen-2-ol",KRAS G12D inhibitor 1|2621928-43-4,582.600,C33H32F2N6O2,86.600,1070.000,5.100,43,2,10,6,"InChI=1S/C33H32F2N6O2/c1-2-19-5-3-6-20-11-24(42)12-25(27(19)20)29-28(35)30-26(14-36-29)31(40-16-22-7-8-23(17-40)37-22)39-32(38-30)43-18-33-9-4-10-41(33)15-21(34)13-33/h1,3,5-6,11-12,14,21-23,37,42H,4,7-10,13,15-18H2",C#CC1=CC=CC2=CC(=CC(=C21)C3=NC=C4C(=C3F)N=C(N=C4N5CC6CCC(C5)N6)OCC78CCCN7CC(C8)F)O,HQVNRYKTWPMSGZ-UHFFFAOYSA-N,"4-[4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-[(2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl)methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynylnaphthalen-2-ol",582.255,582.255,0,1,0,4,0,4,0,0,0,0,0,0,"",Classification,1,"",20230427,AA BLOCKS|BOC Sciences|Mcule|Probes & Drugs portal,Chemical Vendors|Research and Development,""
172835699,Potassium;radium,"",265.123,KRa,0.000,0.000,"",2,0,0,0,InChI=1S/K.Ra,[K].[Ra],WCWQNQILVSTHQD-UHFFFAOYSA-N,potassium;radium,264.989,264.989,0,2,0,0,0,0,0,0,0,0,5,5,"","",0,"",20250311,Google Patents,Research and Development,""
170836277,pan-KRAS-IN-5,pan-KRAS-IN-5|HY-163299|CS-0998830,642.500,C31H36FIN4O2,48.700,855.000,"",39,1,7,9,"InChI=1S/C31H35FN4O2.HI/c1-4-36(5-2)26-13-9-23-18-24(31(37)38-30(23)20-26)10-12-25-11-8-22-19-27(32)28(21-29(22)34(25)3)33-14-17-35-15-6-7-16-35;/h8-13,18-21H,4-7,14-17H2,1-3H3;1H/b12-10+;",CCN(CC)C1=CC2=C(C=C1)C=C(C(=O)O2)/C=C/C3=[N+](C4=CC(=C(C=C4C=C3)F)NCCN5CCCC5)C.[I-],VNLMNCKBXYKVCA-VHPXAQPISA-N,7-(diethylamino)-3-[(E)-2-[6-fluoro-1-methyl-7-(2-pyrrolidin-1-ylethylamino)quinolin-1-ium-2-yl]ethenyl]chromen-2-one;iodide,642.187,642.187,0,2,0,0,0,0,1,1,0,0,0,0,"","",0,"",20240302,AbaChemScene|MedChemexpress MCE|TargetMol,Chemical Vendors,""
168355661,Kras G12D(8-16),KRAS G12D(8-16)|HY-P5192|CS-0785232,800.900,C34H60N10O12,359.000,1410.000,-6.700,56,12,14,26,"InChI=1S/C34H60N10O12/c1-16(2)26(36)31(52)44-28(18(5)6)33(54)38-13-22(45)40-19(7)29(50)42-21(12-25(48)49)30(51)37-15-24(47)43-27(17(3)4)32(53)39-14-23(46)41-20(34(55)56)10-8-9-11-35/h16-21,26-28H,8-15,35-36H2,1-7H3,(H,37,51)(H,38,54)(H,39,53)(H,40,45)(H,41,46)(H,42,50)(H,43,47)(H,44,52)(H,48,49)(H,55,56)/t19-,20-,21-,26-,27-,28-/m0/s1",C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N,KYXPKTKDZBTZIR-YPUHKWPASA-N,(2S)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]propanoyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoic acid,800.439,800.439,0,1,0,6,6,0,0,0,0,0,0,0,"","",0,"",20230706,AbaChemScene|MedChemexpress MCE,Chemical Vendors,""
137796984,KRAS G12C inhibitor 11,KRAS G12C inhibitor 11|2158297-63-1,551.700,C32H37N7O2,88.800,969.000,4.100,41,0,8,7,"InChI=1S/C32H37N7O2/c1-3-30(40)39-19-18-38(20-24(39)13-15-33)31-27-14-17-37(29-12-6-9-23-8-4-5-11-26(23)29)21-28(27)34-32(35-31)41-22-25-10-7-16-36(25)2/h3-6,8-9,11-12,24-25H,1,7,10,13-14,16-22H2,2H3/t24-,25-/m1/s1",CN1CCC[C@@H]1COC2=NC3=C(CCN(C3)C4=CC=CC5=CC=CC=C54)C(=N2)N6CCN([C@@H](C6)CC#N)C(=O)C=C,OBKBMFMBHWUYHS-JWQCQUIFSA-N,"2-[(2R)-4-[2-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]-7-naphthalen-1-yl-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-prop-2-enoylpiperazin-2-yl]acetonitrile",551.301,551.301,0,1,0,2,2,0,0,0,0,0,0,0,"","",0,"",20190423,DC Chemicals|Starshine Chemical,Chemical Vendors,""
168013125,"KRAS G13D peptide, 25 mer","KRAS G13D peptide, 25 mer|145019-94-9|AKOS040756827|DA-54681",2634.100,C118H201N29O36S,1080.000,5730.000,-9.000,184,36,40,90,"InChI=1S/C118H201N29O36S/c1-24-62(17)93(115(179)134-75(118(182)183)37-40-83(123)153)144-106(170)78(48-57(7)8)137-102(166)73(36-39-82(122)152)132-114(178)94(63(18)25-2)145-117(181)96(67(22)150)147-107(171)76(46-55(3)4)135-98(162)65(20)128-109(173)81(54-148)139-100(164)71(30-26-28-43-119)129-85(155)53-126-110(174)89(58(9)10)140-108(172)80(50-88(159)160)130-86(156)52-124-97(161)64(19)127-84(154)51-125-111(175)90(59(11)12)142-113(177)92(61(15)16)143-112(176)91(60(13)14)141-105(169)77(47-56(5)6)136-101(165)72(31-27-29-44-120)131-104(168)79(49-68-32-34-69(151)35-33-68)138-103(167)74(38-41-87(157)158)133-116(180)95(66(21)149)146-99(163)70(121)42-45-184-23/h32-35,55-67,70-81,89-96,148-151H,24-31,36-54,119-121H2,1-23H3,(H2,122,152)(H2,123,153)(H,124,161)(H,125,175)(H,126,174)(H,127,154)(H,128,173)(H,129,155)(H,130,156)(H,131,168)(H,132,178)(H,133,180)(H,134,179)(H,135,162)(H,136,165)(H,137,166)(H,138,167)(H,139,164)(H,140,172)(H,141,169)(H,142,177)(H,143,176)(H,144,170)(H,145,181)(H,146,163)(H,147,171)(H,157,158)(H,159,160)(H,182,183)/t62-,63-,64-,65-,66+,67+,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,89-,90-,91-,92-,93-,94-,95-,96-/m0/s1",CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCSC)N,WZHGQEKYPICRGJ-SLRYOGHSSA-N,"(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]propanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoic acid",2633.45,2632.45,0,1,0,26,26,0,0,0,0,0,0,0,"","",0,"",20230517,"AKos Consulting & Solutions|BLD Pharm|Debye Scientific Co., Ltd|InvivoChem|TargetMol",Chemical Vendors,""
171391848,pan-KRAS-IN-8,pan-KRAS-IN-8|HY-162441|CS-1048645,880.100,C48H61N7O7S,189.000,1690.000,4.800,63,3,12,9,"InChI=1S/C48H61N7O7S/c1-8-54-40-14-13-32-20-34(40)36(44(54)35-19-31(23-49-43(35)30(4)60-7)11-9-15-53-17-18-61-25-33(53)24-56)22-48(5,6)27-62-47(59)37-12-10-16-55(52-37)46(58)38(21-41-50-39(32)26-63-41)51-45(57)42-28(2)29(42)3/h13-14,19-20,23,26,28-30,33,37-38,42,52,56H,8,10,12,15-18,21-22,24-25,27H2,1-7H3,(H,51,57)/t28-,29+,30-,33+,37-,38-,42?/m0/s1",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)C[C@@H](C(=O)N5CCC[C@H](N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)C#CCN7CCOC[C@H]7CO)[C@H](C)OC)(C)C)NC(=O)C8[C@@H]([C@@H]8C)C,OXNMDFCABBFAJZ-GELNLEHPSA-N,"(2R,3S)-N-[(7S,13S)-21-ethyl-20-[5-[3-[(3R)-3-(hydroxymethyl)morpholin-4-yl]prop-1-ynyl]-2-[(1S)-1-methoxyethyl]pyridin-3-yl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tetrazapentacyclo[17.5.2.12,5.19,13.022,26]octacosa-1(25),2,5(28),19,22(26),23-hexaen-7-yl]-2,3-dimethylcyclopropane-1-carboxamide",879.435,879.435,0,1,0,6,6,0,0,0,0,0,0,0,"","",0,"",20240530,AbaChemScene|MedChemexpress MCE,Chemical Vendors,""
171391850,pan-KRAS-IN-10,pan-KRAS-IN-10|HY-162443|CS-1048649,808.000,C45H57N7O5S,159.000,1540.000,5.800,58,2,10,8,"InChI=1S/C45H57N7O5S/c1-10-51-37-16-15-30-20-31(37)33(41(51)32-19-29(13-11-17-50(7)8)23-46-40(32)28(4)56-9)22-45(5,6)25-57-44(55)34-14-12-18-52(49-34)43(54)35(21-38-47-36(30)24-58-38)48-42(53)39-26(2)27(39)3/h15-16,19-20,23-24,26-28,34-35,39,49H,10,12,14,17-18,21-22,25H2,1-9H3,(H,48,53)/t26-,27+,28-,34-,35-,39?/m0/s1",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)C[C@@H](C(=O)N5CCC[C@H](N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)C#CCN(C)C)[C@H](C)OC)(C)C)NC(=O)C7[C@@H]([C@@H]7C)C,GKQWLLRSRMMAGU-BGVZMYBHSA-N,"(2R,3S)-N-[(7S,13S)-20-[5-[3-(dimethylamino)prop-1-ynyl]-2-[(1S)-1-methoxyethyl]pyridin-3-yl]-21-ethyl-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tetrazapentacyclo[17.5.2.12,5.19,13.022,26]octacosa-1(25),2,5(28),19,22(26),23-hexaen-7-yl]-2,3-dimethylcyclopropane-1-carboxamide",807.414,807.414,0,1,0,5,5,0,0,0,0,0,0,0,"","",0,"",20240530,AbaChemScene|MedChemexpress MCE,Chemical Vendors,""
164887481,KRAS inhibitor-19,KRAS inhibitor-19|CS-0530639,2100.500,C98H146N28O20S2,838.000,4500.000,1.400,148,29,26,44,"InChI=1S/C98H146N28O20S2/c1-9-55(6)77-89(142)124-98(8,51-127)93(146)121-70(47-58-32-36-62(129)37-33-58)84(137)118-71(48-75(130)131)91(144)125-43-20-29-74(125)87(140)122-76(54(4)5)88(141)119-72(86(139)115-66(27-18-41-110-96(104)105)81(134)113-64(79(99)132)25-16-39-108-94(100)101)49-147-52-148-50-73(120-82(135)67(28-19-42-111-97(106)107)114-80(133)65(112-56(7)128)26-17-40-109-95(102)103)92(145)126-44-38-63(61-23-14-11-15-24-61)78(126)90(143)117-68(45-53(2)3)83(136)116-69(85(138)123-77)46-57-30-34-60(35-31-57)59-21-12-10-13-22-59/h10-15,21-24,30-37,53-55,63-74,76-78,127,129H,9,16-20,25-29,38-52H2,1-8H3,(H2,99,132)(H,112,128)(H,113,134)(H,114,133)(H,115,139)(H,116,136)(H,117,143)(H,118,137)(H,119,141)(H,120,135)(H,121,146)(H,122,140)(H,123,138)(H,124,142)(H,130,131)(H4,100,101,108)(H4,102,103,109)(H4,104,105,110)(H4,106,107,111)/t55-,63+,64+,65+,66+,67+,68-,69-,70-,71-,72-,73+,74-,76-,77-,78-,98+/m0/s1",CC[C@H](C)[C@H]1C(=O)N[C@](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CSCSC[C@H](C(=O)N3CC[C@@H]([C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC4=CC=C(C=C4)C5=CC=CC=C5)CC(C)C)C6=CC=CC=C6)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)C)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N)C(C)C)CC(=O)O)CC7=CC=C(C=C7)O)(C)CO,FVAXECJYYQOKIH-BFUMUJLBSA-N,"2-[(3S,9R,12S,15S,21S,24S,27R,30S,33S,36S,39S,40R)-3-[[(2R)-2-[[(2R)-2-acetamido-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-9-[[(2R)-1-[[(2R)-1-amino-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]-30-[(2S)-butan-2-yl]-27-(hydroxymethyl)-24-[(4-hydroxyphenyl)methyl]-27-methyl-36-(2-methylpropyl)-2,11,14,20,23,26,29,32,35,38-decaoxo-40-phenyl-33-[(4-phenylphenyl)methyl]-12-propan-2-yl-5,7-dithia-1,10,13,19,22,25,28,31,34,37-decazatricyclo[37.3.0.015,19]dotetracontan-21-yl]acetic acid",2100.07,2099.07,0,1,0,17,17,0,0,0,0,0,0,0,"","",0,"",20220905,AbaChemScene,Chemical Vendors,""
171038129,KRAS G12D inhibitor 20,KRAS G12D inhibitor 20|HY-162366|CS-1012803,342.400,C18H26N6O,81.500,625.000,3.500,25,2,6,5,"InChI=1S/C18H26N6O/c25-18(17-13-7-2-1-3-8-14(13)20-23-17)19-11-6-10-16-22-21-15-9-4-5-12-24(15)16/h4-5,9,12-16,20H,1-3,6-8,10-11H2,(H,19,25)",C1CCC2C(CC1)NN=C2C(=O)NCCCC3N=NC4N3C=CC=C4,KXORVSMEEVZOOV-UHFFFAOYSA-N,"N-[3-(3,8a-dihydro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)propyl]-1,3a,4,5,6,7,8,8a-octahydrocyclohepta[c]pyrazole-3-carboxamide",342.217,342.217,0,1,0,4,0,4,0,0,0,0,0,0,"","",0,"",20240403,AbaChemScene|MedChemexpress MCE,Chemical Vendors,""
134817260,KRAS inhibitor C6ME,KRAS inhibitor C6ME,377.500,C23H27N3O2,66.200,508.000,3.400,28,3,4,7,"InChI=1S/C23H27N3O2/c1-28-23(27)17-7-8-21-18(15-26-22(21)12-17)14-25-19-9-10-24-20(13-19)11-16-5-3-2-4-6-16/h2-8,12,15,19-20,24-26H,9-11,13-14H2,1H3/t19-,20+/m0/s1",COC(=O)C1=CC2=C(C=C1)C(=CN2)CN[C@H]3CCN[C@@H](C3)CC4=CC=CC=C4,LRWPHTNEPQWRBY-VQTJNVASSA-N,"methyl 3-[[[(2R,4S)-2-benzylpiperidin-4-yl]amino]methyl]-1H-indole-6-carboxylate",377.21,377.21,0,1,0,2,2,0,0,0,0,0,0,0,"","",0,"",20181002,DC Chemicals,Chemical Vendors,""
171391847,pan-KRAS-IN-7,pan-KRAS-IN-7|HY-162440|CS-1048640,880.100,C48H61N7O7S,189.000,1690.000,4.800,63,3,12,9,"InChI=1S/C48H61N7O7S/c1-8-54-40-14-13-32-20-34(40)36(44(54)35-19-31(23-49-43(35)30(4)60-7)11-9-15-53-17-18-61-25-33(53)24-56)22-48(5,6)27-62-47(59)37-12-10-16-55(52-37)46(58)38(21-41-50-39(32)26-63-41)51-45(57)42-28(2)29(42)3/h13-14,19-20,23,26,28-30,33,37-38,42,52,56H,8,10,12,15-18,21-22,24-25,27H2,1-7H3,(H,51,57)/t28-,29+,30-,33-,37-,38-,42?/m0/s1",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)C[C@@H](C(=O)N5CCC[C@H](N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)C#CCN7CCOC[C@@H]7CO)[C@H](C)OC)(C)C)NC(=O)C8[C@@H]([C@@H]8C)C,OXNMDFCABBFAJZ-OPEARJKLSA-N,"(2R,3S)-N-[(7S,13S)-21-ethyl-20-[5-[3-[(3S)-3-(hydroxymethyl)morpholin-4-yl]prop-1-ynyl]-2-[(1S)-1-methoxyethyl]pyridin-3-yl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tetrazapentacyclo[17.5.2.12,5.19,13.022,26]octacosa-1(25),2,5(28),19,22(26),23-hexaen-7-yl]-2,3-dimethylcyclopropane-1-carboxamide",879.435,879.435,0,1,0,6,6,0,0,0,0,0,0,0,"","",0,"",20240530,AbaChemScene|MedChemexpress MCE,Chemical Vendors,""
171391849,pan-KRAS-IN-9,pan-KRAS-IN-9|HY-162442|CS-1048648,863.100,C48H62N8O5S,162.000,1660.000,5.700,62,2,11,8,"InChI=1S/C48H62N8O5S/c1-9-55-40-15-14-33-23-34(40)36(44(55)35-22-32(26-49-43(35)31(4)60-8)12-10-16-54-20-18-53(7)19-21-54)25-48(5,6)28-61-47(59)37-13-11-17-56(52-37)46(58)38(24-41-50-39(33)27-62-41)51-45(57)42-29(2)30(42)3/h14-15,22-23,26-27,29-31,37-38,42,52H,9,11,13,16-21,24-25,28H2,1-8H3,(H,51,57)/t29-,30+,31-,37-,38-,42?/m0/s1",CCN1C2=C3C=C(C=C2)C4=CSC(=N4)C[C@@H](C(=O)N5CCC[C@H](N5)C(=O)OCC(CC3=C1C6=C(N=CC(=C6)C#CCN7CCN(CC7)C)[C@H](C)OC)(C)C)NC(=O)C8[C@@H]([C@@H]8C)C,XSBAHLJSFDWPEL-SEAFSABXSA-N,"(2R,3S)-N-[(7S,13S)-21-ethyl-20-[2-[(1S)-1-methoxyethyl]-5-[3-(4-methylpiperazin-1-yl)prop-1-ynyl]pyridin-3-yl]-17,17-dimethyl-8,14-dioxo-15-oxa-4-thia-9,21,27,28-tetrazapentacyclo[17.5.2.12,5.19,13.022,26]octacosa-1(25),2,5(28),19,22(26),23-hexaen-7-yl]-2,3-dimethylcyclopropane-1-carboxamide",862.456,862.456,0,1,0,5,5,0,0,0,0,0,0,0,"","",0,"",20240530,AbaChemScene|MedChemexpress MCE,Chemical Vendors,""
